



PORC

Pharmacotherapy Outcomes Research Center

University of Utah College of Pharmacy



MISSION STATEMENT

Our mission is to optimize patient outcomes and drive personalized healthcare through conducting rigorous pharmacotherapy outcomes research.

This is within the academic mission of the University of Utah Health Sciences Center, which is to further education, research and service to improve patient care. Our center collaborates with foundations, managed care organizations, government, and the pharmaceutical industry. Our research emphasis includes patient reported outcomes and economic evaluations and value to generate real world evidence in support of payer reimbursement decisions in healthcare which leverages our access to the University Health EMR data at the patient level and our participation with the Huntsman Cancer Institute and affiliated centers through the ORIEN network. We also conduct research with health plan partners across the State of Utah and data provided by the Utah All Payer Claims Database.

Pharmacotherapy Outcomes Research Center

University of Utah L.S. Skaggs Pharmacy Institute
30 South 2000 East, 4th Floor, Salt Lake City, UT 84112

Phone: (801) 587-9639 Fax: (801) 587-7923

<http://pharmacy.utah.edu/porc/>

ANNUAL REPORT
2018

TABLE OF CONTENTS

	Page
Overview	1
Faculty	2
Research Associates	5
Adjunct Faculty	7
PORC Fellowships	11
PhD in Pharmacotherapy Outcomes Research and Health Policy	16
Staff	19
Journal Publications	20
Abstracts and Posters	49
Invited Presentations	82
Hosted Conferences	92
Books and Chapters	92
Awards and Honors	93
PORC Organizational Chart	95
Department of Pharmacotherapy Organizational Chart	96

OVERVIEW

The Pharmacotherapy Outcomes Research Center (PORC) was established in 2002 at the University of Utah's College of Pharmacy in Salt Lake City, Utah. Our vision is to be recognized internationally for outstanding contribution to optimize patient care via outcomes research and assessment.

Our mission is to facilitate the interaction of academia and patient care systems in the conduct of outcomes research, the presentation and publication of results, to facilitate the utilization of outcomes research information to improve patient care. We contract with the pharmaceutical industry, foundations, managed care organizations and government to conduct the following types of projects:

- Quality of Life studies
- Patient Registries and observational studies
- Resource utilization and cost analyses
- Economic modeling
- Cost-effectiveness studies
- Retrospective analyses
- Our research emphasis includes patient reported outcomes and economic evaluations and value to generate real world evidence in support of payer reimbursement decisions in healthcare.

The Center is also available for customized training programs in Outcomes Research for healthcare professionals in industry and in practice. Various patient data sources are utilized for these study types including:

- University of Utah Hospital and Clinics Network, which utilizes an Electronic Medical Record (EMR) and centralized billing system
- Managed care research databases including staff and group models, preferred provider networks and PBMs
- Access to several national integrated patient databases representing up to 24 million managed care lives
- TOPS (total outcomes in pain symptoms) database of 5000+ patients with QOL assessment
- Western States Medicaid Consortium of Medicaid data across Utah and several other states
- National EMR database on over 2,000,000 patient lives including lab results and other outcome measures
- Real-time retail pharmacy data for persistency and compliance studies

The Center's personnel have expertise in health economics, modeling, various clinical subspecialties, drug information, statistical analysis and programming, psychometrics, and database management.

FACULTY

Diana I. Brixner, RPh, PhD, FAMCP

Professor, Department of Pharmacotherapy
Executive Director, Outcomes Research Center
Director of Outcomes, Program in Personalized Health Care

Dr. Brixner is currently Professor in the Department of Pharmacotherapy at the University of Utah College Of Pharmacy in Salt Lake City and Executive Director of the Department's Outcomes Research Center. Her focus is on the design, conduct, and communication of pharmaco-economic and outcomes research studies to demonstrate the value of pharmaceutical and related therapies. She is the Director of Outcomes for the Program in Personalized Health Care affiliated with the University of Utah Health Sciences Center, focusing on the tailoring of health care to the individual characteristics of the patient. Dr. Brixner holds adjunct faculty positions in the School of Medicine's Department of Pediatrics Division of Clinical Pharmacology and in the Department of Population Health Sciences Division of Health Systems Innovation Research.



Dr. Brixner is appointed as a Research Associate at the Institute of Public Health, Medical Decision Making and Health Technology Assessment in the Department of Public Health and Health Technology Assessment at UMIT - University for Health Sciences, Medical Informatics and Technology in Hall i.T., Austria. The appointment supports her international collaborations in oncology research, personalized medicine and value assessment.

During her career, Dr. Brixner has published numerous articles in peer-reviewed journals, including the *Journal of National Cancer Center Networks*, *Value in Health*, *Pharmacoepidemiology and Drug Safety*, the *American Journal of Managed Care* and the *Journal of Managed Care Pharmacy*, authored three book chapters, has one issued patent, has been an invited speaker at a variety of national and international professional meetings. She is a founding member, served on the Executive Board, currently serves on the Real World Evidence Task Force and is a past president of the International Society

of Pharmacoeconomics and Outcomes Research (ISPOR). She is also a long standing member of the Academy of Managed Care Pharmacy (AMCP), has served a previous two-year term on the Board of Directors, is currently on the AMCP Format Executive Committee, is a Fellow of the Academy and currently serves as the president of the AMCP.


Dr. Brixner received her BS in Pharmacy from the University of Rhode Island in 1982, and a PhD in Medicinal Chemistry in 1987 from the University of Utah. She received certificates from UMIT in Decision Modeling, Clinical Epidemiology and Health Technology Assessment in 2010, 2013 and 2015, respectively.

Joseph Biskupiak, PhD, MBA

Research Professor

Director, Pharmacotherapy Outcomes Research Center

Joseph E. Biskupiak, PhD, MBA, is a Research Professor in the Department of Pharmacotherapy and the Director of the Outcomes Research Center at the College of Pharmacy, University of Utah. Dr. Biskupiak's research interests include health economics, disease management and the U.S. healthcare system. Dr. Biskupiak is a member of the editorial board for Pharmacy and Therapeutics (a peer-reviewed journal for managed care- and hospital-formulary management). He earned a PhD in medicinal chemistry from the University of Utah, an MBA from Seattle University, and a BS in chemistry from the University of Connecticut.



Prior to joining the University of Utah, Dr. Biskupiak was a Director for Strategyx, a pharmaceutical consulting company located in Somerville, New Jersey. Prior to joining Skila, Dr. Biskupiak was vice president of health services research at Hastings Healthcare Group, Pennington, New Jersey. In addition, he was a research assistant professor conducting health economics research in the Office of Health Policy and Clinical Outcomes at Thomas Jefferson University Hospital, Philadelphia, PA. He was also a research scientist and research assistant professor in the Department of Radiology at the University of Washington School of Medicine in Seattle involved in the development of imaging agents for positron emission tomography (PET) and a research investigator in the new drug discovery group at E. R. Squibb and Sons. Dr. Biskupiak

has published widely, particularly in the basic and applied sciences and health services research field. He contributed the chapters “Disease Management Programs” in the textbook *The Role of Pharmacoeconomics in Outcomes Management* and “Managed Care Models of Disease Management” in *Disease Management: A Systems Approach to Improving Patient Outcomes*, both 1996 publications of AHA Press. He has also written chapters on health assessment tools and changing patient behavior.

Trang Au, PharmD, MPH, BCPS

Research Assistant Professor

Dr. Au’s research interests lie in patient outcomes across a broad spectrum of solid cancers and hematologic malignancies. She received her PharmD from Creighton School of Pharmacy in Nebraska and subsequently completed hematology/oncology residency training at the Huntsman Cancer Institute and a post-doctoral outcomes research fellowship at the Pharmacotherapy Outcomes Research Center, University of Utah. Outside of pharmacy practice and research, she enjoys being with family and friends, cooking, running, and traveling to new places.

RESEARCH ASSOCIATES

Sudhir Unni, PhD, MBA

Senior Research Associate

Sudhir Unni is a Research Associate at the Pharmacotherapy Outcomes Research Center (PORC). He joined PORC in 2009 and has been involved in numerous HEOR studies in diabetes, hypertension, cardiovascular diseases, breast and ovarian cancers, and cystic fibrosis. He is involved in developing study concepts, proposals and statistical analysis plans, data analysis, and dissemination of study results. He has publications in various peer-reviewed journals and has presented at national and international conferences. Prior to joining PORC, Sudhir was with Xcenda as a Research Analyst. Sudhir received his PhD in Pharmacy Administration and MBA in General Business from the University of Louisiana at Monroe and Bachelors in Pharmacy from the University of Pune, India.

Hillevi Bauer, BPharm

Research Associate

Hillevi Bauer joined the Pharmacotherapy Outcomes Research Center at the University of Utah in 2010 as a pharmacist intern. She received her pharmacist license in the State of Utah in October 2012 and is now a Research Associate. She is involved in multiple projects focusing on cancer research and the development of patient surveys. She graduated in 2008 from the Philipps University, Marburg in Germany with a Bachelor of Science in Pharmacy.

Anindit Chhibber, MS

Research Associate

Anindit is a research assistant having joint appointments at Department of Pharmacotherapy and Department of Clinical Pharmacology. Anindit received his Bachelor of Technology in biotechnology from Kurukshetra University, India and graduated from University of Kansas with an MS in Pharmacology and Toxicology. Anindit's primary research interests include health outcomes research and health economics.

Minkyung Yoo, PhD
Research Associate

Minkyung Yoo, Ph.D., is a PORC Research Associate at the Pharmacotherapy Outcomes Research Center (PORC) at the University of Utah. She completed her two year fellowship with PORC in 2014. She is specialized in the costs analysis and her research interests include analysis of U.S. health care use and health care spending, and economic evaluation of changes in health insurance provisions and public health interventions. Dr. Yoo has published articles in *The Geneva Papers on Risk and Insurance, Comparative Effectiveness Research, and Breast Cancer: Targets and Therapy*. She received a PhD in Economics from Rutgers University in 2012, an M.A. from Washington University in St. Louis, and a B.A. from Konkuk University, Korea.

ADJUNCT FACULTY

Carrie McAdam-Marx, MSCI, PhD, RPh

Dr. McAdam-Marx is an Associate Professor and Director of the Pharmaceutical Evaluation & Policy Division (PEP) in the UAMS College of Pharmacy. Dr. McAdam-Marx's overarching academic goal is to generate evidence to support policy-relevant decisions in pharmacotherapy. She is also dedicated to developing the next generation of researchers to advance this area of science and health policy. Her research scope includes real-world outcomes studies to demonstrate the real-world effectiveness of diabetes drug therapies, and she also conducts studies to assess the effectiveness, value, and feasibility of clinical pharmacist-led comprehensive medication management in the primary care setting. Prior to joining UAMS, she was an Associate Professor & Director of Graduate Studies with the Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center at the University of Utah. Prior to joining academia, Dr. McAdam-Marx had an established career in the managed care and pharmaceutical industries where she led the development and delivery of disease management and appropriate use of medicines programs, and managed drug pricing and payer contracting strategies. Dr. McAdam Marx has a BS in Pharmacy from the University of Kansas, an MS in Hospital Pharmacy from the University of Minnesota, and a PhD in Health Policy from the University of the Sciences Philadelphia. She also has a Master of Science in Clinical Investigation (MSCI) from the University of Utah as part of a NIH-sponsored KM1 Career Development Program in Translational Comparative Effectiveness Research.



David Stenehjem, PharmD

Dr. Stenehjem is Adjunct Research Assistant Professor within the Department of Pharmacotherapy and member of the Pharmacotherapy Outcomes Research Center. He was an Assistant Professor in the Department from 2011-2016 and is now an Assistant Professor in the Department of Pharmacy Practice and Pharmaceutical Sciences at the University of Minnesota, College of Pharmacy. His expertise is oncology-related outcomes research to inform personalized health care decision-making. Dr. Stenehjem's research focuses on using electronic health record data supporting comparative-effectiveness research to understand the value of personalized medicine and pharmacotherapy.

**Jaewhan Kim, PhD**

Adjunct Assistant Professor

Jaewhan Kim, PhD, is a health economist and statistician at the University of Utah. He is an associate director for the Health Economics Core. Dr. Kim received his PhD from the University of Utah in 2007, and completed a two-year post-doctoral fellowship at PORC in 2009. He is an expert in large claims databases such as Medicare, Medicaid, SEER-Medicare, MarketScan, and Utah's All Payers Claims Database (APCD). He is one of the original developers of the APCD which contains state-wide claims information of those covered by private health insurance, Medicaid and Medicare Advantage.

**James Jorgenson, MS, RPh, FASHP**

Mr. James Jorgenson, MS, RPh, FASHP serves as President of Hospital & Health Systems Services and Chief Operating Officer at Visante, Inc. Mr. Jorgenson is very active with the overall strategy and project development for Visante UK and the International Practice. His more than 30-year career has included pharmacy oversight of some very



large health systems and their network associations as well as academic leadership in graduate pharmacy education.

Anke-Peggy Holtorf, PhD, MBA
Adjunct Research Faculty

Dr. Anke-Peggy Holtorf is adjunct faculty in the Department of Pharmacotherapy at the University of Utah, College of Pharmacy. In the year 2006 to 2007 she was visiting assistant professor at the University of Utah. In addition to her academic contributions, she participates as investigator in a variety of studies conducted by the Pharmacotherapy Outcomes Research Center. Dr. Holtorf obtained her PhD (Dr. rer. nat.) from the University of Marburg (Germany) and her MBA from the University of Birmingham (United Kingdom). Dr. Holtorf is partner of BioBridge Strategies LLC (<http://www.bbstrategies.com>), an international consultancy firm helping pharmaceutical and diagnostic companies aligning their business strategies to the prospective value their products and services can contribute to the healthcare market. Dr. Holtorf looks back on 15 years of experience in the pharmaceutical and chemical industry in research, marketing with global responsibilities. Among others was responsible for the global Disease Management activities and strategy of Novartis Pharma, Inc. Between 2000 and 2004, Dr. Holtorf managed the biotech business unit of a mid-sized Swiss chemical company and held a seat in the executive committee.



John Murphy, PharmD

John E. Murphy, PharmD, FASHP, FCCP, is professor of Pharmacy Practice and Science and associate dean for academic affairs and assessment at the College of Pharmacy, and professor of family and community medicine at the UA College of Medicine in Tucson. In November 2015 he was named interim dean at the College of Pharmacy. He is also an honorary professor at the University of Otago School of



Pharmacy in Dunedin, New Zealand. Dr. Murphy received BS in pharmacy and PharmD degrees from the University of Florida in Gainesville, where he was a recipient of the Distinguished Pharmacy Alumnus Award in 1998.

PORC FELLOWSHIPS

PORC provides a post-doctoral Fellowship in Outcomes Research and Pharmacoeconomics. The Fellowship is designed to provide training and experience at an academic outcomes research center to accomplish the following goals:

- To educate the fellow on outcomes research principles and applications, and their use in evaluating health care products and services;
- To provide experience in designing research studies which examine economic, clinical and humanistic outcomes; and
- To provide the training and experience necessary for the fellow to practice outcomes research in a pharmaceutical company, academic institution, managed care organization or healthcare facility.

Fellowships are generally two years and may include both years at PORC or a year at PORC and one additional year at a sponsoring institution, such as a pharmaceutical company or managed care company. Fellowship funding to date for joint programs has been obtained from Medco Health, Novartis Pharmaceuticals, and TAP Pharmaceuticals.

The majority of the Fellowship is spent working on outcomes research and pharmacoeconomics projects. The Fellow will be involved in all phases of the projects including proposal development, hypothesis generation, planning, data collection, data analysis, and generation of reports, presentations, and manuscripts. It is expected that the Fellow will present at least one abstract at a national meeting, such as AMCP, ASHP or ISPOR, and submit at least one manuscript for journal publication from work completed during the first year, and continue to make similar contributions in the second year.

Fellows are expected to participate in all areas of PORC research projects. In the beginning of the year, they work under the direct supervision of faculty and second year Fellows. As they progress through the Fellowship they will be expected to demonstrate independence in the development of proposals, implementation of research, presentations and peer-reviewed publications.

CURRENT FELLOWS

Natalia Ruiz-Negrón, PharmD

Research Fellow

Natalia received her Doctor of Pharmacy degree from the University of Utah College of Pharmacy in 2016. She is currently doing a 2-year post-doctoral fellowship in health economics and outcomes research at the University of Utah Pharmacotherapy Outcomes Research Center. She is also pursuing a Master of Science in Clinical Investigation at the University of Utah. Her research interests include health economics and outcomes research in diabetes, hypertension, and heart failure.

Kibum Kim, BPharm, MSc, PhD

Research Fellow

Kibum Kim is a Post-Doctoral Research Fellow at the Pharmacotherapy Outcomes Research Center. He is also a Senior Research Analyst at ARUP laboratories, affiliated with the University of Utah Department of Pathology. Prior to becoming an outcomes researcher, his area interest was diverse in that he was an analyst specializing in biological material handling, a pharmacometrician and a clinical pharmacist. He completed his PhD in pharmacoeconomics and outcomes research at the University of Illinois at Chicago. As a collaborator in multidisciplinary research teams, he has made scientific contributions across diverse chronic conditions including cardiovascular disorder, diabetes and oncology. His more recent work has involved the utility and cost-effectiveness of precision medicine, companion diagnostics and patient monitoring strategy.

Jyothi Menon, BPharm, MS, PhD

Research Fellow

Dr. Menon is a post-doctoral Research Fellow within the Department of Pharmacotherapy at University of Utah. Prior to this fellowship, she worked as an epidemiologist in the oncology department in the pharmaceutical industry. She obtained her doctoral degree in the field of health economics and outcomes research. Her research interests include economic evaluations, patient reported outcomes, epidemiology and

health outcomes. She is also an active participant in ISPOR (International Society of Pharmacoeconomics and Outcomes Research) student committees.

Connor Willis, PharmD

Research Fellow

Dr. Willis joined the Pharmacotherapy Outcomes Research Center in 2017 as a postdoctoral fellow. He received his PharmD degree from the University of Utah College of Pharmacy during which he completed a six-week clerkship at PORC. Prior to his current position, Connor worked as an intern at Molina Healthcare in a medication therapy management position. His research interest include pharmacoeconomic analysis and comparative effective research.

Past Fellowship Recipients

Jaewhan Kim, PhD

Associate Professor
Department of Health Promotion & Education
Associate Director
Health Economics Core
University of Utah
Salt Lake City, UT

Junhua Yu, PhD

Research Analyst
HealthCore, Inc.
Wilmington, DE

Swetha Raparla, MS

Research Analyst
HealthCore, Inc.
Wilmington, DE

Brandon Bellows, PharmD

Research Assistant Professor
Department of Pharmacotherapy
University of Utah
Salt Lake City, UT

Arati Dahal, PhD

Health Economics Researcher
University of Washington
Seattle, WA

Beilei Cai, PhD

Associate Director
US Oncology HEOR
Novartis

Scott D. Nelson, MS, PharmD

Vanderbilt University Medical Center
Nashville, TN

Richard E Nelson, PhD

Research Assistant Professor
Division of Epidemiology
University of Utah
Salt Lake City, UT

Ming Yan, MS

Data Analyst
Blue Cross Blue Shield
Detroit, Michigan

Jason Young, MD, MBA

Director
Nanosynth Materials and Sensors, Inc.
Salt Lake City, UT

Karina Raimundo, BS

Health Economist
Genentech
San Francisco, CA

Junji Lin, PhD

Associate Director, HEOR
Vector Oncology

Tina Willson, PhD

Truven Analytics
Ann Arbor, MI

Minkyung Yoo

Research Associate
Department of Economics
University of Utah
Salt Lake City, UT

Joanne LaFleur, PharmD

Associate Professor
Department of Pharmacotherapy
University of Utah
Salt Lake City, UT

Mei-Jen Ho, PharmD, MSPH

Clinical Assistant Professor
University of South Florida

Vijay N. Joish, PhD

Executive Director, Head of HEOR &
Epidemiology
Lexicon Pharmaceuticals, Inc.

Qayyim Said, PhD

Associate Director
Novartis Pharmaceuticals Corp.

Sameer R. Ghate, PhD

Director, HEOR
Novartis Oncology

Mark Roper, PharmD

Clinical Pharmacist
University Hospital
University of Utah
Salt Lake City, UT

Jordan King, PharmD

Clinical Pharmacy Specialist, Research
Kaiser Permanente
Denver, CO

Amy Sainski-Nguyen, PhD

Sr. Research Analyst
Truven Health Analytics

Trang H. Au, PharmD, MPH, BCPS

Research Assistant Professor
Pharmacotherapy Outcomes Research Center
University of Utah
Salt Lake City, UT

For more information on our Fellowship program, please visit our website at:

<http://pharmacy.utah.edu/porc/fellowships/>

PH.D. IN PHARMACOTHERAPY OUTCOMES RESEARCH & HEALTH POLICY

The Doctor of Philosophy in Pharmacotherapy Outcomes Research & Health Policy is offered to qualified and motivated students with interest in pharmacotherapy outcomes research careers based in the pharmaceutical industry, academia, governmental agencies, and the healthcare industry. Students graduate with core competencies in health economics, epidemiology, research design, and statistics. Application of these disciplines to health policy decision-making is the primary program focus along with these principles:

- Provide students with training and education in outcomes evaluation of pharmacotherapy
- Expose and train students to the tools necessary for conducting outcomes research in pharmacotherapy, including quantitative and qualitative analysis and study design
- Ensure that students have core competencies in health economics, epidemiology, research design and statistics and understand how these disciplines are applied to health policy decisions
- Create leaders in healthcare resource utilization decision making based upon evidence in research settings.



A Few of the Current PORC PhD Students: Tianze, Yan, Marisa, Kaitlin, Eman, Hillevi (Research Assoc), Mukul

CURRENT Ph.D. STUDENTS

Marisa Brailsford Schauerhamer, PharmD

Marisa is in her fifth year of pursuing a PhD degree in Pharmacotherapy Outcomes Research and Health Policy at the University of Utah. Her dissertation is titled 'The Effect of Value-Based Insurance Design on Diabetes Medication Adherence, Glycemic Control and Medical and Pharmacy Costs in Patients with Diabetes in an Employer-Insured Population'. Marisa has been a past recipient of a Pre-Doctorate PhRMA Foundation Fellowship in Adherence Improvement to support her dissertation project. Marisa's research interests include medication adherence, outcomes related to pharmacist-led interventions and managed care.

Casey Tak, MPH, CCRP

Casey is a 4th year PhD student in Pharmacotherapy Outcomes Research and Health Policy. He graduated from Westminster College in 2014 with a Master of Public Health degree. Before joining the Department of Pharmacotherapy, he worked as a Clinical Research Coordinator in the Pediatric Clinical Trials Office at the University of Utah. His research interests are centered on women's health, including drug utilization in pregnancy and access to health services.

Casey's dissertation aims to illuminate some of the underlying issues surrounding low rates of zoster vaccination. Specifically, he is looking at cost-sharing requirements and access to the vaccine. This project will ultimately serve to inform payer coverage decisions on the vaccine and health policy. Casey has received pre-doctoral fellowships from the Skaggs Research Institute and the American Foundation for Pharmaceutical Education to support his dissertation work.

Junjie Ma, MS

Junjie Ma is a PhD candidate in Pharmacotherapy Outcomes Research and Health Policy at the University of Utah College of Pharmacy. Junjie received his MS degree in Pharmacoeconomics from the China Pharmaceutical University. He completed a fellowship in Health Economics at the Peking University. His research interests include

pharmacoepidemiologic methods, cost-effectiveness models, and health economics. His research aims to understand the impact of time-dependent bias in observational studies.

Past PhD Recipients

Kuan-Ling (Kaitlin) Kuo, PhD
Health Economics and Outcomes Researcher
Center for Drug Evaluation
Taipei City, Taiwan

Yan Cheng, PhD
Post Doctoral Fellow
George Washington University Medical Informatics Center
Washington, DC

Mukul Singhal, PhD
Health Outcomes Researcher
HealthCore, Inc.
Wilmington, DE

Eman Biltaji, PhD
Post Doctoral Research Associate
Department of Pediatrics
University of Utah
Salt Lake City, UT

Tianze Jiao, PhD
Research Associate
Department of Othopaedics
University of Utah
Salt Lake City, UT

Rishi Deka, PhD
Post Doctoral Research Fellow
Department of Radiation Oncology
University of California San Diego
San Diego, CA

For more information on our PhD program, please visit our website at:
<http://pharmacy.utah.edu/pharmacotherapy/graduate-studies/phD.php>

STAFF

Stephanie Halander

Administrative Assistant

Stephanie is the Administrative Assistant for the Pharmacotherapy Outcomes Research Center. Stephanie has attended the University of Utah and has extensive administrative and managerial experience working in academia, law firms, and engineering/construction offices. She joined PORC in April 2015 and supports faculty and research staff with all administrative functions.

Louis Carpio

Project Facilitator

Louis Carpio is the Project Facilitator in the Pharmacotherapy Outcomes Research Center. Louis manages all of PORC's current and pending research projects. He also maintains and keeps track of the finances in PORC. He has previously worked at Primary Children's Hospital in their laboratory as a Clinical Lab Assistant and Myriad Genetics as a Patient Advocate. He is also an experienced and licensed Realtor in the State of Utah. He is currently working on his Bachelor's degree in Business at the University of Utah. In his off time, Louis enjoys photography, the outdoors, and his new family.

PUBLICATIONS, ABSTRACTS AND PRESENTATIONS

As of January 2018, the Pharmacotherapy Outcomes Research Center has generated over 243 abstracts, 333 peer reviewed publications, and 97 presentations that have been presented nationally and internationally within Europe, Latin American, and Asia Pacific countries.

JOURNAL PUBLICATIONS

2017

1. Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M, Bundo M, **Stenehjem D, Brixner D**, Krahn M, Siebert U. Personalized Treatment of Women with Early Breast Cancer: a Risk-Group Specific Cost-Effectiveness Analysis of Adjuvant Chemotherapy Accounting for Companion Prognostic Tests OncotypeDX and Adjuvant!Online. *BMC Cancer*. 2017 Oct 16;17(1):685.
2. Cox N, **Tak CR**, Cochella S, Leishman EW, Gunning K. Impact of pharmacist pre-visit engagement with providers on chronic opioid prescribing safety at a family medicine residency clinic. *J Am Board Fam Med*. In Press.
3. **Tak CR**, Job KM, Schoen-Gentry K, Campbell SC, Carroll P, Costantine M, Brixner DI, Birnbaum A, Sherwin CMT. The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. *Eur J Clin Pharmacol*. 2017 Sep;73(9):1055-1069.
4. Berger ML, Sox H, Willke RJ, **Brixner DI**, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel Mullens C. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. *Pharmacoepidemiol Drug Saf*. Sept. 2017; 26(9): 1033-1039.
5. Bellows BK, Sainski-Nguyen A, Olsen CJ, Boklage SH, Charland S, Mitchell MP, **Brixner DI**. Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. *J Manag Care Spec Pharm*. Sept 2017;23(9):926-34.
6. **Unni S**, Wittbrodt E, **Ma J**, **Schauerhamer M**, Hurd J, **Ruiz-Negrón N**, **McAdam-Marx C**. Comparative Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists with Regard to 6-Month Glycaemic Control and Weight Outcomes in Patients with Type 2 Diabetes. *Diabetes Obes Metab*. 2017 Sep 1. [Epub ahead of print]

7. **King JB**, Azadani PN, Suksaranjit P. **Bress AP**, Witt DM, Han FT, Chelu MG, Silver MA, **Biskupiak J**, Wilson BD, Morris AK, Kholmovski EG, Marrouche N. J Am Coll Cardiol. 2017 Sep 12;70(11):1311-1321.
8. Nelson RE, **Deka R**, Khader K, Stevens VW, Schweizer ML, Rubin MA. Dynamic Transmission Models for Economic Analysis Applied to Health Care-Associated Infections: A Review of the Literature. Am J Infect Control. 2017 Sep 25. pii: S0196-6553(17)30190-6. [Epub ahead of print].
9. **Brixner D**, Maniadakis N, Kalo Z, Hu S, Shen J, Wijaya K. Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. Value in Health Regional Issues, Vol 13, Sept 2017, 1-6.
10. **Unni S**, Wittbrodt E, **Ma J**, **Schauerhamer M**, Hurd J, **Ruiz-Negrón N**, **McAdam-Marx C**. Comparative Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists with Regard to 6-Month Glycaemic Control and Weight Outcomes in Patients with Type 2 Diabetes. Diabetes Obes Metab. 2017 Sep 1. [Epub ahead of print]
11. Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, **Stenehjem D**, Agarwal N. Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer. 2017 Aug;15(4):e599-e602. Epub 2017 Jan 5.
12. Kong AM, Hurley D, Evans KA, **Brixner D**, Csoboth C, Visootsak J. A Retrospective, Longitudinal, Claims-Based Comparison of Concomitant Diagnoses Between Individuals With and Without Down Syndrome. JManag Care Spec Pharm, 2017 Jul;23(7):761-770.
13. Nelson KL, **Stenehjem D**, Driscoll M, Gilcrease GW. Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Front Oncol. 2017 Jul 17;7:150. eCollection 2017.
14. **Au TH**, Wang K, **Stenehjem D**, Garrido-Laguna I. Personalized and Precision Medicine: Integrating Genomics into Treatment Decisions in Gastrointestinal Malignancies. J Gastrointest Oncol. 2017 Jun;8(3):387-404.
15. **Tak CR**, Job KM, Schoen-Genry K, Campbell SC, Carroll P, Costantine M, **Brixner D**, Birnbaum AK, Sherwin CMT. The Impact of Exposure to Antidepressant Medications during Pregnancy on Neonatal Outcomes: A Review of Retrospective Database Cohort Studies. Eur J Clin Pharmacol, 2017 Sep;73(9):1055-1069.
16. **King JB**, Shah RU, **Sainski-Nguyen A**, **Biskupiak J**, Munger MA, **Bress AP**. Pharmacotherapy. 2017 Jun;37(6):662-672.
17. Feehan M, Morrison MA, **Tak CR**, Morisky DE, DeAngelis MM, Munger MA. Factors predicting self-reported medication low adherence in a large sample of adults in the US general population. *BMJ Open*. 2017 Jun 23;7(6):e014435.

18. Moorman K, MacDonald EA, Trovato A, **Tak CR**. Assessment and use of drug information references in Utah pharmacies. *Pharmacy Practice (Granada)*. 2017. Jan-Mar; 15(1):839.
19. **Tak CR**, Malheiro MC, Bennett HK, Crouch BI. The value of a poison control center in preventing unnecessary emergency department visits and hospital charges: A multi-year analysis. *Am J Emerg Med*. 2017 Mar;35(3):438-443.
20. **Singhal M, Unni S, Schauerhamer M**, Nguyen H, Hurd J, **McAdam-Marx C**. Real-World Glycemic Control from GLP-1RA Therapy With and Without concurrent Insulin in Patients with Type 2 Diabetes. *J Manag Care Spec Pharm*. 2017 Mar;23(3):267-275.
21. **Biltaji E, Yoo M**, Jennings BT, Leiser JP, **McAdam-Marx C**. Outcomes Associated with Pharmacist-Led Diabetes Collaborative Drug Therapy Management in a Medicaid Population. *J Pharm Health Serv Res*. 2017 Mar;8(1):59-62. Epub 2016 Dec 19
22. Humphries MD, Suckow BD, Binks JT, **McAdam-Marx C**, Kraiss LW. Elective Endovascular Aortic Aneurysm Repair Continues to Cost More than Open Abdominal Aortic Aneurysm Repair. *Ann Vasc Surg*. 2017 Feb;39:111-118. Epub 2016 Aug 10.
23. Kawamoto K, Anstrom KJ, Anderson JB, Bosworth HB, Lobach DF, **McAdam-Marx C**, Ferranti JM, Shang H, Yarnall KS. Long-Term Impact of an Electronic Health Record-Enabled, Team-Based, and Scalable Population Health Strategy Based on the Chronic Care Model. *AMIA Annu Symp Proc*. 2017 Feb 10;2016:686-695. eCollection 2016.
24. Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, **Stenehjem DD**, Agarwal N. Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. *J Oncol Pharm Pract*. 2017 Jan 1:1078155217693426. [Epub ahead of print]
25. Kuzman JA, **Stenehjem DD**, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. *BMC Urol*. 2017 Jan 5;17(1):1.

2016

26. **McAdam-Marx C**, Nguyen H, **Schauerhamer MB**, **Singhal M**, **Unni S**, **Ye X**, Cobden D. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis. *Clin Ther*. 2016 Dec;38(12):2642-2651. Epub 2016 Nov 23.
27. Senekjian L, Nirula R, **Bellows B**, Nelson R. Interval Appendectomy: Finding the Breaking Point for Cost-Effectiveness. *J Am Coll Surg*. 2016 Oct;223(4):532-43.

28. Suksaranjit P, McGann CJ, Akoum N. **Biskupiak J**, Stoddard GJ, Kholmovski EG, Navaravong L, Rassa A, Bieging E, Chang L, Haider I, Marrouche NF, Wilson BD. *Am J Cardiol.* 2016 Oct 1;118(7):991-7
29. Dahal A, **Bellows BK**, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-Analysis. *Am J Clin Oncol.* 2016 Oct;39(5):497-506.
30. **Au TH**, Cavalieri CC, **Stenehjem DD**. Ceritinib: A Primer for Pharmacists. *J Oncol Pharm Pract.* 2016 Oct 13. pii: 1078155216672315. [Epub ahead of print] Review.
31. **Brixner DI**, **Stenehjem DD**, Ulrich C. Aspirin and Cancer Risk. *JAMA Oncol.* 2016 Oct 1;2(10):1370-1371.
32. **Stenehjem D**, Udomaksorn S, Cheng Y, Pflieger L, **Au T**, Buys S, **Brixner D**. Evaluation of the Relevance and Access of HER-Based Variables to Support Personalized Medicine in Breast Cancer. *Cogent Medicine*, Vol 3, Oct 2016, Issue 1.
33. Gill DM, **Stenehjem DD**, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N. Conditional Survival of Metastatic Renal Cell Carcinoma Patients Treated with High-Dose Interleukin-2. *Ecancermedicalscience.* 2016 Sep 29;10:676. eCollection 2016.
34. **Biltaji E**, **Tak C**, **Ma J**, **Ruiz-Negron N**, **Bellows BK**. Using Electronic Medical Records to Assess the Effectiveness of Pharmacotherapy in Pain: A Review of Recent Observational Studies. *J Pain Palliat Care Pharmacother.* 2016 Sep;30(3):210-7.
35. **Stenehjem DD**, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A. Extension of Overall Survival Beyond Objective Responses in Patients with Metastatic Renal Cell Carcinoma Treated with High-Dose Interleukin-2. *Cancer Immunol Immunother.* 2016 Aug;65(8):941-9
36. **Brixner D**, Egami M, Garrison L, Jönsson, Neumann P, Kamae I. Regenerative Medicine and Health Technology Assessment: Vision and Challenges. *JJ Regener Med.* Aug 2016, 1(3): 014.
37. **Bellows BK**, Olsen CJ, Voelker J, Wander C. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. *J Manag Care Spec Pharm.* 2016 Aug;22(8):892-900.
38. Kuo Kuan-Ling, **Brixner D**, Lipman A, Goodman M, Hung M, Odera G. Single-Versus Multiple – Drug Pharmacotherapy in the Management of Diabetic Painful Neuropathy. *Journal of Pain & Palliative Care Pharmacotherapy.* 2016, 30(3):184-94. Aug 2016.

39. **Tak CR**, Yu T, Sherwin CMT, Mihalopoulos NL. Optimizing recruitment in a longitudinal pediatric clinical study: reflections on setting, flexibility, and support. *Int J Adolesc Med Health*. 2016 July 2.
40. Augustine J, Warholak TL, Hines LE, Sun D, Brown M, Hurwitz J, Taylor AM, **Brixner D**, Cobaugh DJ, Schlaifer M, Malone DC. Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up. *J Manag Care Spec Pharm*. 2016 Jun;22(6):618-25.
41. Gurgle HE, White K, **McAdam-Marx C**. SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives. *Vasc Health Risk Manag*. 2016 Jun 4;12:239-49. eCollection 2016. Review.
42. Shane-McWhorter L, **McAdam-Marx C**, Lenert L, Petersen M, Woolsey S, Coursey JM, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L. Augmenting Telemonitoring Interventions by Targeting Patient Needs in a Primarily Hispanic Underserved Population. *Diabetes Spectr*. 2016 May;29(2):121-7.
43. Yu T, Campbell SC, Stockmann C, **Tak C**, Schoen K, Clark EA, Varner MW, Spigarelli MG, Sherwin CM. Pregnancy-induced changes in pharmacokinetics of caffeine and its metabolites. *J Clin Pharmacol*. 2016. May; 56(5):590-6.
44. **King BJ**, Shah RU, **Bress AP**, Nelson RE, **Bellows BK**. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared with Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail*. 2016 May;4(5):392-402.
45. Ben-Joseph R, Bell JA, **Brixner D**, Kansal A, Paramore C, Chitnis A, Holly P, S Burgoyne D. Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone. *J Manag Care Spec Pharm*. 2016 Apr;22(4):358-66.
46. **Bellows BK**, DuVall SL, Kamauu AW, Supina D, Pawaskar M, Babcock T, LaFleur J. Characteristics and Use of Treatment Modalities of Patients with Binge-Eating Disorder in the Department of Veteran Affairs. *Eat Behav*. 2016 Apr;21:161-7.
47. Ben-Joseph R, Bell JA, **Brixner D**, Kansal A, Paramore C, Chitnis A, Holly P, S Burgoyne D. Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone. *J Manag Care Spec Pharm*. 2016 Apr;22(4):358-66.
48. **Unni SK**, **Schauerhamer MB**, **Deka R**, Tyczynski JE, Fernandes AW, Stevens V, **Brixner DI**, **Stenehjem DD**. BRCA Testing, Treatment Patterns and Survival in Platinum-Sensitive Recurrent Ovarian Cancer – An Observational Cohort Study. *J Ovarian Res*. 2016 Mar 22;9:18.
49. Stenehjem DD, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U, Brixner DI. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. *Oncologist*. 2016 Feb;21(2):196-204.
50. Ruble JH, **Brixner DI**. Pharmacy Expenditures for Children with Serious Chronic Illness. *JAMA*. 2016 Feb 16;315(7):706.

51. **Bress AP, King JB, Brixner D**, Kielhorn A, Patel HK, Maya J, Lee VC, **Biskupiak J**, Munger M. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. *Pharmacotherapy*. 2016 Feb;36(2):174-86.
52. **Unni SK**, Quek RG, **Biskupiak J**, Lee VC, **Ye X**, Gandra SR. Assessment of Statin Therapy, LDL-C Levels, and Cardiovascular Events Among High-Risk Patients in the United States. *J Clin Lipidol*. 2016 Jan-Feb;10(1):63-71.e3.
53. Brown KA, Daneman N, **Stevens VW**, Zhang Y, Greene TH, Samore MH, Arora P. Integrating Time-Varying and Ecological Exposures into Multivariate Analyses of Hospital-Acquired Infection Risk Factors: A Review and Demonstration. *Infect Control Hosp Epidemiol*. 2016 Feb 16:1-9.
54. **Stenehjem DD, Bellows BK**, Yager KM, Jones J, Kaldate R, Siebert U, **Brixner DI**. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. *Oncologist*. 2016 Feb;21(2):196-204.
55. **Bress AP**, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT Results to the U.S. Adult Population. *J Am Coll Cardiol*. 2016 Feb 9;67(5):463-72.
56. **LaFleur J**, Rillamas-Sun E, Colón-Emeric CS, Knippenberg KA, Ensrud KE, Gray SL, Cauley JA, LaCroix AZ. Fracture Rates and Bone Density Among Postmenopausal Veteran and Non-Veteran Women From the Women's Health Initiative. *Gerontologist*. 2016 Feb;56 Suppl 1:S78-90.
57. **Unni SK, Schauerhamer MB, Deka R**, Tyczynski JE, Fernandes AW, Stevens V, **Brixner DI**, Stenehjem DD. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. *J Ovarian Res*. 2016 Jan 1;9(1):18-8.
58. Kachroo S, Hamilton M, Liu X, Pan X, **Brixner D**, Marrouche N, **Biskupiak J**. Oral Anticoagulant Discontinuation in Patients with Nonvalvular Atrial Fibrillation. *Am J Manag Care*. 2016 Jan 1;22(1):e1-8.
59. **Bellows BK**, Nelson RE, **Oderda GM, LaFleur J**. Long-Term Cost-Effectiveness of Initiating Treatment for Painful Diabetic Neuropathy with Pregabalin, Duloxetine, Gabapentin, or Desipramine. *Pain*. 2016 Jan;157(1):203-13.
60. **King JB, Sainski-Nguyen AM, Bellows BK**. Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis. *J Pain Palliat Care Pharmacother*. 2016;30(1):55-65.

2015

61. Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, **Brixner D**, Siebert U. The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. *Appl Health Econ Health Policy*. 2015 Aug; 13 Suppl 1:S21-33.
62. **Nickman NA, Ye X**, Gaffney DK, Barney RB, **Biskupiak JE**, Okano GJ, Lee VC, Arellano J. Cost of Palliative External Beam Radiotherapy (EBRT) Use for Bone

Metastases Secondary to Prostate Cancer. *J Community Support Oncol*. 2015 Mar;13(3):95-103.

63. Rochau U, Kluibenschaedl M, **Stenehjelm D**, Kuan-Ling K, Radich J, **Oderda G**, **Brixner D**, Siebert U. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. *Leuk Res Treatment*. 2015;2015:982395.
64. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervary A, **Brixner D**, Siebert U. Systematic Overview of Cost-Effectiveness Thresholds in Ten Countries Across Four Continents. *J Comp Eff Res*. 2015 Sep;4(5):485-504.
65. Kuo KL, **Stenehjelm D**, Albright F, Ray S, **Brixner D**. Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories. *J Natl Compr Canc Netw*. 2015 Aug;13(8):987-94.
66. Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, **Brixner D**. Need for Multicriteria Evaluation of Generic Drug Policies. *Value Health*. 2015 Mar;18(2):346-51.
67. **Unni S**, White K, Goodman M, **Ye X**, Mavros P, Bash LD, **Brixner D**. Hypertension Control and Antihypertensive Therapy in Patients with Chronic Kidney Disease. *Am J Hypertens*. 2015 Jun;28(6):814-22.
68. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, **Stenehjelm D**, **Brixner D**, Radich J, Gastl G, Siebert U. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. *Leuk Lymphoma*. 2015 Aug;56(8):2315-25.
69. **Oderda GM**, **Lake J**, Rüdell K, Roland CL, Masters ET. Economic Burden of Prescription Opioid Misuse and Abuse: A Systematic Review. *J Pain Palliat Care Pharmacother*. 2015 Dec;29(4):388-400.
70. Apfel C, Jahr JR, Kelly CL, Ang RY, **Oderda GM**. Effect of i.v. Acetaminophen on Total Hip or Knee Replacement Surgery: A Case-Matched Evaluation of a National Patient Database. *Am J Health Syst Pharm*. 2015 Nov 15;72(22):1961-8.
71. Gan TJ, Robinson SB, **Oderda GM**, Scranton R, Pepin J, Ramamoorthy S. Impact of Postsurgical Opioid Use and Ileus on Economic Outcomes in Gastrointestinal Surgeries. *Curr Med Res Opin*. 2015 Apr;31(4):677-86.
72. Mansour IN, **Bress AP**, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, Cavallari LH. Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. *J Card Fail*. 2015 Dec 22.
73. **King JB**, **Bress AP**, Reese AD, **Munger MA**. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. *Pharmacotherapy*. 2015 Sep;35(9):823-37.

74. Sharabiani A, **Bress A**, Douzali E, Darabi H. Revisiting Warfarin Dosing Using Machine Learning Techniques. *Comput Math Methods Med*. 2015;2015:560108.
75. **Bress A**, Kittles R, Wing C, Hooker SE Jr, King A. Genetic Ancestry as an Effect Modifier of Naltrexone in Smoking Cessation Among African Americans: An analysis of a Randomized Controlled Trial. *Pharmacogenet Genomics*. 2015 Jun;25(6):305-12.
76. Drozda K, Wong S, Patel SR, **Bress AP**, Nutescu EA, Kittles RA, Cavallari LH. Poor Warfarin Dose Prediction with Pharmacogenetic Algorithms that Exclude Genotypes Important for African Americans. *Pharmacogenet Genomics*. 2015 Feb;25(2):73-81.
77. **LaFleur J**, Hoop R, Korner E, **DuVall S**, Morgan T, Pandya P, Han J, **Knippenberg K**, Nelson RE. Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. *Gastroenterol Nurs*. 2015 Nov-Dec;38(6):417-28.
78. Nelson RE, Xie Y, **DuVall SL**, Butler J, Kamauu AW, **Knippenberg K**, Schuerch M, Foskett N, **LaFleur J**. Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans. *Int J MS Care*. 2015 Sep-Oct;17(5):221-30
79. Gundlapalli AV, Nelson RE, Haroldsen C, Carter ME, **LaFleur J**. Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009. *PLoS One*. 2015 Jul 13;10(7):e0132056.
80. Colón-Emeric C, Pieper CF, Grubber J, Van Scoyoc L, Schnell ML, Van Houtven CH, Pearson M, **Lafleur J**, Lyles KW, Adler RA. Correlation of hip fracture with other fracture types: Toward a rational composite hip fracture endpoint. *Bone*. 2015 Dec;81:67-71
81. **Bellows BK**, DuVall SL, Kamauu AW, Supina D, Babcock T, **LaFleur J**. Healthcare costs and resource utilization of patients with binge-eating disorder and eating disorder not otherwise specified in the Department of Veterans Affairs. *Int J Eat Disord*. 2015 Dec;48(8):1082-91.
82. Nelson SD, Malone D, **Lafleur J**. Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation. *Pharmacoeconomics*. 2015 Sep;33(9):887-92.
83. Varier RU, Biltaji E, Smith KJ, Roberts MS, Kyle Jensen M, **LaFleur J**, Nelson RE. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Infect Control Hosp Epidemiol*. 2015 Apr;36(4):438-44.
84. **LaFleur J**, Steenhoek CL, Horne J, Meier J, Nebeker JR, Mambourg S, Swislocki A, Carmichael J. Comparing fracture absolute risk assessment (FARA) tools: an osteoporosis clinical informatics tool to improve identification and care of men at high risk of first fracture. *Ann Pharmacother*. 2015 May;49(5):506-14.

85. Willson T, Nelson SD, Newbold J, Nelson RE, **LaFleur J**. The clinical epidemiology of male osteoporosis: a review of the recent literature. *Clin Epidemiol*. 2015 Jan 9;7:65-76.
86. **King JB, Schauerhamer MB, Bellows BK**. A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain. *Ther Clin Risk Manag*. 2015 Aug 10;11:1163-75.
87. Shane-McWhorter L, **McAdam-Marx C**, Lenert L, Petersen M, Woolsey S, Coursey JM, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L. Pharmacist-provided diabetes management and education via a telemonitoring program. *J Am Pharm Assoc* (2003). 2015 Sep-Oct;55(5):516-26.
88. **McAdam-Marx C**, Dahal A, Jennings B, **Singhal M**, Gunning K. The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes. *J Manag Care Spec Pharm*. 2015 Jun;21(6):452-68.
89. **Schauerhamer MB**, Gurgle H, **McAdam-Marx C**. Once-weekly exenatide as a treatment for Type 2 diabetes. *Expert Rev Cardiovasc Ther*. 2015 Jun;13(6):611-26.
90. Nelson RE, Samore MH, Jones M, Greene T, **Stevens VW**, Liu CF, Graves N, Evans MF, Rubin **MA**. Reducing Time-dependent Bias in Estimates of the Attributable Cost of Health Care-associated Methicillin-resistant *Staphylococcus aureus* Infections: A Comparison of Three Estimation Strategies. *Med Care*. 2015 Sep;53(9):827-34.
91. Jones BE, Jones MM, Huttner B, Stoddard G, Brown KA, **Stevens VW**, Greene T, Sauer B, Madaras-Kelly K, Rubin M, Goetz MB, Samore M. Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010. *Clin Infect Dis*. 2015 Nov 1;61(9):1403-10.
92. Nelson RE, Nelson SD, Khader K, Perencevich EL, Schweizer ML, Rubin MA, Graves N, Harbarth S, **Stevens VW**, Samore MH. The Magnitude of Time-Dependent Bias in the Estimation of Excess Length of Stay Attributable to Healthcare-Associated Infections. *Infect Control Hosp Epidemiol*. 2015 Sep;36(9):1089-94.
93. **Stevens VW**, Khader K, Nelson RE, Jones M, Rubin MA, Brown KA, Evans ME, Greene T, Slade E, Samore MH. Excess Length of Stay Attributable to *Clostridium difficile* Infection (CDI) in the Acute Care Setting: A Multistate Model. *Infect Control Hosp Epidemiol*. 2015 Sep;36(9):1024-30.
94. Coon SA, **Stevens VW**, Brown JE, Wolff SE, Wrobel MJ. Comparison of dietary supplement product knowledge and confidence between pharmacists and health food store employees. *J Am Pharm Assoc* (2003). 2015 Mar-Apr;55(2):161-8
95. Chrastil J, Anderson MB, **Stevens V**, Anand R, Peters CL, Pelt CE. Is Hemoglobin A1c or Perioperative Hyperglycemia Predictive of Periprosthetic Joint Infection or Death Following Primary Total Joint Arthroplasty? *J Arthroplasty*. 2015 Jul;30(7):1197-202.

96. Nelson RE, **Stevens VW**, Jones M, Samore MH, Rubin MA. Health care-associated methicillin-resistant *Staphylococcus aureus* infections increases the risk of postdischarge mortality. *Am J Infect Control*. 2015 Jan;43(1):38-43.
97. Patel SB, **Stenehjem DD**, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. *Clin Genitourin Cancer*. 2015 Dec 17. pii: S1558-7673(15)00341-9
98. Bailey H, **Stenehjem DD**, Sharma S. Panobinostat for the treatment of multiple myeloma: the evidence to date. *J Blood Med*. **2015** Oct 8;6:269-76.
99. Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, **Stenehjem DD**, Agarwal N. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. *J Oncol*. 2015;2015:181926.
100. Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, **Stenehjem DD**, Agarwal N. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. *Clin Genitourin Cancer*. 2015 Jun;13(3):e131-7.
101. **Brixner D, Biltaji E, Bress A, Unni S, Ye X**, Mamiya T, Ashcraft K, **Biskupiak J**. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. [J Med Econ](#). 2015 Oct 19:1-16.
102. Varier RU, **Biltaji E**, Smith KJ, Roberts MS, Kyle Jensen M, **LaFleur J**, Nelson RE. Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection. *Infect Control Hosp Epidemiol*. 2015;36(4):438-444.
103. Grimsrud KN; Zuppa A; Constance JE; **Tak CR**; Sherwin CMT; Spigarelli MG; Mihalopoulos NL. **Special Population Considerations and Regulatory Affairs for Clinical Research**. *Clinical Research and Regulatory Affairs*. 2015.
104. Yu T; Campbell S; Stockmann C; **Tak CR**; Schoen K; Clark EA; Varner MW; Spigarelli MG; Sherwin CMT. Pregnancy-induced Changes in the Pharmacokinetics of Caffeine and its Metabolites. *Journal of Clinical Pharmacology*. 2015.
105. **LaFleur J, DuVall SL**, Willson T, Ginter T, Patterson O, Cheng Y, Knippenberg K, Haroldsen C, Adler RA, Curtis JR, Agodoa I, Nelson RE. Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans. *Bone*. 2015 Apr 17.
106. Grimsrud KN, Zuppa A, Constance JE, **Tak CR**, Sherwin CMT, Spigarelli MG, Mihalopoulos NL. Special population considerations and regulatory affairs for clinical research. *Clin Res Regul Aff*. 2015; 32(2):47-56.

2014

107. Nelson RE, Hoop R, Korner E, **DuVall S**, Morgan T, Pandya P, Han J, **LaFleur J**. Predicting discontinuation of pegylated interferon as a result of lack of efficacy in United States Veterans with chronic hepatitis C on dual therapy. *Annals of Pharmacotherapy*. 2014; In Press.
108. **LaFleur J**, Hoop R, Korner E, **DuVall S**, Mortan T, Pandya P, **Knippenberg K**, and Nelson RE. Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. *Gastroenterology Nursing*. 2014; In Press.
109. **Willson T**, **Nelson S**, Newbold J, Nelson RE, **LaFleur J**. The clinical epidemiology of male osteoporosis: A review of the recent literature. *Clinical Epidemiology*. 2014; In Press.
110. **Nelson SD**, **LaFleur J**, Hunter E, Archer M, Steinvooort C, Madden C, **Oderda G**. Clinically meaningful drug-drug interactions: Examples from the Utah Medicaid Drug Regimen Review Center. *Journal of Pharmacy Practice*. 2014; In Press.
111. **Nelson SD**, Nelson RE, Cannon GW, Lawrence P, Battistone MJ, Grotzke M, Rosenblum Y, **LaFleur J**. Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures. *Osteoporosis International*. 2014; In Press.
112. **McAdam-Marx C**, **Bellows BK**, **Unni S**, Wygant G, Mukherjee J, **Ye X**, **Brixner DI**. Impact of Adherence and Weight Loss on Glycemic Control in Patients with Type 2 Diabetes: Cohort Analyses of Integrated Medical Record, Pharmacy Claims, and Patient-Reported Data. *J Manage Care Pharm*. 2014; Accepted for publication.
113. **Stenehjem DD**, **Yoo M**, **Unni S**, **Singhal M**, **Bauer H**, Saverno K, Quah C, Masaquel A, **Brixner DI**. Assessment of single-institution HER2 testing patterns, rate of HER2+ disease and utilization of trastuzumab in early breast cancer. *Breast Cancer: Targets and Therapy*. 2014. Accepted. In press.
114. **LaFleur J**, Hoop R, Morgan T, Pandya P, Korner E, **Knippenberg K**, Hayden C, **DuVall S**, Nelson R. High rates of early treatment discontinuation in HCV-infected US veterans. *BMC Research Notes*. 2014; 7(1):266.
115. **Bellows BK**, **LaFleur J**, Kamauu A, Ginter T, Forbush TB, Agbor S, **DuVall SL**. Automated identification of patients with binge-eating disorder from narrative electronic health records. *Journal of the American Medical Informatics Association*. 2014;21:e1 e163-e168.
116. **Stenehjem DD**, **Albright FS**, **Kuo K-L**, Raimundo K, **Bauer H**, Shami PJ, Deininger MW, Chen L, **Brixner DI**. Response Monitoring, Tolerability and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database. *J Natl Compr Canc Netw*. 2014;12(8):1113–1121.

117. Buu J, Mullin S, **McAdam-Marx C**, Solomon M, and Jennings BT. Identifying Barriers to Influenza Vaccination Recommendation Adherence in an Academic Outpatient Primary Care Clinic Setting. *Innov Pharm*. 2014; 5(3): Article 4.
118. Shane-McWhorter L, Lenert L, Petersen M, Woolsey S, **McAdam-Marx C**, Coursey J, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L. The Utah Remote Monitoring Project: Improving Health Care One Patient at a Time. *Diab Tech & Ther*. 2014; 16(10). Epub ahead of print.
119. **LaFleur J**, Hoop R, Korner E, **DuVall S**, Mortan T, Pandya P, **Knippenberg K**, and Nelson RE. Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. *Gastroenterology Nursing*. 2014; In Press.
120. **Bellows BK, Kuo KL, Biltaji E, Singhal M, Jiao T, Cheng Y, McAdam-Marx C**. Real-world evidence in pain research: A review of data sources. *J Pain Palliat Care Pharmacother*. 2014 Aug 19. Epub ahead of print
121. **McAdam-Marx C, Bellows BK, Unni S, Mukherjee J, Wygant G, Iloeje U, Liberman JN, Ye X, Bloom FJ, Brixner DI**. Determinants of Glycemic Control in a Practice Setting: The Role of Weight Loss and Treatment Adherence (The DELTA Study). *Int J Clin Pract*. 2014; Aug 12. Epub ahead of print.
122. **Cai B, McAdam-Marx C**. The Determinants of antihypertensive use and expenditure inpatients with hypertension in the United States. *Journal of Pharmaceutical Health Services Research*. 2014. Accepted for publication Sept 30, 2013.
123. Munger M, Ruble J, **Nelson S**, Ranker L, Petty R, Silverstein S, Barton E, Feehan M. National Evaluation of Prescriber Drug Dispensing. *Pharmacotherapy*. 2014 Jul 23. [Epub ahead of print]
124. **Yoo M, Cheng Y, Rhien TJ, Biskupiak J**. Current issues in comparative effectiveness research for hepatitis C. *DovePress*. June 2014; 2014(4):13-27.
125. **Bellows BK, LaFleur J, Kamau A, Ginter T, Forbush TB, Agbor S, DuVall SL**. Automated identification of patients with binge-eating disorder from narrative electronic health records. *Journal of the American Medical Informatics Association*. 2014 Feb; 21(e1):e163-8.
126. Gilreath JA, **Stenehjem D**, Rodgers GM. Diagnosis and treatment of cancer-related anemia. *Am J Hematol*. 2014 Feb; 89(2):203–212.
127. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, **Brixner D**, Radich J, Gastl G, Siebert U. Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. *Leuk Lymphoma*. 2014 Feb 6. [Epub ahead of print]
128. Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, **Brixner D**, Gastl G, Siebert U. Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia. *Appl Health Econ Health Policy*. 2014 Jan 3. [Epub ahead of print]

129. **McAdam-Marx C**, Mukherjee J, **Bellows BK**, **Unni S**, **Ye X**, Iloeje U, **Brixner DI**. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. *Diabetes Res Clin Pract*. 2014; 103(3):402-11.

2013

130. Nelson RE, Hoop R, Korner E, **DuVall S**, Morgan T, Pandya P, Han J, **LaFleur J**. Pegylated-interferon discontinuation due to lack of efficacy in United States veterans with chronic hepatitis C. *Annals of Pharmacotherapy*. 2013; In Press.
131. Saverno K, Gothe H, Schuessel K, **Biskupiak JE**, Schulz M, Siebert U, **Brixner DI**. Consideration of International Generic Distribution Policies on Patient Outcomes in the United States and Germany. *Die Pharmazie*. 2013. In Press.
132. **Brixner DI**, Malone D, Hines L, Tang D, Warholak T, Taylor A. (2013) Evaluation of Pharmacy and Therapeutic (P & T) Committee Member Knowledge, Attitudes and Ability Regarding the Use of Comparative Effectiveness Research (CER) in Health Care Decision-Making. *Research in Social & Administrative Pharmacy*. 2013 Dec 3. [Epub ahead of print]
133. Nelson RE, **Stenehjem D**, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. *Lung Cancer*. 2013 Dec; 82(3):461-8.
134. **Biskupiak J**, **Ghate SR**, **Jiao T**, **Brixner D**. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. *J Manag Care Pharm*. 2013 Nov-Dec; 19(9):789-98.
135. Villa L, Warholak TL, Hines LE, Taylor AM, Brown M, Hurwitz J, **Brixner D**, Malone DC. Health care decision makers' use of comparative effectiveness research: report from a series of focus groups. *J Manag Care Pharm*. 2013 Nov-Dec; 19(9):745-54.
136. **Nelson S**, Munger M. Icosapent Ethyl for Treatment of Elevated Triglyceride Levels: A Review of the Literature. *Ann Pharmacother*. 2013 Nov; 47(11):1517-2.
137. Smelick GS, Heffron TP, Chu L, Dean B, West DA, **DuVall SL**, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development. *Mol Pharm*. 2013 Oct. [Epub ahead of print]
138. Blouin R, **Brixner DI**, Cutler S, Derendorf HC, Poloyak SM, Ellingrod Ringold VL, Schnellman RG, Swaan P, Lau YS. The Report of the 2012-2013 Research and Graduate Affairs Committee. *Am J Pharm Educ*. 2013 Oct; 77(8):s9.

139. Ferraro JP, Daumé H 3rd, **DuVall SL**, Chapman WW, Harkema H, Haug PJ. Improving performance of natural language processing part-of-speech tagging on clinical narratives through domain adaptation. *J Am Med Inform Assoc*. 2013 Sep-Oct; 20(5):931-9.
140. Robinson M, Gunning K, Pippitt K, **McAdam-Marx C**, Jennings BT. Team-based approach to addressing simvastatin safety concerns. *J Am Pharm Assoc*. 2013 Sep-Oct; 53(5):539-44.
141. **Stevens V**, van Wijngaarden E. Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection. *Evid Based Med*. 2013 Oct; 18(5):193-4.
142. Oottamasathien S, Jia W, Roundy LM, Zhang J, Wang L, **Ye X**, Hill AC, Savage J, Lee WY, Hannon AM, Milner S, Prestwich GD. Physiologic Relevance of LL-37 Induced Bladder Inflammation and Mast Cells. *Journal of Urology*. 2013 Oct; 190(4 Suppl):1596-602.
143. **Stevens V**, Geiger K, Concannon C, Nelson RE, Brown J, Dumyati G. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. *Clin Microbiol Infect*. 2013 Sep. [Epub ahead of print]
144. Petersen H, Sood A, Meek PM, Shen X, **Cheng Y**, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, Celli B, Tesfaigzi Y. Rapid Lung Function Decline in Smokers is a Risk Factor for COPD and is Attenuated by ACE Inhibitor Use. *Chest*. 2013 Sep 5. [Epub ahead of print]
145. Nelson RE, Battistone MJ, Ashworth WD, Barker AM, Grotzke M, Huhtala TA, **LaFleur J**, Tashjian RZ, Cannon GW. Cost effectiveness of training rural providers to perform joint injections. *Arthritis Care and Research*. 2013 Sep 19. [Epub ahead of print]
146. Dhamane AD, Martin BC, **Brixner DI**, Hudson TJ, Said Q. Metabolic monitoring of patients prescribed second-generation antipsychotics. *J Psychiatr Pract*. 2013 Sep;19(5):360-74.
147. **Goodman MJ**, **Ghate SR**, Mavros P, Sen S, Marcus RL, Joy E, **Brixner DI**. Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004. *J Cachexia Sarcopenia Muscle*. 2013 Sep; 4(3):187-97.
148. **Cai B**, **Nickman N**, Gaffney D. The cost-effectiveness of external beam radiation therapy in bone metastases. *Curr Opin Support Palliat Care*. 2013 Sep; 7(3): 278-283.
149. Roundy L, Jia W, Zhang J, **Ye X**, Prestwich G and Oottamasathien S. LL-37 induced cystitis and the receptor for advanced glycation end-products (RAGE) pathway. *Advances in Bioscience and Biotechnology*. 2013 Aug. 4; 1-8.
150. Khadem T, **Stevens V**. Therapeutic options for the treatment of postherpetic neuralgia: a systematic review. [Review]. *J Pain Palliat Care Pharmacother*. 2013 Aug; 27 (3), 268-83.

151. Kirkness CS, **McAdam-Marx C**, Unni S, **Young J**, **Ye X**, Chandran A, Peters CL, **Asche CV**. Characterization of patients undergoing total hip arthroplasty in a real-world setting and pain-related medication prescriptions for management of postoperative pain. *J Pain Palliat Care Pharmacother*. 2013 Aug; 27(3):235-43.
152. **Young J**, **Nickman NA**, **Biskupiak JE**, Barney RB, Gaffney DK, Namjoshi M, Brandt P. Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid. *Breast*. 2013 Aug; 22(4):495-503.
153. Ren J, Ning Z, **Asche CV**, Zhuang M, Kirkness CS, **Ye X**, Fu J, Pan Q. Trends and predictors in methadone maintenance treatment dropout in Shanghai, China: 2005-2011. *Curr Med Res Opin*. 2013 Jul; 29(7):731-8.
154. **McAdam Marx C**. Economic implications of type 2 diabetes management. *Am J Manag Care*. 2013 Jun; 19(8 Suppl):S143-8.
155. **Brixner DI**, Bron M, **Bellows BK**, **Ye X**, Yu J, **Raparla S**, **Oderda GM**. Evaluation of cardiovascular risk factors, events, and costs across four BMI categories. *Obesity (Silver Spring)*. 2013 Jun; 21(6):1284-92.
156. **Kuo KL**, **Saokaew S**, **Stenehjem DD**. The pharmacoeconomics of breakthrough cancer pain. *J Pain Palliat Care Pharmacother*. 2013 Jun; 27(2):167-75.
157. Stanford JB, Martin JC, Gibson M, Birdsall E, **Brixner DI**. Use of clomiphene citrate in the University of Utah Community Clinics. *J Reprod Med*. 2013 May-Jun; 58(5-6):229-33.
158. **Goodman MJ**, **Brixner DI**. New therapies for treating Down syndrome require quality of life measurement. *Am J Med Genet A*. 2013 Apr; 161A(4):639-41.
159. **Lin J**, **Jiao T**, **Biskupiak JE**, **McAdam-Marx C**. Application of electronic medical record data for health outcomes research: a review of recent literature. *Expert Rev Pharmacoecon Outcomes Res*. 2013 Apr; 13(2):191-200.
160. **Stevens V**, Concannon C, van Wijngaarden E, McGregor J. Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated clostridium difficile infection (CDI) within a retrospective cohort. *BMC Infect Dis*, 2013 Mar; 13(1), 150.
161. Garg V, Shen X, **Cheng Y**, Nawarskas JJ, Raisch DW. Use of number needed to treat in cost-effectiveness analyses. *Ann Pharmacother*. 2013 Mar; 47(3):380-7.
162. **Ghate SR**, Porucznik CA, Said Q, Hashibe M, Joy E, **Brixner DI**. Association between second-generation antipsychotics and changes in body mass index in adolescents. *J Adolesc Health*. 2013 Mar; 52(3):336-43.
163. **Oderda GM**, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on outcomes in selected surgical patients. *J Pain Palliat Care Pharmacother*. 2013 Mar; 27(1):62-70

164. **Ghate S**, Porucznik C, Said Q, Hashibe M, Joy E, **Brixner DI**. Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. *Journal of Adolescent Health*. 2013 Mar; 52(3):336-43.
165. **Cai B**, **Nickman NA**, Gaffney DG. The Role of Palliative External Beam Radiation Therapy (EBRT). *Bone Metastases Pain Management*. 2013 Mar; 27(1):28-34.
166. Talal A, **LaFleur J**, Hoop RS, Pandya P, Martin P, Jacobson I, Han J, Korner E. Absolute and relative contraindications to pegylated interferon or ribavirin in the US general patient population with chronic hepatitis: Results from US database of over 45,000 patients. *Alimentary Pharmacology & Therapeutics* 2013 Feb; 37(4):473-81.
167. Chen SY, Lee YC, Alas V, Greene M, **Brixner DI**. Outcomes Associated with Concordance of Oral Antidiabetic Drug Treatments to Prescribing Information in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Journal of Medical Economics*. 2013 Feb; 16(5): 586-95.
168. **Raimundo K**, **Biskupiak J**, **Goodman M**, Silverstein S, **Asche C**. Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma. *J Med Econ*. 2013; 16(5):606-13.
169. Nelson RE, Nebeker JR, Hayden C, Reimer L, Kone K, **LaFleur J**. Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis. *AIDS Behav*. 2013 Jan; 17(1):160-7.

2012

170. Holtorf A, **Brixner DI**, **Bellows B**, Keskinaslan A, Dye J, **Oderda G**. Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. *American Health and Drug Benefits*. 2012 Nov/Dec; 5(7): 428-438.
171. Kirkness CS, **McAdam-Marx C**, **Unni S**, Young J, **Ye X**, Chandran A, Peters CL, **Asche CV**. Characterization of Patients Undergoing Total Knee Arthroplasty in a Real-World Setting and Pain-Related Medication Prescriptions for Management of Postoperative Pain. *J Pain Palliat Care Pharmacother*. 2012 Dec; 26(4):326-333.
172. Jennings BT, **McAdam-Marx C**. Implementation of a Pharmacist-Managed Diabetes Program in a Community Clinic-Based Pharmacy Program. *Am J Health Syst Pharm*. 2012 Nov 15; 69(22):1951-3.
173. **Nickman NA**. Safety of automation technologies in healthcare. *J Ergonom*. 2012 May. Editorial 2:e109.
174. Lau YS, Blouin R, **Brixner DI**, Crismon L, Cutler S, Ho R, Jusko W, Nahata M, Sorkness C, Torchilin VP, Wu-Pong S. Report of the 2011-2012 AACP Special Advisory Committee on Research and Graduate Education. *American Journal of Pharmaceutical Education*. 2012 Oct; 76(8): S14.

175. Garvin JH, **DuVall SL**, South BR, Bray BE, Bolton D, Heavirland J, Pickard S, Heidenreich P, Shen S, Weir C, Samore M, Goldstein MK. Automated extraction of ejection fraction for quality measurement using regular expressions in Unstructured Information Management Architecture (UIMA) for heart failure. *J Am Med Inform Assoc*. 2012 Sep-Oct; 19(5):859-66.
176. **Ghate SR**, Porucznik CA, Said Q, Hashibe M, Joy E, **Brixner DI**. Predictors of Metabolic Parameter Monitoring in Adolescents on Antipsychotics in a Primary Care Setting. *Ment Health Fam Med*. 2012 Sep; 9(3):137-48.
177. **McAdam-Marx C**, Joy E, **Dahal A**, **Brixner DI**. A Retrospective Analysis of Follow-up Timing and Blood Pressure Outcomes after Initiation of Antihypertensive Therapy in Patients with Hypertension Treated in a Utah Community Setting. Accepted for publication, 2012 Sep. *Utah Health* 2012.
178. Jones MM, **DuVall SL**, Spuhl J, Samore MH, Nielson C, Rubin M. Extraction of Methicillin-Resistant Staphylococcus aureus Data from the Nation's Veterans Affairs Medical Centers. *BMC Med Inform Decis Mak*. 2012 Jul; 12:34.
179. **McAdam-Marx C**. Commentary: Managed Care Pharmacy Perspective in Evaluating Current Modes for Insulin Delivery and Glucose Monitoring in Patients with Diabetes. *J Manag Care Pharm*. 2012 Jul; 18(6): S14.
180. **Saverno K**, Rochau U, **Stenehjem D**, Morley K, Siebert U, **Brixner DI**. Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. *Journal of Managed Care Pharmacy*. 2012 Jul/Aug; 18(6): 457-463.
181. **Brixner DI**. This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? [Introduction] *Journal of Managed Care Pharmacy*. 2012 Jun; 18(5):S5.
182. **Brixner DI**, Watkins J, **Oderda G**, Sifford-Wilson S, **Biskupiak J**, Dunn J, Holtorf A. This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? *Journal of Managed Care Pharmacy*. 2012 Jun; 18(5):S6-19.
183. **Goodman M**, Durkin M, Forlenza J, **Ye X**, **Brixner DI**. Assessing Adherence-based quality measures in epilepsy. *International Journal for Quality in Health Care*. 2012 Jun; 24(3):293-300.
184. **Bellows BK**, **Dahal A**, **Jiao T**, **Biskupiak J**. A cost-utility analysis of pregabalin vs. duloxetine for the treatment of painful diabetic neuropathy. *Palliat Care Pharmacother*. 2012 Jun; 26(2):153-64.
185. **Brixner DI**, **Oderda G**. [Introduction] Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. *Journal of Managed Care Pharmacy*. 2012 May; 18(4a):S3-S4.
186. **Brixner DI**, **Oderda G**, Mohr P, Dubois R, Cannon HE. Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. *Journal of Managed Care Pharmacy*. 2012 May; 18(4a):S5-17.

187. Gilreath JA, **Stenehjem DD**, Rodgers GM. Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+? *J Natl Compr Canc Netw*. 2012 May; 10(5):669-76.
188. **McAdam-Marx C**, **Unni S**, **Ye X**, Nelson S, **Nickman NA**. Effect of medicare reimbursement reduction for imaging services on osteoporosis screening rates. *J Am Geriatr Soc*. 2012 Mar; 60(3):511-6.
189. **LaFleur J**, **McAdam-Marx C**, White GL, Lyon JL, **Oderda GM**. Comparing medication adherence methods in lipid-modifying therapy. *Journal of Pharmacy Technology*. 2012 Mar-Apr; 28(2):58-67.
190. **LaFleur J**, Nelson RE, Yao Y, Adler R, Nebeker J. Validated risk rule using computerized data to identify males at high risk for fracture. *Osteoporosis International*. 2012 Mar; 23(3):1017-27.
191. Marcus RL, **Brixner DI**, **Ghate S**, LaStayo P. Fat Modulates the Relationship between Sarcopenia and Physical Function in Nonobese Older Adults. *Current Gerontology and Geriatrics Research*. Epub 2012 Jan 23.
192. Nelson RE, Nebeker JR, Sauer BC, **LaFleur J**. Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture. *Bone*. 2012 Jan 18; 50(4):983-8.

2011

193. **Bellows BK**, **Biskupiak J**. Methodological challenges of comparative effectiveness research in pain pharmacotherapy: implications for investigators, clinicians, and policy makers. *J Pain Palliat Care Pharmacother*. 2011;25(3):267-274.
194. Ram CVS, Ramaswamy K, Quan C, **Biskupiak J**, Ryan A, Quah R, Russo PA. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: A comparative effectiveness analysis from electron medical record data. *Journal of Clinical Hypertension*. 2011 Nov; 13(11):801-12.
195. **Ghate SR**, **Biskupiak J**, **Ye X**, Kwong WJ, **Brixner DI**. All-Cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. *Journal of Managed Care Pharmacy*. 2011 Nov; 17(9):672-84.
196. **LaFleur J**, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: A case study in healthy user bias and hypertension. *Heart*. 2011 Nov; 97(22):1862-9.
197. Kempf J, Buysman E, **Brixner DI**. Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting. *American Health & Drug Benefits*. 2011 Sep/Oct; 4(6).
198. **McAdam-Marx C**, McGarry L, Hane C, **Biskupiak J**, Deniz B, **Brixner D**. All-cause and incremental per patient per year cost associated with chronic hepatitis-C and associated liver complications in the United States: A managed care perspective. *Journal of Managed Care Pharmacy* 2011 Sep; 17(7):531-546.

199. **Raimundo KP, Asche CV.** A review of the efficacy and outcomes studies of currently approved chemotherapy treatments for advanced AIDS-Kaposi's sarcoma. *HIV & AIDS Review*. 2011 Sep; 10(3):56-60.
200. **Ghate S, Biskupiak J, Ye X,** Hagan M, Kwong W, Fox E, **Brixner DI.** Hemorrhagic and Thrombotic Events Associated With Generic Substitution of Warfarin in Patients with Diagnosis of Atrial Fibrillation. A Retrospective Analysis. *Ann Pharmacotherapy*. 2011 Jun; 45:701-12.
201. Nelson RE, **McAdam-Marx C,** Evans M, **Brixner D, LaFleur J.** Patent extension policy for pediatric indications: An evaluation of the impact within three drug classes in a state Medicaid program. *Applied Health Economics and Health Policy*. 2011 May; 9(3):171-81.
202. **Young JR, McAdam-Marx C.** Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog McAdam-Marx, Clinical Medicine Insights: Endocrinology and Diabetes. *Libertas Academica*. 2011 Apr; 3.
203. **LaFleur J, McAdam-Marx C, Asche CV,** Alder S, Sheng X, Nebeker J, **Brixner DI,** Silverman S. Clinical risk factors for fracture among postmenopausal patients at risk for fracture: A historical cohort study using electronic medical record data. *Journal of Bone and Mineral Metabolism*. 2011 Mar; 29(2):193.
204. **Asche C, LaFleur J,** Conner C. Diabetes treatment adherence and the association with economic, clinical, and humanistic outcomes. *Clinical Therapeutics*. 2011 Jan; 33(1):74-109.
205. **McAdam-Marx C,** Bouchard J, Aagren M, Conner C, **Brixner DI.** Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. *Clin Ther*. 2011 Jan; 33(1):110-20.
206. **Bellows BK,** Hunter E, **McAdam-Marx C.** Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes. Clinical Medicine Reviews in Vascular Health. *Libertas Academica*. 2011(3).

2010

207. **Nickman NA,** Haak S, Kim JW. Use of clinical simulation centers in health professions schools for patient-centered research. *Simulation in Healthcare*. 2010 Oct; 5 (5):295-302.
208. **Ghate S,** Haroutiunian S, Winsow R, **McAdam-Marx C.** Cost and Comorbidities Associated with Opioid Abuse in Managed Care and Medicaid Patients in the United States: A Comparison of Two Recently Published Studies. *J Pain Palliat Care*. 2010 Sep; 24(3):251-8.
209. **Goodman MJ,** Nordin JD, Belongia EA, Mullooly JP, Baggs J. Henoch-Schölein purpura and polysaccharide meningococcal vaccine. *Pediatrics*. 2010 Aug; 126(2):e325-9.

210. **Yu J**, Smith K, **Brixner DI**. Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine: A Markov Model Application. *CNS Drugs*, 2010 Aug; 24(8).
211. **Brixner DI**, **McAdam-Marx C**, **Ye X**, Lau H, Munger MA. Assessment of Time to Follow-up Visits in Newly-Treated Hypertensive Patients Using an Electronic Medical Record Database. *Curr Med Res Opin*. 2010 Aug; 26(8): 1881-91.
212. **Asche C**, **Nelson R**, **McAdam-Marx C**, Jhaveri M, **Ye X**. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. *Osteoporosis International*. 2010 Aug; 21(8):1427-36.
213. **McAdam-Marx C**, Gaebler JA, **Bellows BK**, **Brixner DI**. Contemporary Management of Patients with Type 2 Diabetes. *Exp Rev Cardiovasc Ther*. 2010 Jun; 8(6): 767-770.
214. **Asche C**, Shane-McWhorter L, **Raparla S**. Health Economics and Compliance of Vial/Syringe Versus Pen Devices: A Review of the Evidence. *Diabetes Technology & Therapeutics*. 2010 Jun; 12 Suppl 1:S101-8.
215. **Nickman NA**, Haak SW, Kim JW. Cost minimization analysis of different growth hormone pen devices based on time-and-motion simulations. *BMC Nursing*. 2010 Apr; 9(6).
216. **McAdam-Marx C**, Roland CL, Cleveland J, **Oderda GM**. Costs of Opioid Abuse and Misuse Determined from a Medicaid Database. *J Pain Palliat Care Pharmacother*. 2010 Mar; 24(1):5-18.
217. **McAdam-Marx C**, **Yu J**, Bouchard J, Aagren M, **Brixner DI**. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. *Curr Med Res Opin*. 2010 Jan 26; (1):191-201.
218. **McAdam-Marx C**, Bouchard J, Aagren M, **Nelson R**, **Brixner D**. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. *Diabetes, Obesity and Metabolism*. 2010 Jan; 12(1):54-64
219. **McAdam-Marx C**, Field RT, Metraux S, Moelter ST, **Brixner DI**. Physician Utilization by Insurance Type in Youth with Type 2 Diabetes. *Am J Manag Care*. 2010 Jan; 16(1):55-64.

2009

220. **McAdam-Marx C**, **Brixner DI**, Metraux S, Moelter S, Field R. Antidiabetic Treatment and A1C Testing in Youth with Type 2 Diabetes in an Ambulatory Care Setting. *Diabetes*. 2009; 58(S1):A514.
221. **Brixner D**, **McAdam-Marx C**, **Nelson R**, Aagren M, Bouchard J. Analysis of glycemic control and weight changes in patients treated with analog basal insulin in a real-world setting. *Diabetes*. 2009; 58(S1):A514.

222. **McAdam-Marx C, Brixner DI, Ye X, Misurski D, Fabunmi R.** A1C Outcomes at 6 and 18 Months in Insulin Naïve Patients with Type 2 Diabetes Treated with Analog Basal Insulin in an Ambulatory Care Setting. *Diabetes*. 2009; 58(S1):A513.
223. **Yu J, Brixner DI, Ghate SR, Gondor K.** A Pilot Study of Screening Outcomes in Patients at Risk for Atherosclerosis in the Utah Community Clinics. *Utah's Health: An Annual Review IX*. 2009.
224. **Yu J, Goodman MJ, Oderda GM.** Economic evaluation of pharmacotherapy of migraine pain: a review of the literature. *J Pain Palliat Care Pharmacother*. 2009 Dec; 23(4):396-408.
225. **Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R.** Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. *Diabetes, Obesity and Metabolism*. 2009 Dec; 11(12):1122-30.
226. **McAdam-Marx C, Fabunmi R, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Brixner DI.** A1C and Weight outcomes at 18 months in patients with type 2 diabetes treated with Exenatide in an ambulatory care setting. *Diabetes, Obesity and Metabolism*. 2009 Dec; 11(12):1173-4.
227. **Said Q, Marx CM, Schwartz JS, Ben-Joseph R, Brixner DI.** Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More. *Value Health*. 2009 Oct; V13(2): P265-272.
228. **Asche C.** ISPOR International Digest of Databases. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections*. 2009 Sep/Oct.
229. **McAdam-Marx C, Bouchard J, Aagren M, Nelson R, Brixner D.** Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. *Diabetes Obes Metab*. 2009 Sep; 12(1): 54-63.
230. **Asche C.** Use of Patient Registry Data in Evaluating Patient Reported Outcomes. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections*. 2009 Jul/Aug.
231. **LaFleur J, Larsen B, Madden C, Gunning K, Stoddard GJ, Oderda L, Steinvoot C, Oderda G.** Agreement between pharmacists for problem-identification: An initial quality measurement of cognitive services. *Annals of Pharmacotherapy*. 2009 Jul; 43(7):1173-80.
232. **LaFleur J.** Osteoporosis: Need-to-knows for pharmacists about bone health. *Pharmacy Times*. 2009 Jun; 75-85.
233. **McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH.** Results of a Retrospective, Observational Pilot Study Using Electronic Medical Records to Assess the Prevalence and Characteristics of Patients with Resistant Hypertension in an Ambulatory-Care Setting. *Clinical Therapeutics*. 2009 May; 31(5):1116-23.

234. Kane SV, Accortt NA, Magowan S, **Brixner D**. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. *Aliment Pharmacol Ther*. 2009 Apr; 29(8), 855-62.
235. **Brixner DI**, Holtorf AP, Neumann PJ, Malone DC, Watkins JB. Standardizing quality assessment of observational studies for decision making in health care. *J Manag Care Pharm*. 2009 Apr; 15(3), 275-83.
236. Smith MD, Drummond M, **Brixner D**. Moving the QALY forward: rationale for change. *Value Health*. 2009 Mar; 12 Suppl 1, S1-4.
237. **Holtorf AP, McAdam-Marx C**, Schaaf D, Eng B, **Oderda G**. Systematic review on quality control for drug management programs: Is quality reported in the literature? *BMC Health Services Research*. 2009 Feb; 9(1):38.

2008

238. **Kirkness CS, Yu J, Asche CV**. The Effect on Comorbidity and Pain in Patients with Osteoarthritis. *J Pain Palliat Care Pharmacother*. 2008; 22(4) 336 – 48.
239. **Kirkness CS**, Marcus RL, Lastayo PC, **Asche CV**, Fritz JM. Diabetes and associated risk factors in patients referred for physical therapy in a national primary care electronic medical record database. *Phys Ther*. 2008 Nov; 88(11):1408-16.
240. **Brixner DI, McAdam-Marx C**. Cost-Effectiveness of Insulin Analogs. *The American Journal of Managed Care*. 2008 Nov; 14(11): 766-75.
241. **McAdam-Marx C**, Schaaf D, **Holtorf AP**, Eng B, **Oderda G**. Systematic Analysis of Outcomes Evaluations Applied to Drug Management Programs. *American Journal of Managed Care*. 2008 Nov; 14(11 Suppl):SP36-45.
242. **Brixner DI, Gbate SR, McAdam-Marx C**, Ben-Joseph R, **Said Q**. Association between cardiometabolic risk factors and body mass index on diagnosis and treatment codes in an electronic medical record database. *J Manag Care Pharm*. 2008 Oct; 14(8): 756-67. (Nominated as 1 of 15 articles by JMCP Editorial Advisory Board for 2008 JMCP Award of Excellence)
243. **Brixner DI**, Jackson KC 2nd, Sheng X, **Nelson RE**, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. *Curr Med Res Opin*. 2008 Sep; 24(9):2597-607.
244. **Asche CV, Nelson RE**. The benefits and risks of new therapies for type 2 diabetes. *J Manag Care Pharm*. 2008 Sep; 14(7):655-7. Review.
245. Jackson KC, Sheng X, **Nelson RE**, Keskinaslan A, **Brixner DI**. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. *Clin Ther*. 2008 Aug; 30(8):1558-63.
246. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat CA. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. *Diabetes Obes Metab*. 2008 Aug; 10(8):638-45.

247. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat CA. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. *Drugs Aging*. 2008 Jul; 25(7):611-22.
248. Hendlish SK, Horowicz-Mehler NC, **Brixner DI**, Stern LS, Doyle JJ, Chang J, Hagan M. Contraceptive and noncontraceptive benefits of the LNG-IUS in a vertically integrated HMO. *Contraception*. 2008 Jul; 78(1):36-41.
249. **Asche C, Said Q**, Joish V, Hall CO, **Brixner DI**. Assessment of COPD-related outcomes via a national electronic medical record database. *International Journal of COPD*. 2008 Jun; 3(2): 323-6.
250. **Asche CV, McAdam-Marx C**, Seal B, Crookston B, Mullins CD. Treatment Costs Associated with Community-Acquired Pneumonia by Community Level of Antimicrobial Resistance. *Journal of Antimicrobial Chemotherapy*. 2008 May; 61(5):1162-8.
251. Murphy PA, **Brixner DI**. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. *Contraception*. 2008 Apr; 77(4):257-63.
252. **Holtorf AP**, Watkins JB, Mullins CD, **Brixner DI**. Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. *Journal of Managed Care Pharmacy*. 2008 Apr; 14(3), 302-8.
253. **Said Q**, Gutterman EM, Kim MS, Firth SD, Whitehead R, **Brixner DI**. Somnolence effects of antipsychotic medications and the risk of unintentional injury. *Pharmacoepidemiol Drug Saf*. 2008 Apr; 17(4):354-64.
254. Merrill RM, Layman AP, **Oderda G, Asche CV**. Risk Estimates of Hysterectomy and Selected Conditions Commonly Treated with Hysterectomy. *Annals of Epidemiology*, 2008 Mar; 18(3): 253-60.
255. **LaFleur J, McAdam-Marx C, Kirkness C, Brixner DI**. Clinical risk factors for fracture in post-menopausal osteoporotic women: a review of the recent literature. *Ann Pharmacother*. 2008 Mar; 42(3): 375-86.
256. Muszbek N, **Brixner DI**, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. *Int J Clin Pract*. 2008 Feb; 62(2):338-51.
257. Kane SV, **Brixner DI**, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. *J Manag Care Pharm*. 2008 Jan; 14(1 Suppl A):s2-12; quiz s13-5.

2007

258. **Holtorf AP, LaFleur J**, Servatius D, Jeffries B, McBeth C, **Brixner DI**. Statin treatment of diabetic patients in Utah Medicaid. *Utah's Health: An Annual Review*. 2007; 12(Supplement):57-71.

259. **Holtorf AP, LaFleur J**, Servatius D, Jeffries B, **Brixner DI**. Prescription drug use by women and men in Utah Medicaid. *Utah's Health: An Annual Review*. 2007; 12(Supplement):97-99.
260. **Asche CV, Kirkness C, McAdam-Marx C**, Fritz J. The societal costs of low back pain A Review of Studies Published Between 2001 and 2007. *J Pain Palliat Care Pharmacother*. 2007; 21(4):25-33.
261. **LaFleur J, Said Q, McAdam-Marx C, Jackson K**, Mortazavi M. The problems of studying the association between race and pain in outcomes research. *J Pain Palliat Care Pharmacother*. 2007; 21(3):57-62.
262. **Brixner DI**, Rubin DT, Sewitch MJ. The Complexity of Compliance and Persistence in Ulcerative Colitis. *Gastroenterology and Hepatology*. 2007; 3(Suppl 9) S1-10 .
263. **Asche C, Kirkness C, McAdam-Marx C**, Fritz J. The societal costs of low back pain: A Review of Studies Published Between 2001 and 2007. *Journal of Pain and Palliative Care Pharmacotherapy*, 2007 Dec; 21(4):25-33.
264. **Brixner DI**. Prevalence and burden of migraine and the impact on managed care. Currents: Pain Management News and Research. E-Newsletter of the *American Academy of Pain Management*. 2007 Nov.
265. **Brixner DI**, Lenhart G, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. *Current Medical Research and Opinion*. 2007 Nov; 23(11):2887-95.
266. **Nickman NA, Biskupiak J**, Creekmore F, Shah H, **Brixner DI**. Antiplatelet medication management in patients hospitalized with ischemic stroke. *Am J Health Syst Pharm*. 2007 Nov 1; 64(21):2250-6.
267. **Oderda G, Asche CV**, Jones K, Merrill R, Spalding J. Characterization of Therapy and Costs for Patients with Uterine Fibroids in Utah Medicaid. *Archives of Gynecology and Obstetrics*. 2007 Sep; 276(3):211-8.
268. **Brixner DI**. Prevalence and burden of migraine and the impact on managed care. *Manag Care*. 2007 Jul; 16 (7 Suppl 7):2-3; discussion 15-7.
269. **McAdam-Marx C, LaFleur, J, Kirkness C, Asche CV**. Postmenopausal osteoporosis: current and future treatment options. *P&T*. 2007 Jul; 32(7):392-402.
270. Wick J, **LaFleur J**. Fatigue: Implications in the elderly. *The Consultant Pharmacist*. 2007 Jul; 22(7):566-70, 573-4, 576-8.
271. **Brixner DI, Joish V, Oderda GM**, Avey S, Hanson D, Cannon HE. Effects of Benefit Change Across 5 Disease States. *The American Journal of Managed Care*. 2007 Jun; 13(6 pt 2):370-6.

272. **Asche CV.** Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: Results of a small survey of managed care organizations and pharmaceutical manufacturers. Commentary on the article by Nichols MB et al. *J Manag Care Pharm.* 2007 May; 13(4):360-71.
273. Brooks T, Creekmore F, Young D, **Asche CV, Oberg B, Samuelson W.** Rates of Hospitalizations and Emergency Department Visits in Patients with Asthma and Chronic Obstructive Pulmonary Disease Taking β -Blockers. *Pharmacotherapy.* 2007 May; 27(5):684-690.
274. **Jackson K, Nahoopii R, Said Q, Dirani R, Brixner DI.** An Employer-Based Cost Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation. *Journal of Occupational and Environmental Medicine.* 2007 Apr; 49(4): 453-60.
275. **Brixner DI, Miller P, Fox J, Calabrese D, Tangalos E, Gruber J, Skinner N.** The Role of Observational Data in Clinical Decision-Making for Osteoporosis: Commentaries from Managed Care and Senior Care [C.E. Program]. *Hotwire for Managed Markets.* 2007 Apr.
276. **Oderda GM, Said Q, Evans RS, Stoddard GJ, Lloyd J, Jackson K, Rublee D, Samore MH.** Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. *Ann Pharmacother.* 2007 Mar; 41(3):400-6.
277. Tuteja AK, **Biskupiak JE.** Chronic Constipation: Overview and Treatment Options. *P&T.* 2007 Feb; 32(2):91-105.
278. **Brixner DI, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G.** Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database. *Value Health.* 2007 Jan/Feb; 10(Suppl 1):S29-36.

2006

279. Ho MJ, Kirkness C, **Brixner DI.** Problem Based Learning in Pharmacy Management. *Journal of Pharmacy Teaching.* 2006; 13(2): 39-56
280. **Asche CV, Seal B, Jackson K, Oderda GM.** Economic evaluations in pain management: Principles and Methods. *Journal of Pain and Palliative Care Pharmacotherapy.* 2006; 20(3):15-23.
281. **Biskupiak JE, Brixner DI, Howard K, Oderda GM.** Gastrointestinal complications of over-the-counter nonsteroidal anti-inflammatory drugs. *J Pain Palliat Care Pharmacother.* 2006; 20(3):7-14.
282. Maio V, Yuen EJ, Smith KD, **Brixner DI, Oderda GM, Asche CV, Morgan S.** Multi-national assessment of outcomes via retrospective database. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections.* 2006; 12(4).
283. **Brixner DI, Oderda GM, Roland CL, Rublee DA.** Opioid expenditures and utilization in the Medicaid system. *Journal of Pain and Palliative Care Pharmacotherapy.* 2006; 20(1):5-13.

284. **LaFleur J**, McBeth C, Gunning K, Oderda L, Steinvoot C, **Oderda GM**. A Pharmacist-Run Drug Regimen Review Center: Prevalence of Drug-Related Problems among Medicaid High Utilizers. *Journal of Managed-Care Pharmacy*. 2006 Oct; 12(8):677-85.
285. Creekmore FM, **Oderda GM**, Pendleton RC, **Brixner DI**. Incidence and Economic Implications of Heparin-Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism. *Pharmacotherapy*. 2006 Oct; 26(10):1438-45.
286. **Joish VN**, Brady E, Stockdale WA, **Brixner DI**, Dirani R. Evaluating diagnosis and treatment patterns of COPD in primary care. *Treatments in Respiratory Medicine*. 2006 Aug; 5(4):283-93.
287. **LaFleur J**, Thompson C, **Joish VN**, Charland SL, **Oderda GM**, **Brixner DI**. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. *Annals of Pharmacotherapy*. 2006 Jul/Aug; 40(7-8):1274-9.
288. **Brixner DI**. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. *Am J Managed Care*. 2006 May; 12(Suppl 7):S191-8. Erratum in *Am J Manag Care*. 2006 Jul; 12(7):370.
289. **Brixner DI**. The case against excessive cost sharing. *American Journal of Managed Care*. 2006 Apr; 12(6 Suppl):S162-4; discussion S167-72; quiz S173-6.
290. **Brixner DI**, **Said Q**, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, **Oderda GM**. Naturalistic impact of second-generation antipsychotics on weight gain. *The Annals of Pharmacotherapy*. 2006 Apr; 40(4):626-32.
291. **Jackson KC**. Pharmacotherapy for neuropathic pain. *Pain Pract*. 2006 Mar; 6(1):27-33. Review.
292. **Brixner DI**, **Oderda GM**, **Nickman NA**, Beveridge R, Vermulen L, Jorgenson J. Documentation of chemotherapy infusion preparation costs in academic and community-based oncology practices. *Journal of the National Comprehensive Cancer Network*. 2006 Mar; 4(3):197-208.
293. Sbarbaro J, Nicolau D, **Asche CV**. Management of community-acquired respiratory tract infections in an era of increasing antibiotic resistance. *Pharmacy and Therapeutics*. 2006 Feb; 31(2):106-111.

2005

294. **Biskupiak, JE**, Korner E. Assessing the value of hospice care: Is documentation of cost savings necessary? *Journal of Pain and Palliative Care Pharmacotherapy*. 2005; 19(4):61-5.
295. **Asche CV**. Outcomes and economics in pain and palliative care Explicit mention of outcomes in prescribing information. *Journal of Pain and Palliative Care Pharmacotherapy*. 2005; 19(2):45-47.

296. **Joish VN, Oderda GM.** Understanding cost-utility analysis and its application. *Journal of Pain and Palliative Care Pharmacotherapy*. 2005; 19(1):57-61.
297. Gerbino PP, **Brixner DI**, Sbarbaro J, Nicolau D. Appropriate antibiotic therapy for community-acquired respiratory tract infections. *Managed Care Interface*. 2005 Dec; 18(12):41-8.
298. Trost LF III, Wender RC, Suter CC, Von Worley AM, **Brixner DI**, Rosenberg JH, Gunter MJ. National Epilepsy Panel. Management of epilepsy in adults. Treatment guidelines. *Postgraduate Medicine*. 2005 Dec; 118(6):29-33.
299. Trost LF III, Wender RC, Suter CC, Rosenberg JH, **Brixner DI**, Von Worley AM, Gunter MJ. National Epilepsy Panel. Management of epilepsy in adults. Diagnosis guidelines. *Postgraduate Medicine*. 2005 Dec; 118(6):22-6.
300. **Brixner DI, Ho MJ.** Clinical, humanistic, and economic outcomes of gout. *American Journal of Managed Care*. 2005 Nov; 11(15Suppl):S459-64.
301. **LaFleur J.** Evaluating the Relationship between treatment and costs-measuring the atom with a yard-stick? *Journal of Managed Care Pharmacy*. 2005 Sep; 11(7):588-589.
302. **Brixner DI.** Improving acute otitis media outcomes through proper antibiotic use and adherence. *The American Journal of Managed Car*. 2005 Aug; 11(6Suppl):S201-10.
303. **Brixner DI.** Managing the continuum of treatment: modeling the economic impact of treating Diabetes. *Journal of Managed Care Pharmacy*. 2005 Aug; 11(6, S-b):S19-S22.
304. **LaFleur J**, Thompson C, Ho M, Stockdale W, Charland SL, **Oderda G, Brixner DI.** Cost analysis of combination vs. single dosage lipid lowering. *Hospital Formulary*. 2005 Jul; 40(7):233-234.
305. **Asche CV, Oderda G, Brixner D.** Has the cost-effectiveness of Xolair® (omalizumab) been underestimated? *The Journal of Allergy and Clinical Immunology*. 2005 May; 115(5):1095; author reply 1095-6.
306. **Joish VN**, Malone DC, Wendel C, Draugalis JR, Mohler MJ. Development and validation of a diabetes severity index (DSI) LA risk adjustment tool for predicting healthcare resource use and costs. *Pharmacotherapy*. 2005 May; 25(5):676-84.
307. Halpern MT, Schmier JK, Snyder LM, **Asche CV**, Sarocco P, Nieman R, Lavin B, Mandell L. Meta-analysis of bacterial resistance to macrolides. *Journal of Antimicrobial Chemotherapy*. 2005 May; 55(5):748-57.
308. **Joish VN**, Donaldson G, Stockdale WA, **Oderda GM**, Crawley J, Sasane R, Joshua-Gotlib S, **Brixner DI.** Economic impact of GERD and PUD: examination of direct and indirect costs due to worker absenteeism using a large integrated patient database. *Current Medical Research and Opinion*. 2005 Apr; 21(4):535-44.

309. Sullivan PW, Valuck R, **Brixner DI**, Armstrong EP. A pharmacoeconomic model for making value-based decisions about serotonin reuptake inhibitors. *Pharmacy and Therapeutics*. 2005 Feb; 30(2):96-106.
310. **Ho MJ, Joish VN, Biskupiak J**. The role of pharmacoeconomics in formulary management: Triptan Case Study for Migraine. *Pharmacy and Therapeutics*. 2005 Jan; 30(1):36-46.
311. McWhorter L, **Oderda GM**. Providing diabetes education and care to underserved patients in a collaborative practice at the Utah community health center. *Pharmacotherapy*. 2005 Jan; 25(1):96-109.

2004

312. **Brixner DI**. Standardizing managed care formulary submissions: the AMCP format. *Managed Care*. 2004; 13(5):14-17.
313. **Ho MJ, Biskupiak J**. Would Depression Management Relieve Pain and Improve Function? *Journal of Pain and Palliative Care Pharmacotherapy*. 2004; 18(4):81-87.
314. **LaFleur J, Oderda G**. Methods to measure Patient Compliance with Medication Regimens. *Journal of Pain and Palliative Care Pharmacotherapy*. 2004; 18(3):81-7.
315. **Ho MJ, LaFleur J**. The Treatment Outcomes of Pain Survey (TOPS): A Clinical Monitoring and Outcomes Instrument for Chronic Pain Practice and Research. *Journal of Pain Palliative Care Pharmacotherapy*. 2004; 18(2):49-59.
316. **Joish VN, Brixner DI**. Back pain and productivity: measuring worker productivity from an employer's perspective. *Journal of Pain and Palliative Care Pharmacotherapy*, 2004; 18(2):79-85.
317. Gunter MJ, Worley AV, Carter S, Gregory C, **Brixner DI**. Impact of a seizure disorder disease management program on patient-reported quality of life. *Disease Management Journal*. 2004 Winter; 7(4):333-347.
318. **Brixner DI**. Clinical and economic outcomes in the treatment of lower respiratory tract infections. *The American Journal of Managed Care*. 2004 Oct; 10(12):S400-407.
319. Kane S, Borisov NN, **Brixner DI**. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. *The American Journal of Managed Care*. 2004 Aug; 10(7):S216-226.
320. Brandes JL, **Brixner DI**. Migraine Matters: The role of triptans in relieving the burden in management care. *Journal of Managed Care Pharmacy*. 2004 Aug; 10(4, S-b):S2-12.

321. Briggs DD, **Brixner DI**, Cannon HE, George DL. Overview of chronic obstructive pulmonary disease: new approaches to patient management in managed care systems. *Journal of Managed Care Pharmacy*. 2004 Jul; 10(4, S-a):S2-10.
322. Young D, Bleyl K, Clark T, **Oderda G**, Liou T. Increasing pneumococcal vaccination rates among adult patients with cystic fibrosis. *American Journal of Health Systems Pharmacists*. 2004 Jul; 61(14):1490-3.
323. **Ho MJ, Joish VN, LaFleur J**, Christensen RL, **Brixner DI**. Pharmacoeconomic Analysis of Oral Triptans. *Formulary*. 2004 Jul; 39:356-357.
324. **Joish VN**, Malone DC, Wendel C, Mohler MJ. Profiling quality of diabetes care in a Veterans Affairs healthcare system. *American Journal of Medical Quality*. 2004 May/Jun; 19(3):112-120.

2003

325. **Oderda GM**. Cost-of-Illness Studies. *Journal of Pain and Palliative Care Pharmacotherapy*. 2003; 17(1):59-62.
326. **Joish VN**, Sahai A. Evaluating the role of confounding in pharmacoeconomic studies. *Managed Care Interface*. 2003 Dec; 16(12):L 30-35.
327. Eppele C, Wright AL, **Joish VN**, Bauer M. The role of the active family nutritional support in Type II diabetes metabolic control. *Diabetes Care*. 2003 Oct; 26(10):2829-34.
328. **Joish VN**, Malone DC, Miller JM. A cost benefit analysis of vision screening methods for preschoolers and school-aged children. *Journal of American Association of Pediatric Ophthalmology & Strabismus*. 2003 Aug; 7(4):283-290; (2004) Letter to the Editor & Reply, *JAAPOS*. 8:74-75.
329. **Oderda G.M.**, Evans R.S., Lloyd J., Lipman A., Chen C., Ashburn M., Burke J., Samore M. Cost of Opioid Related Adverse Drug Events in Surgical Patients. *Journal of Pain and Symptom Management*. 2003 Mar; 25(3):276-83.

2002

330. **Oderda G.M**. The Importance of Perspective in Pharmacoeconomic Analyses. *Journal of Pain Palliative Care Pharmacotherapy*. 2002; 16(4):65-69.
331. **Oderda G.M**. Outcomes Research and Pharmacoeconomics – What it is and what it isn't. *Journal of Pain Palliative Care Pharmacotherapy*. 2002; 16(3):83-91.

2000

332. Vermeulen LC, Windisch PA, Rydman RJ, Bruskiwitz RH, **Brixner DI**, Vlasses PH. Using a Multihospital Systems Framework to Evaluate and Establish Drug use Policy. *Journal of Medical Systems*. 2000; 24(4):235-46.

ABSTRACTS and POSTERS

2017 Abstracts and Posters

1. Cheung A, Brown K, **Tak CR**, Bennett HKW, Malheiro M, Crouch BI. The relationship between health insurance type and choice of non-poison center alternative care by callers of a poison center: Results from 2016 survey. North American Congress of Clinical Toxicology. October 2017. Vancouver, BC, Canada.
2. **Jiao T**, Zhang Y, Liou TG, Stevens V, Young DC, **Brixner DI**. The Optimal Treatment Regime to Delay the Onset of Mucoid Pseudomonas Aeruginosa Pulmonary Infection on Pediatric CF Patients. ISPOR 22ND Annual International Meeting. Boston, MA. May 20-24, 2017. [PODIUM].
3. **Tak CR**, Feehan M, Munger M. Do Stress and Satisfaction Drive Professionalism in PharmD Students? American Association of Colleges of Pharmacy Annual Meeting. July 2017. Nashville, Tennessee.
4. **Tak CR**, **Biltaji E**, Kohlmann W, Maese L, Sherwin CMT, **Brixner DI**, Schiffman J. Early cancer surveillance strategy for patients with Li-Fraumeni Syndrome predicted to be cost-effective using Markov decision modeling. International Society of Pharmacoeconomics and Outcomes Research (ISPOR). May 2017. Boston, MA.

2016 Abstracts and Posters

5. Liu X, **Tak CR**, Sherwin CMT, Shakib JH. Population modeling of the influence of maternal influenza vaccination on infant immunity. American Association of Pharmaceutical Scientists. November 2016. Denver, CO.
6. Liu X, **Tak CR**, Sherwin CMT, Shakib JH. Population modeling of infant immunity and assessment of maternal vaccination benefits. American College of Pharmacometrics. October 2016. Bellevue, WA.
7. Munger MA, Feehan M, **Tak CR**. PharmD students stress, satisfaction, and professional attitudes survey. American Association of Colleges of Pharmacy Annual Meeting. July 2016. Anaheim, CA.
8. Bellows BK, **Tak CR**, Sanders J, Turok D, Schwarz EB. Cost-effectiveness analysis of emergency contraception. North American Forum on Family Planning. June 2016. Denver, CO.
9. **Stenehjem DD**, Tyczynski JE, **Unni SK**, **Bauer H**, **Sainski A**, **Deka R**, **Schauerhamer M**, **Tak C**, **Ma J**, Gutierrez L, Kaye JA, Telford C, **Brixner DI**, **Biskupiak JE**. Increasing germline BRCA testing in breast cancer patients at a NCI designated comprehensive cancer center . BRCA Congress. May 2016. Montreal, Quebec, Canada.
10. **Stenehjem DD**, Telford C, **Unni SK**, **Bauer H**, **Sainski A**, **Deka R**, **Schauerhamer M**, **Ye X**, **Tak C**, **Ma J**, Gutierrez L, Kaye JA, Tyczynski JE, **Brixner DI**, **Biskupiak JE**. Utilization of neoadjuvant chemotherapy in women

with breast cancer tested for BRCA mutations at a NCI designation comprehensive cancer center. BRCA Congress. May 2016. Montreal, Quebec, Canada.

11. Ferreira K, Pippitt K, **Tak C**, Snow K, Gunning K. Improving pneumococcal vaccination rates of diabetic patients with use of a pharmacist workflow within a family medicine residency clinic. Mountain States Conference. May 2016. Salt Lake City, UT.
12. Garcia BJ, Gunning K, **Tak CR**, Diesterhaft K. Implementation of a pharmacy workflow process intended to improve Prevnar-13 immunization rates in patients 65 years and older. Mountain States Conference. May 2016. Salt Lake City, UT.
13. Nyman H, **Jiao T**, Raphael K, Low C, Greene T, Witt D, LaFleur J. Agreement Between CKD-EPI and COCKCROFT-GAULT Equations for Determining Drug Doses in a Hospitalized Population. American Association of Colleges of Pharmacy Annual Meeting 2016. Anaheim, CA. July 23-27, 2016. [POSTER]
14. **Jiao T, Biskupiak J, Ye X, Unni S**, Dowd C, Fink A, Feng L, Erdo J, **Brixner D**. Development of a Linked Database for Cystic Fibrosis Research by Integrating a Patient Registry with Administrative Claims Data. Value in Health 2016. ISPOR 21st Annual International Meeting. Washington, DC. May 21-25, 2016. [POSTER]
15. **Biskupiak J, Unni S, Jiao T, Ye X**, Dowd C, Fink A, Feng L, Erdo J, **Brixner D**. Evaluation of a Linked Database for Cystic Fibrosis Research on Clinical, Demographic and Resource Use Variables. AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016. San Francisco, CA. Apr 19-22, 2016. [POSTER].

2015 Abstracts and Posters

16. **Kuan-Ling Kuo, Diana Brixner, Arthur Lipman**, Man Hung, **Gary Oderda**. Characteristics of Combination Pharmacotherapy in Patients with Diabetic Painful Neuropathy (DPN) ISPOR 20th Annual International Meeting, Philadelphia, PA, USA, May 16- May 20, 2015
17. **Bress A, Biltaji E**, Ye E, Mamiya T, **Biskupiak J, Brixner D**. Characterization of an Elderly Population with Potential for Drug-Gene Interactions to Determine the Value of Pharmacogenetic Risk Screening. To be presented at the 27th Annual Meeting and Expo of the Academy of Managed Care Pharmacy, April 7-10, San Diego, CA
18. **C McAdam-Marx**, H Nguyen, **M Shauerhammer, X Ye, M Singhal**, D Cobden. Real-World 1-Year HbA1c and Weight Outcomes in Patients Treated with Exenatide Once Weekly or Liraglutide Once Daily. American Diabetes Association Scientific Sessions. June 5-9, 2015. Boston MA.
19. **Singhal M**, Nguyen H, **Schauerhamer M, Unni S**, Cobden D, **McAdam-Marx C**. Effect of Daily or Weekly GLP-1 Receptor Agonists on Glycemic Control in Insulin-Naïve Patients with Poorly Controlled Type 2 Diabetes: A Real-World Study. International Society for Pharmacoeconomic and Outcomes Research, Annual Meeting. May 17-20, 2015, Philadelphia, PA.

20. **Unni S, Nguyen N, Schauerhamer M, Ye X, Cobden D, McAdam-Marx C.** Achievement of Glycemic Control and Antidiabetic Therapy Changes in Type 2 Diabetes Patients Initiating Glucagon-like Peptide-1 Receptor Agonist Therapy. Academy of Managed Care Pharmacy Annual Meeting. April 7-10, 2015. San Diego, CA.

2014 Abstracts and Posters

21. **Biksacky M, Crook J, Cheng Y, Knippenberg K, LaFleur J.** Reasons for switching and discontinuing bisphosphonate therapy: A historical chart review of postmenopausal veterans. *495th ASHP Midyear Clinical Meeting and Exhibition*. Anaheim, California. December 2014. [Poster]
22. **Nelson SD, LaFleur J, Del Fiore G, Evans RS, Weir CR.** Research in Progress: Information Seeking by pharmacists in the electronic health record (INSPIRE) study. Murray, Utah. August 2014.
23. **Stenehjem DD, Unni SK, Bauer H, Kuo K-L, Deka R, Brailsford M, Cajacob BC, Balu S, Hirst C, Stevens V, Brixner DI.** BRCA testing patterns and survival in platinum-sensitive recurrent (PSR) ovarian cancer (OC). *J Clin Oncol* [ASCO Meeting Abstracts] 2014 32: e16522. *ASCO Annual Meeting*, Chicago, IL. June 2014. [Abstract]
24. **Stenehjem DD, Bellows BK, Kaldete RR, Jones JT, Siebert U, Brixner DI.** A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis. *J Clin Oncol* [ASCO Meeting Abstracts] 2014 32: e18509. *ASCO Annual Meeting*, Chicago, IL. June 2014. [Abstract]
25. **Nelson S, Willson T, LaFleur J.** Where do Veterans receive their care for non-traumatic bone fractures? *Value in Health 2014. ISPOR 19th Annual International Meeting*. Montreal, Canada May 31-June 4, 2014. [Poster]
26. **Bellows B, LaFleur J, Kamauu AWC, Pawaskar M, Supina D, Babcock T, DuVall SL.** Healthcare costs of patients with binge eating disorder compared to patients with eating disorder not otherwise specified and no eating disorder. *Value in Health 2014. ISPOR 19th Annual International Meeting*. Montreal, Canada May 31-June 4, 2014. [Poster]
27. **Nelson S, Malone D, LaFleur J.** Calculating the baseline fracture incidence in non-risk patients: A strategy for cost-effectiveness modeling. *Value in Health 2014. ISPOR 19th Annual International Meeting*. Montreal, Canada May 31-June 4, 2014. [Poster]

28. **Biltaji E**, Varier RU, Smith KJ, Roberts MS, **LaFleur J**, Nelson RE. Cost-effectiveness analysis of treatment strategies for initial clostridium difficile infection. *Value in Health 2014. ISPOR 19th Annual International Meeting*. Montreal, Canada May 31-June 4, 2014. [Poster]
29. **Stenehjem DD, Bellows BK**, Kaldate RR, Jones J, Siebert U, **Brixner D**. Cost-Effectiveness of Using a Prognostic Test to Guide Treatment Decisions in Early Stage Non-Small Cell Lung Cancer (NSCLC). *Value in Health*. 2014 17: A89. *ISPOR 19th Annual International Meeting*. Montreal, Canada May 31-June 4, 2014. [Poster]
30. **Kuo KL, Stenehjem DD**, Kluibenschaedl M, Rochau U, **Brixner D**. Quality of Life Outcomes of the United States Chronic Myeloid Leukemia (CML) Patients. *Value in Health*. 2014 17: A92–A93. *ISPOR 19th Annual International Meeting*. Montreal, Canada May 31-June 4, 2014. [Poster]
31. Varier RU, **Biltaji E**, Roberts MS, Smith KJ, **LaFleur J**, Nelson RE. Cost-effectiveness analysis of fecal microbiota transplantation versus vancomycin for recurrent Clostridium difficile infection. *Digestive Disease Week*. Chicago, IL. 2014 May. [Poster]
32. **Stevens V**, Korgenski EK, Wilkes J, Pavia AT. Patterns and Outcomes of Treatment in Pediatric Patients with Clostridium difficile Infection. *Pediatric Academic Societies*. Vancouver, Canada. 2014 May. [Poster]
33. **Bellows BK, LaFleur J**, Kamauu AWC, Supina D, Hodgkins P, **Duvall SL**. Characteristics of patients with BED compared to patients with EDNOS and patients without eating disorder. *American Psychiatric Association 167th Annual Meeting*. New York, NY. 2014 May. [Poster Presentation]
34. **Biltaji E, Singhal M, Kuo K, McAddam-Marx C**, Stoddard G, **LaFleur J**. Risk of hypoglycemia associated with different insulin delivery systems in Type I diabetes Mellitus: A meta-analysis. *9th Annual Utah Health Services Research Conference*. Salt Lake City, Utah. April 2014. [Poster]
35. Shane-McWhorter L. **McAdam-Marx C. Deka R**. Pharmacist-Provided Diabetes Education and Care Via Telemonitoring: The Utah Remote Monitoring Project. *9th Annual Utah Health Services Research Conference*. April 30, 2014. Salt Lake City, UT [Poster]
36. **Stenehjem DD, Jaio T, Brixner DI**. Economic analysis of alternative genetic tests for BRCA1 and BRCA2 mutations. *31st Miami Breast Cancer Conference*. Miami, FL. 2014 Mar. [Poster]

37. Tantravahi SK, **Stenehjem DD**, Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D, Wang J, Liu T, Agarwal N. Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC). *Genitourinary Cancers Symposium*. San Francisco, CA. 2014 Jan. [Poster]
38. Parikh K, **Stenehjem DD**, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Tantravahi SK, Agarwal N. Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2). *Genitourinary Cancers Symposium*. San Francisco, CA. 2014 Jan-Feb. [Poster]
39. Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sageser D, Grossmann K, Tantravahi SK, **Stenehjem DD**, Agarwal N. The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2). *Genitourinary Cancers Symposium*. San Francisco, CA. 2014 Jan-Feb. [Poster Presentation]
40. Agarwal N, Parikh K, Tantravahi SK, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, **Stenehjem DD**. Clinical benefit (CB) of high dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). *Genitourinary Cancers Symposium*. San Francisco, CA. 2014 Jan-Feb. [Poster]
41. **Stenehjem DD**, Parikh K, Batten JA, VanAtta J, Crispin H, Sagesser D, Grossmann K, Tantravahi SK, Samlowski W, Agarwal N. Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). *Genitourinary Cancers Symposium*. San Francisco, CA. 2014 Jan-Feb. [Poster Presentation]
42. **LaFleur J**, Steenhoek CL, Horne J, Meier J, Mambourg S, Nebeker JE, Swislocki A, Carmichael J. Comparing fracture absolute risk assessment tools: An osteoporosis clinical informatics tool to improve identification and care of males at high risk of first fracture. *American Federation for Medical Research Western Regional Meeting*. Carmel, CA. 2014 Jan. [Poster]

2013 Abstracts and Posters

43. Spence B, **McAdam-Marx C**, Mullins S, Choudhary K. Association Between Clinically Aligned Pain Assessment and Opioid Use Compared to a Numeric Rating Scale Pain Assessment in Hospitalized Patients. *American Society of Hospital Pharmacist Mid-Year Meeting*. Orlando, FL. 2013 Dec. [Poster]

44. Wong R, **McAdam-Marx C**, **Bellows B**. Cost-effectiveness of lorcaserin in treating overweight or obese patients with type 2 diabetes. *American Society of Hospital Pharmacist Mid-Year Meeting*. Orlando, FL. 2013 Dec. [Poster]
45. Winter B, Turner K, **McAdam-Marx C**, **Biltaji E**, Gunning K. Survey of smoking cessation practices among pharmacists. *American Society of Hospital Pharmacist Mid-Year Meeting*. Orlando, FL. 2013 Dec. [Poster]
46. Tran E, Jennings B, **Singhal M**. A multidisciplinary team approach to patient care at a free community health clinic: the role of pharmacy on improving patient outcomes. *American Society of Hospital Pharmacist Mid-Year Meeting*. Orlando, FL. 2013 Dec. [Poster]
47. **Brixner DI**, Mavros P, **Goodman M**, **Unni S**, **Ye X**. Prevalence Of Hypertension And Extent Of Blood Pressure Control In Patients With Chronic Kidney Disease: Evidence From Ambulatory Care Data In The US. *American Heart Association Scientific Sessions*. Dallas, TX. 2013 Nov. [Poster]
48. Hamilton M, **Biskupiak J**, **Brixner DI**, Xianying P, Xianchen L, **Ghate S**. Oral Anticoagulant Discontinuation in Patients with Nonvalvular Atrial Fibrillation and Cardiac Surgery. *American Heart Association Scientific Sessions*. Dallas, TX. 2013 Nov. [Poster]
49. **Biskupiak J**, **Ghate S**, **Singhal M**, Marrouche N. Cost Minimization Analysis of Selective Ablation compared to Ablating All Atrial Fibrillation Patients Using DECAAF Trial Data. *American Heart Association Scientific Sessions*. Dallas, TX. 2013 Nov. [Podium Presentation]
50. **Stevens V**, **Yoo M**, Brown J. Cost and Length of Stay Associated with Vancomycin-Induced Nephrotoxicity. *ISPOR 16th Annual European Congress*. Dublin, Ireland. 2013 Nov. [Poster]
51. **Jiao T**, Liou TG, Young D, **Brixner DI**. A Comparison of Demographic and Clinical Variables of Down Syndrome Patients in Utah and the United States. *ISPOR 16th Annual European Congress*. Dublin, Ireland. 2013 Nov. [Poster]
52. **Udomaksorn S**, **Stenehjem D**, Welch B, **Cheng Y**, Anderson L, Colonna S, Neumayer L, **Brixner DI**. Evaluation of Variable Relevance and Accessibility to Support Personalized Medicine in Breast Cancer. *ISPOR 16th Annual European Congress*. Dublin, Ireland. 2013 Nov. [Poster]

53. Schall I, **Saverno K**, Luzak A, Mitrovic M, Gothe H, **Brixner D**, Siebert U. The Impact of Generic Substitution on Health Outcomes and Costs: A Systematic Review. *ISPOR 16th Annual European Congress*. Dublin, Ireland. 2013 Nov. [Poster]
54. **Stenehjem D**, Yoo M, Unni S, Singhal M, Bauer H, **Savarno K**, Quaah C, Masaquel A, **Brixner DI**. Assessment of Single-institution HER2 Testing Patterns, Rate of HER2+ Disease and Utilization of Trastuzumab in Early Breast Cancer. *ASCO's Quality Care Symposium*. San Diego, CA. 2013 Nov. [Poster]
55. Turner K, Gurgle H, Hardcastle A, **McAdam-Marx C**. Assessment of student pharmacist experience at an interprofessional student-run free clinic. *American College of Clinical Pharmacy Annual Meeting*. Albuquerque, NM. 2013 Oct. [Poster]
56. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Conrads-Frank A, **Stenehjem D**, **Brixner DI**, Radich J, Gastl G, Siebert U. Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. *Society of Medical Decision Making 35th Annual Meeting*. Baltimore, MD. 2013 Oct.[Poster]
57. **LaFleur J**, **DuVall S**, Curtis JR, Adler RA, **Willson T**, Agodoa I, Stolshek B, and Nelson RE. Association between Bisphosphonate Switching Behavior and Cost Outcomes in Postmenopausal United States Veterans. *American College of Rheumatology Annual Meeting*. San Diego, CA. 2013 Oct. [Poster]
58. **LaFleur J**, Ginter T, Curtis J, Adler R, Agodoa I, Stolshek B, and Nelson R, **DuVall S**. A novel method for obtaining bone mineral densities from a dataset of radiology reports and clinic notes: Natural language processing in a national cohort of postmenopausal veterans. *ASBMR Annual Meeting*. Baltimore, MA. 2013 Oct. [Poster]
59. **McAdam-Marx C**, **Dahal A**, Jennings B, **Singhal M**, Gunning K. Evaluation of Clinical Outcomes Associated with a Pharmacist-Coordinated Diabetes Chronic Care Management Program. *AMCP 2013 Educational Conference*. San Antonio, TX. 2013 Oct.
60. **Dahal A**, **Bellows BK**, **Stenehjem D**, **Brixner D**. An empirical assessment of non-small cell lung cancer charges by survival. *Eur J Cancer*. 2013; 49(Suppl 2):341. *European Cancer Congress*. Amsterdam, Netherlands. 2013 Sep. [Poster]
61. **Bellows BK**, **Dahal A**, **Stenehjem D**, **Brixner D**. The impact of survival on ovarian and non-ovarian cancer-specific health care charges during ovarian cancer treatment. *Eur J Cancer*. 2013; 49(Suppl 2):248. *European Cancer Congress*. Amsterdam, Netherlands. 2013 Sep. [Poster]

62. **Stenehjem DD, Cai B, Kuo K**, Martel M, Ray S, McLaughlin T, **Brixner D**. Treatment patterns and survival in patients with metastatic brain tumors. *European Cancer Congress*. Amsterdam, Netherlands. 2013 Sep. [Poster]
63. **Bellows BK, DuVall SL**, Ginter T, Kamauu AWC, Supina D, Hodgkins P, Erder H, **LaFleur J**. Using natural language processing to identify US veterans with binge eating disorder. *Pharmacoepidemiol Drug Saf*. 2013; 22(Suppl 1):287. *International Conference on Pharmacoepidemiology (ICPE) 29th Annual Meeting*. Montreal, Canada. 2013 Aug. [Poster] *Included on Database Special Interest Group Poster Walk.
64. Nelson RE, Xie Y, **DuVall SL**, Butler J, Kamauu AWC, Schuerch M, Foskett N, **LaFleur J**. Multiple sclerosis subtypes and serious infections resulting in a hospitalization in the Veterans Health Administration. *International Conference on Pharmacoepidemiology (ICPE) 29th Annual Meeting*. Montreal, Canada. 2013 Aug. [Poster]
65. **DuVall SL**, Butler J, **LaFleur J**, Kamauu AWC, Schuerch M, Foskett N, Nelson RE. Determining multiple sclerosis subtype from electronic medical records. *International Conference on Pharmacoepidemiology (ICPE) 29th Annual Meeting*. Montreal, Canada. 2013 Aug. [Poster]
66. Rochau U, Kallinger S, Schmidt S, **Savernio K**, Holzner B, Schwarzer R, Arvandi M, **Brixner DI**, Gastl G, Siebert U. Cross-sectional Pilot Study to Assess the Quality of Life of Chronic Myeloid Leukemia Patients in Innsbruck Using the EQ-5D. *16th Academic Conference of the Austrian Society of Public Health*. St. Pollen, Austria. 2013 Jun. [Poster]
67. **McAdam-Marx C, Bellows B**, Wygant G, Mukherjee J, **Unni S, Ye X**, Liberman JN, Iloeje U, **Brixner DI**. Association of >5% Weight Loss and Self-Reported Adherence with 6-Month Glycemic Control in Type 2 Diabetes Mellitus (T2DM): the DELTA Study. *American Diabetes Association's 73th Scientific Sessions*. Chicago, IL. 2013 Jun. [Poster]
68. Concannon C, van Wijngaarden E, **Stevens V**, Thevenet-Morrison K, Dumyati G. The Effect of Multiple Concurrent Central Venous Catheters on Central Line Associated Bloodstream Infections. *40th Annual Conference of the Association for Professionals in Infection Control*. Ft. Lauderdale, FL. 2013 Jun. [Poster]
69. **Stenehjem DD, Dahal A, Bellows BK, Brixner DI**. An empirical assessment of breast cancer treatment charges by survival status. *J Clin Oncol*. 2013 May; 31(15_suppl):e11541. *ASCO Annual Meeting Proceedings*. [Printed Abstract]

70. **Brixner DI, Bellows BK, Dahal A, Stenehjem DD.** Impact of survival on health care charges during melanoma treatment. *J Clin Oncol.* 2013 May; 31(15_suppl):e20043. *ASCO Annual Meeting Proceedings.* [Printed Abstract]
71. **Dahal A, Bellows BK,** Sonpavde G, Galsky MD, Agarwal N. Incidence of severe nephrotoxicity with cisplatin vs. non-cisplatin regimens: a meta-analysis with sub-group analyses based on renal eligibility criteria. *J Clin Oncol.* 2013 May; 31(15_suppl):e15549. *ASCO Annual Meeting Proceedings.* [Printed Abstract]
72. **Bellows BK, Dahal A,** Galsky MD, Sonpavde G, Agarwal N. Incidence of neurotoxicity and ototoxicity with cisplatin vs. non-cisplatin regimens: a meta-analysis with subgroup analyses based on renal eligibility criteria. *ASCO Annual Meeting Proceedings.* [Printed Abstract]
73. **Nickman N, Ye X,** Gaffney D, Barney R, **Biskupiak J,** Okano G, Lee V, Arellano J. Cost of palliative external beam radiotherapy (EBRT) utilization for bone metastases secondary to prostate cancer (PC). *Journal of Clinical Oncology.* 2013 May; 31(15_suppl): e160912013. *ASCO Annual Meeting Proceedings.* [Printed Abstract]
74. **Bellows BK, Dahal A,** Agarwal N. Risk of death at one year in patients with non-small cell lung cancer (NSCLC) treated with cisplatin regimens: an indirect comparison meta-analysis based on renal eligibility criteria. *Value Health.* 2013 May; 16(3):A131. *ISPOR 18th Annual International Meeting.* New Orleans, LA. 2013 May. [Poster]
75. **Dahal A, Bellows BK,** Sonpavde G, Galsky M, Agarwal N. Meta-analysis of nephrotoxicity in patients with solid tumors treated with cisplatin versus non-cisplatin regimens with sub-group analyses based on renal eligibility criteria. *Value Health.* 2013 May; 16(3):A127. *ISPOR 18th Annual International Meeting.* New Orleans, LA. 2013 May. [Poster]
76. **McAdam-Marx C, Bellows B,** Wygant G, Mukherjee J, **Unni S, YeX,** Iloeji U, **Brixner DI.** Associations Between Claims Based Adherence, Weight Loss and Glycemic Control in Patients with Type 2 Diabetes. *ISPOR 18th Annual International Meeting.* New Orleans, LA. 2013 May. [Poster]
77. Xie Y, **LaFleur J,** Kamauu A, Schuerch M, Foskett N, Nelson RE. Multiple sclerosis early treatment rates in US veterans. *ISPOR 18th Annual International Meeting.* New Orleans, LA. 2013 May. [Poster]
78. Nelson RE, Xie Y, Kamauu A, Schuerch M, Foskett N, **LaFleur J.** Multiple sclerosis increases the risk of infections resulting in a hospitalization among United States veterans. *ISPOR 18th Annual International Meeting.* New Orleans, LA. 2013 May. [Poster]

79. Xie Y, **LaFleur J**, Kamauu A, Schuerch M, Foskett N, Nelson RE. Multiple sclerosis early treatment rates in US veterans. *ISPOR 18th Annual International Meeting*. New Orleans, LA. 2013 May. [Poster]
80. Welch B, **Udomaksorn S**, **Cheng Y**, **Stenehjem D**, Colonna S, Kawamoto K, **Brixner DI**. Desired Attributes for a Point-of-Care Breast Cancer Clinical Dashboard Supporting Personalized Health Care. *Cleveland Clinic Personalized Healthcare Summit*. Cleveland, OH. 2013 May. [Poster]
81. Chen S, Lee Y, Alas V, Angalakuditi M, **Brixner DI**. Prevalence of Undiagnosed Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus. *National Kidney Foundation Spring Meeting*. Orlando, FL. 2013 Apr. [Poster]
82. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, **Brixner DI**, Gastl G, Radich J, Siebert U. Choosing a Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia under The Uncertainty of Long-term Effectiveness and Safety. *Evidence Based Medicine Conference*. Berlin, Germany. 2013 Mar. [Poster]
83. **Singhal M**, Corbett ST, **Bellow BK**, **Biskupiak J**. Frequency of INR measurements, every six weeks vs. three times per year, and the risk of stroke: a cost-effectiveness analysis. *Western Pharmacoeconomics Conference*. Tucson, AZ. 2013 Mar. [Podium Presentation]
84. **Jiao T**, **Goodman M**, **Brixner DI**. Are Utah and United States Down Syndrome Patients Different? *Western Pharmacoeconomics Conference*. Tucson, AZ. 2013 Mar. [Poster]
85. **LaFleur J**, **Willson T**, Hayden C., Adler RA, Nebeker JR. Validation of a fracture risk rule using computerized data to identify veterans at high risk for fracture. *Western Pharmacoeconomics Conference*. Tucson, AZ. 2013 Mar. [Podium Presentation]
86. **Cheng Y**, **Lafleur J**. Association between Sunlight Exposure and Risk of Breast Cancer: A Meta-analysis Systematic Review. *Western Pharmacoeconomics Conference*. Tucson, AZ. 2013 Mar. [Poster]
87. **Dahal A**, **Bellows BK**, Sonpavde G, Galsky M, Agarwal N. Cisplatin-associated nephrotoxicity in clinical trials using serum creatinine (SCr) versus calculated glomerular filtration rate (GFR) as inclusion criterion: A meta-analysis. *J Clin Oncol*. 2013 May; 31(6_suppl):272. *American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium*. 2013 Feb. [Poster]

2012 Abstracts

88. **DuVall SL**, Nebeker JR. VA Informatics and Computing Infrastructure (VINCI). *University of Maryland, Baltimore County Center for Hybrid Multicore Productivity Research (CHMPR) Semi-Annual Industry Advisory Board Meeting*. Baltimore, MD. 2012 Dec. [Poster]
89. Schmier J, Cifaldi MA, Shaw JW, Halpern MT, **Nickman NA**. Hospital infusion center costs for anti-tumor necrosis factor agents. *ASHP 47th Annual Midyear Clinical Meeting and Exhibition*. Las Vegas NV. 2012 Dec. [Poster]
90. Onufrak N, **Stevens V**, Forrest A, Brown J. Association between Vancomycin AUC₂₄/MIC and Attainment and Time-to-Clinical Cure among Patients with Enterococcal Bloodstream Infections. *ASHP 47th Annual Midyear Clinical Meeting and Exhibition*. Las Vegas NV. 2012 Dec. [Poster]
91. Coon S, **Stevens V**, Brown J, Wrobel M. (December 4, 2012). Comparison of product knowledge and confidence between pharmacists and health food store employees. *ASHP 47th Annual Midyear Clinical Meeting and Exhibition*. Las Vegas NV. 2012 Dec. [Poster]
92. Bossard W, Brown J, Albanese N, Slazak E, **Stevens V**. Anti-diabetic Agents and the Risk of Clostridium Difficile Infections. *ASHP 47th Annual Midyear Clinical Meeting*. Las Vegas NV. 2012 Dec. [Poster]
93. Patterson OV, **DuVall SL**. Advanced Concept Mapping to RadLex using the MetaMap Engine. *RSNA Scientific Assembly and Annual Meeting*. Chicago, IL. 2012 Nov. [Poster]
94. Potter JM, Halls CH, Malohi BK, **DuVall SL**. Project Management and Coordination: Selecting Communication Tools for Multi-Site, Multidisciplinary Collaboration. *American Medical Informatics Association (AMIA) Annual Symposium*. Chicago, IL. 2012 Nov. [Poster]
95. Cornia R, Patterson OV, **DuVall SL**. JMX Analysis Module: Multi-thread aggregate NLP performance monitoring. *American Medical Informatics Association (AMIA) Annual Symposium*. Chicago, IL. 2012 Nov. [Poster]
96. Forbush TB, Adams B, Shen S, South BR, Nebeker JR, **DuVall SL**. CASPR: Friendly Annotation Management. *American Medical Informatics Association (AMIA) Annual Symposium*. Chicago, IL. 2012 Nov. [Poster]
97. Suo Y, Shen S, **DuVall SL**, Uzuner O, South BR. Evaluation and Visualization of Human Annotator Learning Patterns. *American Medical Informatics Association Annual Symposium*. Chicago, IL. 2012 Nov. [Poster]

98. Baddley J, Yang S, Brizendine K, **DuVall SL**, Winthrop KL, Burton MJ, Patkar NM, Delzell ES, Safford MM, Singh JA, Navarro IE, Cannon GW, Mikuls TR, Chen L, Saag KG, Alexander K, Napalkov P, Kamauu AWC, Curtis JR. Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy. *ACR/ARHP Annual Scientific Meeting*. Washington, DC. 2012 Nov. [Poster]
99. Navarro-Millan I, Yang S, **DuVall SL**, Chen L, Baddley J, Cannon GW, Delzell ES, Zhang J, Safford MM, Patkar NM, Mikuls TR, Singh JA, Curtis J. Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration. *ACR/ARHP Annual Scientific Meeting*. Washington, DC. 2012 Nov. [Poster]
100. Kerr GS, Richards JS, Nunziato CA, Patterson OV, **DuVall SL**, Maron DD, Amdur RL. Natural Language Processing in the Evaluation of Gout Quality Indicators. *ACR/ARHP Annual Scientific Meeting*. Washington, DC. 2012 Nov. [Poster]
101. **McAdam-Marx C, Bellows B**, Wygant G, Mukherjee J, **Unni S, Ye X**, Liberman J, Lloje U, **Brixner D**. Association of a $\geq 3\%$ loss of body weight and self-reported adherence with glycemic control at 6 months after initiating new anti-diabetic therapy in patients with type 2 diabetes (T2DM) – the DELTA Study. *The Conference on Diabetes and Hypertension Europe (CODHy EU)*. Barcelona, Spain. 2012 Nov. [Poster]
102. **McAdam-Marx C, Bellows B**, Wygant G, Mukherjee J, **Unni S, Ye X, Brixner DI**, Lloje U. Weight Loss of $\geq 3\%$ of Body Weight After Initiating New Anti-diabetic Therapy is Associated With Glycemic Control at 6 Months in Patients With Type 2 Diabetes. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
103. **Saokaew S, Cai B, Kuo K, Bauer H, Albright F, Brixner DI, Stenehjem D**. Treatment Patterns and Outcomes of Breast Cancer Patients in a Patient-centered Retrospective Research Registry. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
104. **Cai B, Saokaew S, Stenehjem D, Kuo K, Bauer H, Albright F, Brixner DI**. Treatment Pattern and Outcomes of Ovarian Cancer Patients in a Patient-Centered Retrospective Research Registry. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
105. **Kuo K, Saokaew S, Cai B, Bauer H, Albright F, Brixner DI, Stenehjem D**. Treatment Patterns and Outcomes of Melanoma Patients in a Patient Centered Retrospective Research Registry. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]

106. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, **Saverno K, Brixner DI**, Gastl G, Radich J, Siebert U. Decision-analytic Model for the First-line Therapy of Chronic Myeloid Leukemia. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
107. Rochau U, Kallinger S, Schmidt S, **Saverno K**, Holzner B, Schwarzer R, Arvandi M, **Brixner DI**, Gastl G, Siebert U. Quality of Life Assessment of Chronic Myeloid Leukemia Patients in Austria: Cross-Sectional Pilot Study Using the EQ-5D. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
108. Jahn B, **Stenehjem D, Saverno K**, Rochau U, **Cai B**, Siebert U, **Brixner DI**. Application of Real World Data to Inform a Breast Cancer Decision-analytic Model in Austria and the U.S. – Preliminary Outcomes of Data Collection. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
109. **Brixner DI**, Lising A, Gothe H, Haussler B, Dragovich C. Supporting Payers with Collaborative HTA Tools in Making Evidence-based Decisions: The U.S. Experience and International Needs in Europe and Globally. *ISPOR 15th Annual European Congress*. Berlin, Germany. 2012 Nov. [Poster]
110. Hamilton M, Liu X, **Brixner DI, Biskupiak J**. Utilization Patterns of Anticoagulants in Non-Valvular Atrial Fibrillation after the entry of Novel Oral Anticoagulants in the United States. *American Heart Association*. Los Angeles, CA. 2012 Nov. [Poster]
111. **McAdam-Marx C**, Jennings BT, **Dahal A**, Gunning K. Pharmacist-led diabetes chronic care management program improves glycemic control without increasing costs in patients with uncontrolled type 2 diabetes. *American College of Clinical Pharmacy Annual Meeting*. Hollywood, FL. 2012 Oct. [Poster]
112. **McAdam-Marx C**, Jennings BT, **Dahal A**, Gunning K. Pharmacist-led diabetes collaborative drug therapy management program improves glycemic control in patients with uncontrolled type 2 diabetes treated with insulin. *American College of Clinical Pharmacy Annual Meeting*. Hollywood, FL. 2012 Oct. [Poster]
113. Jahn B, **Stenehjem D, Saverno K, Cai B**, Siebert U, **Brixner DI**. Preliminary Outcomes Towards a Risk-Based Microsimulation Decision-Model based on Treatment and Cost Inputs From a Real World Cohort of Breast Cancer Patients. *34th Annual Meeting of the Society for Medical Decision Making*. Phoenix, AZ. 2012 Oct. [Poster]

114. **Stenehjem D, Kuo K, Bauer H, Barney R, Albright F, Brixner DI.** Outcomes and treatment patterns of hepatocellular carcinoma patients stratified by staging-guided treatment categories in a patient-centered retrospective research registry. *ISPOR 5th Asia-Pacific Conference*. Taipei, Taiwan. 2012 Sep. [Poster]
115. **Stenehjem D, Albright F, Guo A, Chen L, Raimundo K, Bauer H, Brixner DI.** Assessing real-world response monitoring and tolerability of imatinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP) and a chart review analysis of monitoring and patterns of treatment switching in patients with chronic myeloid leukemia in chronic phase (CML-CP) on imatinib. *14th International Conference CML- Biology and Therapy*. Baltimore, MD. 2012 Sep. [Poster]
116. Marcus RL, **Ghate S, Brixner DI, LaStayo P.** Relative Sarcopenia and Not Absolute Sarcopenia Impacts Physical Performance in Non-Obese Older Adults. *The Gerontological Society of America*. Albuquerque, NM. 2012 Jul. [Poster]
117. **Saverno K, Rochau U, Schmidt S, Stenehjem D, Kallinger S, Gastl G, Brixner DI, Siebert U.** Comparison of Chronic Myeloid Leukemia Registries in Austria and Utah, USA. *9th Annual Meeting of Health Technology Assessment International*. Bilbao, Spain. 2012 Jun. [Poster]
118. **Oderda G, Holtorf AP, Brixner DI.** Health Economic and Outcomes Research (HEOR) Evidence in Health Technology Assessment (HTA) for Drug Formulary and Reimbursement Decisions across Global Regions. *9th Annual Meeting of Health Technology Assessment International*. Bilbao, Spain. 2012 Jun. [Poster]
119. **Bellows BK, Ye X, Unni S, Mukherjee J, Iloeje U, McAdam-Marx C.** Impact of Anti-diabetic Drug Selection on Weight Change and HbA1c Outcomes in Treatment Naïve Patients with Type 2 Diabetes. *American Diabetes Association Scientific Sessions*. Philadelphia PA. 2012 Jun. [Poster] *Included in Guided Audio Poster Tour.
120. **Bellows BK, Dahal A, Jiao T, Biskupiak J.** A cost-utility analysis of pregabalin vs. duloxetine in painful diabetic neuropathy. *Value Health*. 2012 ;15(4):A181. *ISPOR 17th Annual International Meeting*. Washington, D.C. 2012 Jun. [Poster]
121. **Ghate S, Porucznik C, Said Q, Joy EA, Hashibe M, Brixner DI.** Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. *ISPOR 17th Annual International Meeting*. Washington, D.C. 2012 Jun. [Poster]

122. **Stenehjem D, Albright F, Kuo K, Raimundo K, Brixner DI.** Evaluating Contemporary Practice in CML via a Retrospective Research Registry of Patients across a Comprehensive Cancer Center Database. *ISPOR 17th Annual International Meeting*. Washington, D.C. 2012 Jun. [Poster]
123. **Stenehjem D, Albright D, Gou A, Chen L, Raimundo K, Bauer H, Brixner, DI.** Real-world response monitoring and tolerability of imatinib treated chronic myeloid leukemia patients captured in a retrospective research registry. *ASCO Meeting*. Chicago, IL. 2012 Jun. [Poster]
124. **LaFleur J, Nelson RE, Hoop R, Pandya P, Morgan T, Hayden C, Yao Y, Hamzeh F.** Discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. *International Liver Congress: 47th Annual Meeting of the European Association for the Study of the Liver*. Barcelona, Spain. 2012 Apr. [Poster]
125. Zhang J, Tian H, Gorsh B, **Lin J, Goodman M.** Prescription of inhaled corticosteroids and GOLD severity stage among patients with chronic obstructive pulmonary disease. *AMCP Educational Conference*. San Francisco, CA. 2012 Apr. [Poster]
126. Dye J, **Bellows B, Holtorf A, Brixner DI.** Use of Pharmacoeconomic and Outcomes Research in Formulary Decision Making: A Tale of Two Surveys *AMCP Educational Conference*. San Francisco, CA. 2012 Apr. [Poster]
127. **Bellows B, McAdam-Marx C, Unni S, Ye X, Mukherjee J, Brixner DI.** 12-month HbA1c and Weight Outcomes by Drug Class in Treatment Naïve Patients with Type 2 Diabetes. *AMCP Educational Conference*. San Francisco, CA. 2012 Apr. [Poster]

2011 Abstracts

128. **Brixner DI, Mukherjee J, McAdamMarx C.** Weight loss of 3% or more in a 12-month period is associated with glycaemic control in newly treated type 2 diabetes patients in the usual care setting. *47th EASD Annual Meeting*. Lisbon, Portugal. 2011 Sep. [Poster]
129. **Goodman M.** Use of Internet to generate adverse event hypothesis. *ISPE 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management*. Chicago, IL. 2011 Aug. [Poster]
130. **McAdam-Marx C, Jennings B, Sayler M, Gunning K.** An Evaluation of Clinical and Economic Outcomes Associated with a Pharmacist-Coordinated Diabetes Chronic Care Management Program. *American Association of Colleges of Pharmacy Annual Meeting*. San Antonio, TX. 2011 Jul. [Poster]

131. **Albright F, Brixner DI.** Baseline Results from a 6 Cancer HER Retrospective Study. *American Society Clinical Oncology*. Chicago, IL. 2011 Jun. [Poster]
132. **Brixner DI.** Better Evidence, Better Decision: Enhancing Your P&T Committee Using Comparative Effectiveness Research. *American Society of Health Systems Pharmacist*. Denver, CO. 2011 Jun. [Poster]
133. **McAdam-Marx C, Oderda GM.** Baseline characteristics and antidiabetic exposure in patients with type 2 diabetes treated with Liraglutide. *ISPOR 16th Annual International Meeting*. Baltimore, MD. 2011 May. [Poster]
134. **McAdam-Marx C, Oderda GM.** Bootstrapping used to provide robust mean and variance estimates for comparing patients treated Liraglutide to a large comparison cohort. *ISPOR 16th Annual International Meeting*. Baltimore, MD. 2011 May. [Poster]
135. **McAdam-Marx C, Oderda GM.** Research on Methods: Economic Evaluations. *ISPOR 16th Annual International Meeting*. Baltimore, MD. 2011 May. [Poster]
136. **Albright F, Bollu V, Kuo K, Raimundo K, Barney R, Stenehjem D, Brixner D.** Integrating Data Sources to Conduct Comprehensive Oncology based Outcomes Research. *ISPOR 16th Annual International Meeting*. Baltimore, MD. 2011 May. [Podium Presentation]
137. **McAdam-Marx C, Unni S, Nelson S, Ye X, Nickman N.** An evaluation of bone mineral density screening and technology frequency (2005-2008) among US women age 50 and older in a commercial medical claims database. *17th Annual Meeting of the International Society of Clinical Densitometry*. Miami, FL. 2011 Apr. *Recipient of the ISCD New Investigator Award.
138. **Asche C.** Health Economics and Compliance of Vials/Syringes Versus Pen Devices: A Review of the Evidence. *Western Pharmacoeconomics Conference*. Seattle, WA. 2011 Apr. [Poster]
139. **Albright F, Bollu V, Kuo K, Raimundo K, Barney R, Stenehjem D, Brixner D.** Integrating Data Sources to Conduct Comprehensive Oncology based Outcomes Research. *Western Pharmacoeconomics Conference*. Seattle, WA. 2011 Apr.[Poster Presentation]
140. **Nickman N, McAdam-Marx C.** An Evaluation of Bone Density Screening and Technology Frequency (2005-2008) among US Women age 50 and older in a commercial medical claims database. *American Association of Clinical Endocrinologist Annual Meeting*. San Diego, CA. 2011 Apr. [Poster]

141. **Young JR**, Oderda LH, **Asche CV**, Pepper, GA. Antipsychotic Medications and Risk of Falls Leading to Hip Fracture in Older Adults. *Center on Aging Research Retreat Poster Session*. Salt Lake City, UT. 2011 Feb. [Poster]
142. Heise B, **Asche CV**, Oderda LH. RAISE Elderly: Readiness of Older Adults to Use a Personal Health Record. *Center on Aging Research Retreat Poster Session*. Salt Lake City, UT. 2011 Feb. [Poster]

2010 Abstracts

143. Kwong J, Cho S, **Ghate S**, **Brixner DI**, Fox E. Adverse Outcomes Following Substitution of Warfarin Products in Atrial Fibrillation Patients *45th ASHP Midyear Clinical Meeting & Exposition*. Anaheim, CA. 2010 Dec. [Poster Presentation]
144. **Brixner DI** Evaluation of Support Services to Colorectal Cancer Patients in Mexico. *ISPOR 13th Annual European Congress*. Prague, Czech Republic. 2010 Nov. [Poster Presentation]
145. **Brixner DI** Current and Future Use of Pharmacoeconomic and Outcomes Research Data in Decision Making in the USA. *ISPOR 13th Annual European Congress*. Prague, Czech Republic. 2010 Nov. [Poster Presentation]
146. **Asche CV**, Kim J, Chakravarti P. Assessment of Association of Increased Heart Rate to Cardiovascular Events Among Healthy Patients. *ISPOR 13th Annual European Congress*. Prague, Czech Republic. 2010 Nov. [Poster]
147. **Asche CV**, Kim J, Chakravarti P. Assessment of Association of Increased Heart Rate to Cardiovascular Events Among Healthy Patients. *International Continence Society (ICS/IUGA) Annual Meeting*. Toronto, Canada. 2010 Aug. [Poster]
148. **Asche CV**. Assessment of Comorbidities in Patients with Overactive Bladder Disorder: An Electronic Medical Record (EMR) Data Analysis. *International Continence Society (ICS/IUGA) Annual Meeting*. Toronto, Canada. 2010 Aug. [Poster]
149. Pepper MJ, Shane-McWhorter L, **Bellows B**, **McAdam-Marx C**, **Albright F**, **Osborne B**. Exercise in Hispanic patients with type 2 diabetes mellitus: can a Spanish exercise DVD help? *American Association of Diabetes Educators Annual Conference*. San Antonio, TX. 2010 Aug. [Poster]
150. Kim J, **Asche CV**, Kahler K, Kulkarni A, Andersson K. Assessment of Association of Increased Heart Rate to Cardiovascular Events Among Healthy Patients. *Canadian Urology Association (CUA) Annual Meeting*. Charlottetown, Canada. 2010 Jun. [Poster]

151. **Asche CV.** Utilization of the Chronic Kidney Disease Epidemiology Collaboration Equation to Measure the Impact of Elevated Intact Parathyroid Hormone on Mortality and Renal Disease Progression in Patients with Stage 3 and 4 Chronic Kidney Disease. *European Renal/Dialysis Transplant Association Congress*. 2010 Jun. Munich, Germany. [Poster]
152. Yu J, **Asche CV**, Fairchild C. The Economic Burden of Dry Eye in the United States: A Decision Tree Analysis Model. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]
153. **McAdam-Marx C, Brixner DI.** Approach To Matching Alzheimer's Disease Patient and Their Spouses to Assess Caregiver Burden in an Administrative Claims Database. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster Presentation]
154. Dhamane AD, Martin B, **Brixner DI**, Hudson TJ, Said Q. Assessment of Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics (SGAS) Using Electronic Medical Record (EMR) Data. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster Presentation]
155. **Tasic D, Brixner DI, Goodman MJ.** The Impact of Oral Antidiabetics on Weight in the Elderly with Type 2 Diabetes Mellitus in the Ambulatory Setting. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]
156. **Nickman NA**, Haak SW, Kim JW. Use Of Clinical Simulation Centers To Conduct Patient-Centered Time-And-Motion Simulations As A Basis For Economic Analysis. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]
157. Kim J, **Nickman N.** Comorbidities, quality of life, and US healthcare access by risk cohort characteristics of people calculated using Framingham risk percent from the US national health and nutrition examination survey (NHANES). *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]
158. Kim J, **Nickman N.** Spatial Dependence (Or Cluster) In Total Number Of Prescription Drugs Filled At Retail Pharmacies In US. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]
159. **Brixner DI, McAdam-Marx C**, Van Den Bos J, Perlman D. Approach to Matching Patients with Alzheimer's Disease and their Spouse to Control Patients in Spouses in an Administrative Claims Database. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]
160. **Asche CV, Yu J.** Economic Burden of Dry Eye Syndrome in the U.S.: Application to a Decision Tree Analysis Model. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Poster]

161. **Brixner DI, McAdam-Marx C, Van Den Bos J, Perlman D.** Costs One Year Post Diagnosis for Alzheimer Patients and their Spouses vs. Matched Controls. *American Geriatrics Society Annual Scientific Meeting*. 2010 May. Orlando, FL. [Poster]
162. **Brixner DI, McAdam-Marx C, Van Den Bos J, Perlman D.** Resource Use for Caregivers vs. Matched Controls One-Year Pre vs. Post Patient Diagnosis for Alzheimer Disease. *American Geriatrics Society Annual Scientific Meeting*. 2010 May. Orlando, FL. [Poster]
163. **Goodman MJ.** Relationship between Body Mass Index and Muscle Mass among the Elderly (Age>64 years). *American Geriatrics Society Annual Scientific Meeting*. 2010 May. Orlando, FL. [Poster]
164. **Biskupiak J.** Blood pressure outcomes associated with the use of ARBs in a primary care electronic medical record database. *American Society of Hypertension Annual Scientific Meeting and Exposition*. New York, NY. 2010 May. [Poster]
165. **Brixner DI, Goodman MJ.** Comparing Adherence Measures against One-Year Outcomes for Patients with Epilepsy. *AMCP 22nd Annual Meeting & Showcase*. San Diego, CA. 2010 Apr. [Poster]
166. **Asche CV, Shane-McWhorter L, Raparla S.** Health Economics and Compliance of Vial/Syringe Versus Pen Devices: A Review of the Evidence. *6th Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2010 Apr. [Poster]

2009 Abstracts

167. **LaFleur J, Nelson RE, Sauer BS, Sheng X, Pickard S, Ong SH, Brixner DI, Nebeker J.** Any-cause hospitalization outcomes associated with poor patient adherence to antihypertensives. *2nd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia, and Diabetes Mellitus*. Valencia, Spain. 2009 Dec. [Podium Presentation]
168. Kim J, **Asche CV, Yaldo A, Panish J, Ascher S, Dirani R.** The Economic Impact of Switching Treatment from Risperidone to Paliperidone ER, Aripiprazole, Olanzapine, Ziprasidone or Quetiapine. *U.S. Psychiatric & Mental Health Congress*. Las Vegas, NV. 2009 Nov. [Poster]
169. **Biskupiak J, Kim J.** A Comparison of Blood Pressure Outcomes Associated with the Use of ARBs in Patients Seen Predominantly in Primary Care Practices. *ISPOR 12th Annual European Congress*. Paris, France. 2009 Oct. [Poster]
170. **Asche C, Marx SE, Jaewhan K, Sterz R, Audhya P.** Impact of Elevated Intact Parathyroid Hormone (iPTH) on Mortality and Renal Disease Progression in Patients with Stage 3 and 4 Chronic Kidney Disease (CKD). *ASN Renal Week*. San Diego, CA. 2009 Oct. [Poster]

171. **McAdam-Marx C**, Nelson R, Aagren M, Bouchard J, **Brixner DI**. Analysis of glycaemic control outcomes vs. baseline in patients treated with analog basal insulin in a real-world setting. *International Diabetes Federation 20th World Diabetes Congress*. Montreal, Canada. 2009 Oct. [Poster]
172. **McAdam-Marx C**, **Yu J**, Shankar V, Bouchard J, Aagren M, **Brixner DI**. Average daily dose of analog basal insulins in patients with type 2 diabetes: a matched case control analysis. *International Diabetes Federation 20th World Diabetes Congress*. Montreal, Canada. 2009 Oct. [Poster].
173. **LaFleur J**, **Nelson RE**, Pickard S, Nebeker J. A risk stratification rule for at risk of fracture based on clinical and administrative data. *ASBMR 31st Annual Meeting*. Denver, CO. 2009 Sep. [Poster]
174. **Asche C**, Jhaveri M, **Nelson R**, **McAdam-Marx C**, **Ye X**. Predictors of Oral Bisphosphonate Treatment Amongst Post-Menopausal Women with Low Bone Mineral Density or an Osteoporosis Diagnosis in a Real World Setting. *ASBMR 31st Annual Meeting*. Denver, CO. 2009 Sep. [Poster]
175. Golden W, Bigal ME, **Yu J**, Hu XHenry, **Brixner D**, Lipton RB, **LaFleur J**. Acute Treatment of Migraine in Patients with Cardiovascular Disease or Risk Factors. *14th International Headache Congress*. Philadelphia, PA. 2009 Sep. [Poster]
176. Golden W, Bigal ME, **Yu J**, Hu XH, **Brixner D**, Lipton RB, **LaFleur J**. Patterns of Acute Medication Use in Individuals with Cardiovascular Disease or Risk Factors. *14th International Headache Congress*. Philadelphia, PA. 2009 Sep. [Poster]
177. Augustovski F, **Asche C**, Pinto D, Bosi Ferraz M, Contreras Hernandez I. Reimbursement Review Process Across Latin America. *ISPOR 2nd Annual Latin American Meeting*. Rio de Janeiro, Brazil. 2009 Sep. [Educational Symposium]
178. **Ghate SR**, **Biskupiak J**, Casciano J, Hagan M, **Brixner DI**. Rate of Bleeding Events and Comorbidities among Atrial Fibrillation Patients Treated With or Without Warfarin. *25th Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ISPE)*. Rhode Island. 2009 Aug. [Poster]
179. **Kim J**, **Asche C**, Kahler K, Kulkarni A. Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) Disorder in a Real-World Setting. *25th Annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ISPE)*. Rhode Island. 2009 Aug. [Poster]

180. **Brixner D, McAdam-Marx C, Nelson R**, Aagren M, Bouchard J. Analysis of glycemic control and weight changes in patients treated with analog basal insulin in a real-world setting. *American Diabetes Association 69th Annual Scientific Meeting*. New Orleans, LA. 2009 Jun. [Published Abstract]
181. Fabunmi R, **McAdam-Marx C, Ye X**, Misurski D, **Brixner D**. Blood Pressure Outcomes after 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study. *American Diabetes Association 69th Annual Scientific Meeting*. New Orleans, LA. 2009 Jun. [Poster]
182. **Kim J**, Phatak H, **Biskupiak J**, Wu D. Assessment Of The Status Of Hypertension Management In Newly Diagnosed And Established Hypertension Patients In Primary Care Practice. *ISPOR 14th Annual International Meeting*. Orlando, FL. 2009 May. [Poster]
183. **Kim J, Asche CV**, Anderson KH, Kahler KH, Kulkarni A. Assessment Of Cardiovascular (CV) Comorbidity In Patients With Overactive Bladder (OAB) Disorder In A Real-World Setting. *ISPOR 14th Annual International Meeting*. Orlando, FL. 2009 May. [Poster]
184. **McAdam-Marx C, Yu J**, Shankar V, Bouchard J, **Brixner DI**. Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes. *ISPOR 14th Annual International Meeting*. Orlando, FL. 2009 May. [Poster]
185. **Kim J**. Finite Mixture Regressions in Modeling Prescription Drug Utilization and Prescription Drug Expenditures of Patients with Rheumatoid Arthritis (Ra). *ISPOR 14th Annual International Meeting*. Orlando, FL. 2009 May. [Poster]
186. **McAdam-Marx C, Brixner DI, X Ye**, Misurski D, Fabunmi R. A1C and Weight Outcomes Following 6 Months of Analog Basal Insulin in Insulin Naïve Patients with Type 2 Diabetes in an Ambulatory Care Setting. *ISPOR 14th Annual International Meeting*. Orlando, FL. 2009 May. [Poster]
187. **Brixner DI, McAdam-Marx C, X Ye**, Misurski D, Wintle M, Fabunmi R. 18 month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type 2 Diabetes in a Real-World Study. *ISPOR 14th Annual International Meeting*. Orlando, FL. 2009 May. [Poster]
188. **Kim J, Asche CV**. Pharmacological Side Effects of Antimuscarinic Drugs on Heart Rate: GEE and Multilevel Approaches. *5th Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2009 May. [Podium Presentation]

189. **Yu J, Brixner DI, Ghate S**, Gordon K. A Pilot Study of Screening Outcomes in Patients at Risk for Atherosclerosis in the Utah Community Clinics. *5th Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2009 May. [Podium Presentation]
190. **Kim J, Biskupiak JE**, Phatak H, Wu D. Assessment of the Presence of High Risk Cardiovascular Conditions and the Status of Hypertension Management among Elderly Adults in the US Primary Care Practices. *5th Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2009 May. [Podium Presentation]
191. **Oderda GM, McAdam-Marx C**, Cleveland J, Roland CL. Direct Costs of Opioid Abuse in Medicaid Patients. *AMCP 21st Annual Meeting & Showcase*. Orlando, FL. 2009 Apr. [Poster]
192. **Kim J, Asche CV**, Kahler K, Kulkarni A. Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) Disorder in a Real-World Setting. *Western Pharmacoeconomics Conference*. Pasadena, CA. 2009 Mar. [Poster]
193. **Nelson RE, LaFleur J**, Pickard SG, Nebeker JR. Predictors of Bisphosphonate Treatment in Male United States Veterans. *Western Pharmacoeconomics Conference*. Pasadena, CA. 2009 Mar. [Poster]
194. **Kim J, Biskupiak J**. Assessment Of The Status Of Hypertension Management In Newly Diagnosed And Established Hypertension Patients In Primary Care Practice. *Western Pharmacoeconomics Conference*. Pasadena, CA. 2009 Mar. [Poster]
195. **Nelson RE, LaFleur J**, Pickard S, Nebeker J. Predictors of an osteoporosis diagnosis in male United States veterans. *Western Pharmacoeconomics Conference*. Pasadena, CA. 2009 Mar. [Podium Presentation]
196. **McAdam-Marx C, Yu J**, Shankar V, Bouchard J, **Brixner DI**. Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes. *Western Pharmacoeconomics Conference*. Pasadena, CA. 2009 Mar. [Poster]
197. **LaFleur J, Nelson R**, Pickard S, Nebeker J. Gathering evidence for clinical decision support in male osteoporosis in veterans. *University of Utah Center on Aging Research Retreat*. Salt Lake City, Utah. 2009 Mar. [Podium Presentation]
198. **LaFleur J, Nelson R, McAdam-Marx C**, Pickard S, Nebeker J. Electronic clinical and administrative data can be used to predict patients at risk of fragility fracture. *HSR&D (Health Services Research and Development) National Meeting*. Baltimore, MD. 2009 Feb. [Podium Presentation]

2008 Abstracts

199. **Brixner DI**, Malone, D, Watkins J. Advancing the Use of Real World Data in Formulary and Reimbursement Decision Making. *AMCP Educational Conference*. Kansas City, MO. 2008 Oct. [Poster]
200. **LaFleur J, McAdam-Marx C**, Pickard SG, Nebeker JR. Recognition and treatment of male osteoporosis is low. *ASBMR 30th Annual Meeting*. Montreal, Canada. 2008 Sep. [Poster]
201. **Brixner DI, Oderda G, Ye X**, Boye KS, Wintle M, Fabunmi R. Clinical Effectiveness of Exenatide in Patients with Type 2 Diabetes in a Primary Care Electronic Medical Record Database. *American Diabetes Association 68th Scientific Sessions*. San Francisco, CA. 2008 Jun. [Poster]
202. **Nelson RE, Lafleur J, McAdam-Marx C, Brixner DI**, Ward R. Patent extension policies for pediatric indications: an evaluation of the impact within one drug class in one state Medicaid program. *Academy Health Annual Meeting*. Washington, DC. 2008 Jun. [Poster]
203. Shafazand S, Yang Y, Mitsi G, **Brixner DI**. Heart Failure Quality of Care: Views from a Nationwide Administrative Claims Database. *American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke*. Baltimore, MD. 2008 May. [Poster]
204. **Brixner DI, McAdam-Marx C, Biskupiak J**, Lau HJ, Munger M. Association of Adverse Events of Antihypertensive Therapy by Age in a Physician Practice National EMR Database. *American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke*. Baltimore, MD. 2008 May. [Poster]
205. **Nickman NA**, Haak SW, Harald EA, **Holtorf AP**, Joshi AV, Kim JW, **Brixner DI**. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
206. **Roper M, Biskupiak J**, Alder S, **Oderda G**. Comparison of Men Age 21 Years and Older with and w/out Erectile Dysfunction on Concomitant Prescription Drug, Comorbid Conditions, Smoking Status and BMI. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
207. **McAdam-Marx C, Brixner DI**, Field R, Metraux S. Type 2 Diabetes in Youth: 2002 and 2006 Prevalence and Obesity in a Primary Care Setting. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]

208. **McAdam-Marx C, Brixner DI, Oberg B.** Estimation of Study Population Size for Effectiveness Outcomes at 6 and 12 months via Electronic Medical Records. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
209. **McAdam-Marx C, Brixner DI, Ye X, Sung JC, Kahler KH.** Evaluation of Resistant Hypertension in a Usual-Care Setting. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
210. **Nelson R, McAdam-Marx C, Misurski DA, Nielsen LL.** Descriptive analysis of body weight and clinical effectiveness measures associated with type 2 diabetes therapies in a primary care electronic medical record database. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
211. **Ghate SR, Said Q, Huse D, Ben-Joseph R, Brixner DI.** Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight US Primary Care Patients. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
212. **LaFleur J, Ghate SR, Sauer B.** Updating The RxRisk-V: Creating A Crosswalk Between VA And Firstdatabank Therapeutic Categories. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
213. **LaFleur J, Ghate SR, Ye X.** Estimating Sociodemographic Variables In A Pharmacy Dataset: Applying Data From Us Census 2000. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
214. **Ghate SR, LaFleur J, Charland SL, Sauer B.** A Modified Rxrisk-V Comorbidity Index Predicts Adherence With Lipid Lowering Therapy (LLT). *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May. [Poster]
215. **Hassanein TI, Ye X, Blumentals WA, Brixner DI.** Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. *Digestive Disease Week*. San Diego, CA. 2008 May. [Poster]
216. **McAdam-Marx C, Brixner DI, Asche C.** Identifying potential adverse events in an electronic medical record database. *4th Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2008 Apr. [Poster]
217. **Hassanein TI, Ye X, Blumentals WA, Brixner DI.** Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. *Spring Research and Practice Forum of the American College of Clinical Pharmacy*. Phoenix, AZ. 2008 Apr. [Poster]

218. **Ghate SR**, Doan J, **Nelson R**, Van Den Bos J, **Brixner DI**. Indirect Costs Associated with Patients Treated for Insomnia: An Employer Perspective. *Spring Research and Practice Forum of the American College of Clinical Pharmacy*. Phoenix, AZ. 2008 Apr. [Poster]
219. Hassanein TI, Ye X, Blumentals WA, **Brixner DI**. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. *43rd Annual Meeting European Association for the Study of the Liver*. Milan, Italy. 2008 Apr. [Poster]

2007 Abstracts

220. **Brixner DI**, **Jackson K**, Sheng X, **Biskupiak J**, Keskinaslan A. Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database. *ISPOR 10th Annual European Congress*. Dublin, Ireland, 2007 Oct. [Poster]
221. **Asche CV**, Seal B, **McAdam-Marx C**, Crookston B, Svejda R, Mullins CD. Treatment costs associated with community acquired pneumonia by community level antimicrobial resistance. *ISPOR 10th Annual European Congress*. Dublin, Ireland, 2007 Oct. [Poster]
222. **Nickman NA**, Haak SW, **Holtorf AP**, Joshi AV, **Brixner DI**. Time-and-motion evaluation of different growth hormone formulations. *ISPOR 10th Annual European Congress*. Dublin, Ireland, 2007 Oct. [Poster]
223. **Biskupiak J**, **Brixner DI**, Keskinaslan A. Effectiveness of Multiple-Mechanism Antihypertensive Medication: Valsartan-Amlodipine-HCTZ Triple-Therapy in Primary Care. *ISPOR 10th Annual European Congress*. Dublin, Ireland, 2007 Oct. [Poster]
224. **Oderda G**, Lieberman M, **Asche CV**, **Brixner DI**. Use of electronic medical record (EMR) data in outcomes research. *ISPOR 10th Annual European Congress*. Dublin, Ireland, 2007 Oct. [Poster]
225. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence During the Chronic Phase in Patients with Ulcerative Colitis. *American College of Gastroenterology Annual Scientific Meeting*. Philadelphia, PA. 2007 Oct. [Poster]
226. **LaFleur J**, **McAdam-Marx C**, **Asche CV**, Alder S, Sheng X, **Brixner D**, Silverman S. Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting. *ASBMR 29th Annual Meeting*. Honolulu, HI. 2007 Sept. [Poster]
227. Muszbek N, **Brixner D**, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. *ISPOR 1st Latin America Conference*. Cartagena, Columbia. 2007 Sep. [Poster]

228. **Asche CV**, Machado M, Caro J. ISPOR Digest of International Databases for Pharmacoeconomics and Outcomes Research. *ISPOR 1st Latin America Conference*. Cartagena, Columbia. 2007 Sep. [Poster]
229. **Asche CV**, **Brixner DI**, L'Italien GJ. Pharmacoeconomic Research in Latin America: Gathering the Data for Dossier Requirements. *ISPOR 1st Latin America Conference*. Cartagena, Columbia. 2007 Sep. [Poster]
230. **Asche CV**, **McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Association between oral antidiabetic adverse events and outcomes in a real world setting. *American Diabetes Association (ADA) 67th Scientific Sessions*. Chicago, IL. 2007 Jun. [Poster]
231. Mucha L, Seal B, Lenhart G, **Asche CV**. Direct and Incremental Costs of Acute Respiratory Infections. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May. [Poster]
232. Seal B, Mucha L, Lenhart G, **Asche CV**. Incremental Costs Associated with Antibiotics Prescribed for Acute Otitis Media. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May. [Poster]
233. **Brixner DI**, **Ghate SR**, **McAdam-Marx C**, Ben-JosephR, **Said Q**. Correlation of Weight to Cardiometabolic Risk as Identified by ICD-9 Diagnosis Codes and Prescriptions in Primary Care. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May. [Poster]
234. **Asche CV**, Mucha L, Lenhart G, Seal B. Incremental Costs Associated Antibiotics Prescribed for Community Acquired Pneumonia Episodes. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May. [Poster]
235. **Brixner DI**. Contraceptive and non-contraceptive benefits of a Levonorgestrel-releasing intrauterine in a vertically integrated HMO. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May. [Poster]
236. **Brixner DI**, Magowan S, Accortt N. Prescription Refill Behavior for Nifedipine Therapy is Significantly Dependent on Medication Cost. *8th AHA Scientific Forum*. Washington, D.C. 2007 May. [Poster]
237. **Jackson K**, **Brixner DI**, **Oderda G**, **Oberg B**, Sheng X, Keskinaslan A. Compliance and Economic Outcomes with Valsartan and HCTZ Combination Therapy for Hypertensive Patients. *American Society of Hypertension*. Chicago, IL. 2007 May. [Poster]
238. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence in Patients with Ulcerative Colitis. *Digestive Disease Week*. Washington, D.C. 2007 May. [Poster]

239. **McAdam-Marx C, Brixner D**, Metrau S, Chan V, PharmD3, Field R. Determinants of race and ethnicity reporting for youth with health data in an electronic medical record database. *University of the Sciences Scholarly Day*. Philadelphia, PA. 2007 Apr. [Poster]
240. **LaFleur J, McAdam-Marx C, Asche CV, Alder S**, Sheng X, **Brixner D**, Silverman S. The risk of clinical vertebral fracture for postmenopausal patients with specific combinations of fracture risk factors in a primary-care setting. *7th International Symposium on Osteoporosis: Translating Research into Clinical Practice*. Washington, D.C. 2007 Apr. [Poster] *Osteoporosis International*. 2007; 18(Supplement 2):S210. [Printed Abstract]
241. **LaFleur J**, McBeth C, Steinvort C, Oderda L, Paul M, Gunning K, **Oderda G**. Identification and categorization of drug-related problems among Medicaid patients: Variability between pharmacist reviewers. *ACCP Spring Practice and Research Forum*. Memphis, TN. 2007 Apr. [Poster] *Pharmacotherapy*. 2007; 27(4):31. [Abstract]
242. Atherton A, **LaFleur J**, Mayeda B, Oderda L, **Oderda GM**. Comparison of drug-related problems in nursing home residents versus non-nursing home Medicaid patients. *ACCP Spring Practice and Research Forum*. Memphis, TN. 2007 Apr. [Poster]
243. **Asche CV**, Young D, **Brixner DI**, Phillips A. Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database. *ACCP Spring Practice and Research Forum*. Memphis, TN. 2007 Apr. [Poster]
244. **Holtorf A-P, LaFleur J**, Servatius D, Jeffries B, **Brixner DI**. Prescription drug use by women and men in Utah Medicaid. *Utah Health Services Research Meets Public Health Informatics*. Salt Lake City, UT. 2007 Apr. [Poster]
245. **LaFleur J, Asche CV, McAdam-Marx C**, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. *3rd Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2007 Apr. [Poster]
246. **Holtorf A-P, LaFleur J**, Servatius D, Jeffries B, McBeth C, **Brixner DI**. Statin treatment of diabetic patients in Utah Medicaid. *3rd Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2007 Apr. [Poster]
247. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. *3rd Annual Utah Health Services Research Conference*. Salt Lake City, UT. 2007 Apr. [Poster]

248. **Brixner DI**, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. *AMCP 19th Annual Meeting & Showcase*, San Diego, CA. 2007 Apr. [Poster]
249. **Brixner DI, Said Q, Oderda G, Kirkness C**. Assessment of the clinical risk factors for cardiometabolic risk in a national primary care electronic medical record (EMR) database. *AMCP 19th Annual Meeting & Showcase*, San Diego, CA. 2007 Apr. [Poster]
250. **Asche CV**, Oderda LH, Pepper GA. The Economic Impact of Treatment of Falls-Related Injuries from a U.S. Employers Perspective. *Center on Aging Research Retreat*. Salt Lake City, UT. 2007 Apr. [Poster]
251. **Ghate SR, Kirkness C, Biskupiak J**. Assessment of Comorbidities and Prevalence in Patients with GERD using the GE EMR Database. *Second Western Pharmacoeconomics Conference*. Salt Lake City, UT. 2007 Mar. [Poster]

2006 Abstracts

252. **LaFleur J, Asche CV, McAdam-Marx C**, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. *ASHP 41st Mid-Year Meeting*. Anaheim, CA. 2006 Dec. [Poster]
253. **Asche CV, McAdam-Marx C**, Share-McWhorter L, Plauschinat CA. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. *ASHP 41st Mid-Year Meeting*. Anaheim, CA. 2006 Dec. [Poster]
254. **Brixner DI, McAdam-Marx C**, Gallwitz W, **Roper M, Asche CV**. Value of Reducing Vertebral Fractures in Women with Post-Menopausal Osteoporosis with Multiple Clinical Risk Factors for Fracture Based on the TOP Study. *ASHP 41st Mid-Year Meeting*. Anaheim, CA. 2006 Dec. [Poster]
255. **Brixner DI, Ghate SR, McAdam-Marx C**, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *ISPOR 9th Annual European Congress*. Copenhagen Denmark. 2006 Oct. [Poster]
256. **Asche CV, Brixner DI**, Conoscenti CS, Young D, Shah H, Phillips AL. Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database. *American College of Chest Physicians Meeting*. Salt Lake City, UT. 2006 Oct.

257. **McAdam-Marx C, Joish VN, Brixner DI**, Hoblyuk R. A Comparison of Adherence and Cost of Sulfonyleureas in Combination with TZDs or Metformin. *ADA 66th Specific Meeting*. Washington D.C. 2006 Jun. [Poster]
258. McGarry LJ, Iskander R, Seal B, **Asche CV**, Thompson D, Weinstein MC. Cost-effectiveness of telithromycin in the treatment of community acquired pneumonia. *ISPOR 11th Annual International Meeting*. Philadelphia, PA. 2006 May. [Poster]
259. **LaFleur J, Oderda GM**, Lyon JL, White G. The Case of Lipid-Lowering Therapy: A Comparison of Adherence Measurement Methodologies Using Administrative Claims Data. *ISPOR 11th Annual International Meeting*. Philadelphia, PA. 2006 May. [Poster]
260. Haak S, **Nickman N**, Rusho W, Beck S, **LaFleur J, Brixner D**. Joint Professional Analysis of a Novel Dosage form in the Intensive Care (ICU) Setting. *American Association of Critical Care Nurses*. Anaheim, CA. 2006 May. [Poster]
261. **Oderda GM, Said Q**, Evans RS, Stoddard GJ, Rublee D, Lloyd J, Samore MH. Opioid-related Adverse Drug Events in Surgical Hospitalizations: Impact on Costs and Length of Stay. *25th Annual Scientific Meeting American Pain Society*. San Antonio, TX. 2006 May. [Poster]
262. **Brixner DI, Joish VM, McAdam-Marx C**, Arondekar B, Hoblyuk R. Evaluation of Persistence and Outcomes in Patients on SU Combination Therapy with TZDs or Metformin. *AMCP 18th Annual Meeting*. Seattle, WA. 2006 Apr. [Poster]
263. **Brixner DI, Nickman N, Oderda GM**. Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community based oncology practices. *ISPOR Asian Congress*. Shanghai, China. 2006 Mar. [Poster]

2005 Abstracts

264. **Asche CV, Oderda G**. Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. *College of Pharmacy Research Symposium*. Salt Lake City, UT. 2005. [Poster]
265. Carter O, MacCarter D, Mannebach S, **Biskupiak J**, Stoddard G, Giblert EM, Munger MA. D-Ribose improves peak exercise capacity and ventilatory efficiency in heart failure patients. *JACC*. 2005; 45(Suppl A):185A. [Printed Abstract]

266. **LaFleur J**, Thompson CJ, **Joish VN**, Charland S, **Oderda GM**, **Brixner DI**. Adherence and persistence with lipid-lowering pharmacotherapy: Effects of the covariates copay and disease severity on probabilities of being categorized as compliant. *Pharmacotherapy Outcomes Research Center*; Kos Pharmaceuticals, Inc. 2005.
267. **Joish VN**, **Brixner DI**, **LaFleur J**, **Kirkness C**. Pharmacoeconomic analysis of ARB therapy in patients with mild-to-moderate hypertension. *AMCP Educational Conference*. Nashville, TN. 2005 Oct. [Poster]
268. **Said Q**, **Ho MJ**, Beckwith MC, **Brixner DI**. A Pharmacoeconomic comparison of Oral Fluoroquinolones for Complicated Urinary Tract Infections. *AMCP Educational Conference*. Nashville, TN. 2005 Oct. [Poster]
269. **Biskupiak JE**, **Brixner DI**, **Oderda GM**, Howard K. Gastrointestinal Complications of over-the-counter non-steroidal anti-inflammatory drugs. *ACG 70th Annual Scientific Meeting*. Honolulu, HI. 2005 Oct. [Poster]
270. Maio V, Yuen E, **Brixner D**, **Oderda G**, **Asche CV**, Smith K.D, Morgan S. Multi-national assessment of outcomes via retrospective databases, Healthcare Policy Development Issues, Contributed Workshops. *ISPOR 8th European Congress*. Florence, Italy. 2005 Oct. [Poster]
271. **Brixner DI**, **Nickman N**, **Oderda GM**. Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community based oncology practices. *ISPOR 8th European Congress*. Florence, Italy. 2005 Oct. [Poster]
272. Lipman AG, **Jackson KC**, **Stockdale W**, **Oderda GM**. The Treatment Outcomes of Pain Survey (TOPS): A Validated Health Related Quality of Life (HRQoL) Outcomes Instrument for Research and Practice. *11th World Congress on Pain International Association for the Study of Pain*. Sydney, Australia. 2005 Aug. [Poster]
273. **Oderda G**, **Asche CV**, **Stockdale W**, Spalding J. Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. *13th Annual Congress on Women's Health Congress*. Hilton Head, SC. 2005 Jun. [Poster]
274. **Asche CV**, **Stockdale W**, Pepper G, Gallagher EM. The economic impact of treatment of falls-related injuries from a U.S. Employers Perspective. *International Association of Gerontology*. Rio de Janeiro, Brazil. 2005 Jun. [Poster]

275. **Brixner DI**, Blonde L, **Said Q**, Tuomari V, **Oderda GM**, Corey-Lisle PK, L'Italian GJ. Real World Impact of Second Generation Antipsychotics on Weight Gain. *American Diabetes Association 65th Scientific Sessions*. San Diego, CA. 2005 Jun. [Poster]
276. **Brixner DI**, **Ho MJ**, Sauer BC, **Stockdale WA**. Real world usage of weight gain drugs in patients on second-generation antipsychotics. *American Diabetes Association 65th Scientific Sessions*. San Diego, CA. 2005 Jun. [Poster]
277. Haak S, **Nickman NA**. Nursing and Pharmacy Collaboration in Use of Simulation for Time and Motion Study. *Nursing Learning Resource Center Conference*. Philadelphia, PA. 2005 Jun. [Poster]
278. **Brixner DI**, **Said Q**, Newcomer J, Tuomari V, **Oderda GM**, **Stockdale WA**, L'Italien GJ. Real world usage of weight gain drugs in patients on second-generation anti-psychotics. *American Psychiatric Association*. Atlanta, GA. 2005 May. [Poster]
279. **Brixner DI**, **Ho MJ**, Sauer BC, **Stockdale WA**. Development of an integrated diabetes database across community clinics and hospitals. *ISPOR 10th Annual International Meeting*. Washington, D.C. 2005 May. [Poster]
280. **Joish VN**, **Stockdale WA**, Brady E, Dirani R, **Brixner DI**. An assessment of diagnosis and treatment of COPD in primary care via an electronic medical record database. *ISPOR 10th Annual International Meeting*. Washington, D.C. 2005 May. [Poster]
281. **Joish VN**, Brady E, **Stockdale WA**, Dirani R, **Brixner DI**. Identification and diagnosis of COPD in a primary care setting. International Conference *American Thoracic Society*. San Diego, CA. 2005 May. [Poster]
282. **Asche CV**, **Stockdale W**, Pepper G, Gallagher EM. The Economic Impact of Treatment of Falls-Related Injuries. *Canadian Association of Population Therapeutics*. Vancouver, Canada. 2005 Apr. [Poster]
283. **Brixner DI**, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. *European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis*. Rome, Italy. 2005 Apr. [Poster]
284. **LaFleur J**, Fowler MA, McBeth C, Oderda L, Gunning K, Steinvooort C, **Stockdale W**, **Oderda GM**. Prevalence of drug-related problems among Medicaid high utilizers as identified by clinically-trained pharmacist reviewers *ACCP Spring Practice and Research Forum and Updates in Therapeutics*. Myrtle Beach, SC. 2005 Apr. [Poster]

285. **Brixner DI**, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. *National Osteoporosis Foundation 6th International Symposium on Osteoporosis*. Washington, D.C. 2005 Apr. [Poster]
286. Roland C, **Biskupiak J**. Number of intrathecal pumps being used for chronic intractable pain. *American Pain Society 24th Annual Scientific Meeting*. Boston, MA. 2005 Mar. [Poster]

2004 Abstracts

287. **Joish VN**, Malone DC, Wendel C, Mohler MJ. Development of a diabetes resource consumption index (DRCI): a risk adjustment toll for predicting healthcare resource use and costs. *Value in Health*. 2004. [Printed Abstract]
288. **LaFleur J**, Beckwith C, Fowler M, Tyler L, **Brixner D**. A Pharmacoeconomic Comparison of Oral Third-Generation Cephalosporins for Acute Otitis Media. *39th ASHP Midyear Clinical Meeting*. Orlando, FL. 2004 Dec. [Poster]
289. **Brixner D**, **Asche CV**, Chang J, Stewart J, Paladino JA. Economic value of telithromycin vs clarithromycin in the treatment of community-acquired pneumonia. *39th ASHP Midyear Clinical Meeting*. Orlando, FL. 2004 Dec. [Poster]
290. **Ho MJ**, **Joish VN**, **Stockdale W**, **Oderda GM**, Alder S, White G. Does recommended self-blood glucose monitoring impact overall healthcare resource use. *39th ASHP Midyear Clinical Meeting*. Orlando, FL. 2004 Dec. [Poster]
291. **Ho MJ**, **LaFleur J**, **Brixner DI**. Which atypical antipsychotics for schizophrenia: cost-efficacy versus cost-effectiveness analyses. *AMCP 2004 Educational Conference*. Baltimore, MD. 2004 Oct. [Poster]
292. **LaFleur J**, Thompson C, **Ho MJ**, **Stockdale WA**, Charland S, **Oderda GM**, **Brixner DI**. Adherence, persistence, and cost of lipid-lowering pharmacotherapy: ER-niacin/statin combination therapy within a single dosage-form versus two separate dosage forms in a managed care population. *AMCP 2004 Educational Conference*. Baltimore, MD. 2004 Oct. [Poster]
293. Oderda L, Young E, **Oderda G**. Graduate Employability: A Longitudinal Comparison of Preceptors' Opinions about Hiring Clerkship Students After Multiple Professional Experiences: 2000-2003. *American Association of Colleges of Pharmacy Meeting*. Salt Lake City, UT. 2004 Jul. [Poster]

294. **Brixner DI**, Tabb K. Overview of databases used in managed care research. *ISPOR 9th Annual International Meeting*. Washington, DC. 2004 May. [Presentation]
295. **Joish VN**, Donaldson G, **Stockdale WA**, **Oderda GM**, **Brixner DI**, Sasane R, Joshua-Gotlib S, Crawely JA. Economic burden of GERD and PUD in an employed population. *ISPOR 9th Annual International Meeting*. Arlington, VA. 2004 May. [Poster]
296. **Stockdale WA**, **Brixner DI**. Comorbidity influence index. *ISPOR 9th Annual International Meeting*. Arlington, VA. 2004 May. [Poster]
297. **Asche CV**, **Stockdale W**, Pepper G, Gallagher EM. The economic impact of treatment of falls-related injuries. *Canadian Association of Population Therapeutics*. Canada. 2004 Apr. [Poster]
298. **LaFleur J**, **Oderda G**, **Stockdale W**, Gunning K, Orlando P, Steinvoot C, Tyler L. Impact of Pharmacist Reviews on Prescribing Behavior. *ACCP Spring Meeting*. Paris, France. 2004 Apr. [Poster]
299. **Oderda GM**, **LaFleur J**, Gunning K, **Stockdale W**, Orlando P, Steinvoot C. Impact of Structured Patient Reviews of High Prescription Utilizers on the Cost of Care. *ACCP Spring Meeting*. Paris, France. 2004 Apr. [Poster]
300. **Oderda GM**, **LaFleur J**, Gunning K, **Stockdale W**, Orlando P, Steinvoot C. Reducing Drug Costs via a Structured Review of High Utilizers in the Utah Medicaid Program. *ACCP Spring Meeting*. Paris, France. 2004 Apr. [Poster]
301. Christensen RL, **LaFleur J**, **Ho MJ**, **Joish VN**, **Brixner DI**. Which HMG-CoA reductase inhibitor for hyperlipidemia: a cost-effectiveness analysis based on the STELLAR trial. *AMCP 16th Annual Meeting and Showcase*. San Francisco, CA. 2004 Mar. [Poster]
302. **Brixner DI**, Cannon HE, **Oderda GM**, **Stockdale WA**, **Joish VN**, Hanson D. Impact of varying copays on patient prescribing behavior in a managed care organization: focus on hypertension. *AMCP 16th Annual Meeting and Showcase*. San Francisco, CA. 2004 Mar. [Poster]
303. **Ho MJ**, **Joish VN**, **LaFleur J**, Christensen RL, **Brixner DI**. Which oral triptan for migraine: a cost-efficacy analysis from a managed care perspective. *AMCP 16th Annual Meeting and Showcase*. San Francisco, CA. 2004 Mar. [Poster]

2003 Abstracts

304. Gunning KM, **Oderda GM**, **Stockdale WA**, **LaFleur J**, Orlando PL, Steinvort C, Dang K, Tyler LS, **Brixner DI**. Controlling Utah

- Medicaid drug spending through a regimen review program. *American College of Clinical Pharmacy*. Atlanta, GA. 2003 Nov. [Poster]
305. Sahai A, Skrepnek G, **Joish VN**. On improved confidence-interval estimation of cost-effectiveness ratios. International Conference on Statistics, Combinatorics and Related Areas, *10th Conference of the Forum for Interdisciplinary Mathematics*. Portland, ME. 2003 Oct. [Poster]
 306. **Brixner DI**, Avey SG, Malone D. Practical decision analysis for the decision maker. *ISPOR 8th Annual International Meeting*. Arlington, VA, 2003 May. [Poster]
 307. **Oderda GM**, Gunning KM, **LaFleur J**, **Stockdale WA**, Tyler LS, Parke D, **Brixner DI**. Reviews of Utah Medicaid high utilizers to control drug costs. *ISPOR 8th Annual International Meeting*. Arlington, VA, 2003 May. [Poster]
 308. Oderda LH, **Stockdale WA**, **Oderda GM**, Donaldson G, Ashburn M, **Brixner DI**, Lipman AG. Age and gender-stratified differences in quality of life in elderly chronic pain patients. *ISPOR 8th Annual International Meeting*. Arlington, VA, 2003 May. [Poster]
 309. **Brixner DI**, Cannon HE, **Oderda GM**, **Biskupiak JE**, **Stockdale WA**, **Joish VN**, Hanson D. Impact of varying copays on patient prescribing behavior in a managed care organization; preliminary results. *AMCP 15th Annual Meeting*. Minneapolis, MN. 2003 Apr. [Poster]
 310. **Brixner DI**, Tabb K. Overview of database used in managed care research. *AMCP 15th Annual Meeting*. Minneapolis, MN. 2003 Apr. [Presentation]

2002 Abstracts

311. **Oderda GM**, Lipman AG, Ashburn MA, **Stockdale W**. Use of the Tops as A Pain-Specific HRQOL Instrument. *ISPOR 5th Annual European Congress*. Rotterdam, Netherlands. 2002 Nov. [Poster]
312. **Brixner DI**, Todd W. Compliance and persistency programs as a component of disease management programs in managed care. *AMCP 14th Annual Meeting*. Salt Lake City, UT. 2002 Apr. [Poster]

INVITED PRESENTATIONS

2015 Presentations

1. **Ma J**, Xuan S, **Tak C**, **Brixner D**. Meta-Analysis of the Safety of Sipuleucel-T Immunotherapy in Prostate Cancer. Podium presentation at the Western

Pharmacoeconomics and Outcomes Research Conference, Denver, Colorado, March 2015

2. **Bress AP, King J, Singhal M, Brixner D,**Kielhorn A, Patel H, Maya J, **Biskupiak J, Munger M.** Outcomes And Health Resource Utilization Among Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) At An Academic Medical Center (AMC) In The United States. Presented as a podium presentation at the ISPOR 20th Annual International Meeting to be held May 16-20, 2015, Philadelphia, PA.
3. Van Wagoner E, **Moorman K, Nickman N, Tak C, Stevens V, Jennings B.** Assessing employee perception of patient safety culture within a university-based health system's community pharmacies using the AHRQ community pharmacy survey on patient safety culture. APhA Annual Meeting, San Diego, CA: 2015 March 28. [Poster]
4. **McAdam-Marx C,** Value of Pharmacists on Patient Care Teams. University of Utah College of Pharmacy, Pharmacy Ambassadors Advisory Council. April 15, 2015. Salt Lake City, UT.

2014 Presentations

5. **McAdam-Marx C.** Generating Real-World Evidence for Pharmacotherapy Effectiveness: A Case Study in Diabetes. *American Association of Pharmaceutical Sciences, Rocky Mountain Discussion Group. Annual Meeting.* August 13, 2014. Missoula MT.
6. **McAdam-Marx C.** Is There a Pharmacist in the (Medical) Home? The Impact of Pharmacist-Led Diabetes Collaborative Drug Therapy Management on Patient Outcomes. 2014 *Skaggs Biomedical Research Symposium.* August 14, Missoula, MT.

2012 Presentations

7. **DuVall SL.** Big Data and the VA Informatics and Computing Infrastructure. *University of Maryland, Baltimore County Center for Hybrid Multicore Productivity Research (CHMPR) Semi-Annual Industry Advisory Board Meeting.* Baltimore, MD. 2012 Dec.
8. **Brixner DI.** Panel Discussion: Outcomes and Cost Effectiveness in Personalized Health Care. *University of Utah Personalize Health Care Meeting.* Salt Lake City, UT. 2012 Nov.
9. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell ES, Saag KG, Safford MM, **DuVall SL,** Alexander K, Napalkov P, Kamauu AWC, Baddley J. Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents. *ACR / ARHP 2012 Annual Scientific Meeting.* Washington, DC. 2012 Nov.

10. **DuVall SL.** VINCI: A convergence of policy and technology for enabling big data analytics in the Department of Veterans Affairs. *IBM Canada Software Laboratory Centre for Advanced Studies Research 22nd Annual International Conference*. Toronto, Canada. 2012 Nov.
11. **Bellows BK, McAdam-Marx C, Unni S, Ye X, Mukherjee J, Brixner DI.** 12-month HbA1c and weight outcomes by drug class in treatment naïve patients with type 2 diabetes. *Meeting in the Middle Western Pharmacoeconomic Conference*. Austin, TX. 2012 Jun.
12. **Stevens V.** Pharmacologic Risk Factors for Clostridium difficile Infection (CDI). *Salt Lake City Veterans Affairs Informatics, Decision Enhancement, and Surveillance (IDEAS) Center*. Salt Lake City, UT. 2012.
13. **Stevens V.** Clostridium difficile Infections in Adult and Pediatric Patients. *Pediatric Infectious Disease Division Meeting, University of Utah*. Salt Lake City, UT. 2012.
14. **LaFleur J, Smith J, Nelson S, Nelson R, Adler RA, Nebeker JR, Malone DC.** Cost-effectiveness analysis of different strategies for fragility fracture prevention in United States veterans. *ISPOR 17th International Meeting*. Washington, DC. 2012 Jun. *Value in Health*; 15(4):A8. [Printed Abstract]
15. **Ghate SR, Brixner DI.** Predictors of Monitoring of Metabolic Parameters in Adolescents on Antipsychotics. *2012 APA Annual Meeting*. Philadelphia, PA. 2012 May.
16. **Brixner DI.** Decision Modeling, Outcomes Research and Health Technology Assessment: Experiences from my Austrian Sabbatical. *University of Utah, Department of Family and Preventive Medicine Grand Rounds*. Salt Lake City, UT. 2012 May.
17. **Brixner DI.** Personalized Health Care Research Opportunities. *University of Utah*. Salt Lake City, UT. 2012 Apr.
18. **Brixner DI.** Adherence: The Key to Success for Gout Treatment. *AMCP 24th Annual Meeting and Expo*. San Francisco, CA. 2012 Apr.
19. **Brixner DI.** Pioneering Outcomes in Personalized Medicine at the University of Utah. *University of Utah President's National Advisory Council*. Salt Lake City, UT. 2012 Apr.
20. **Brixner DI.** Using Real World Data (RWD) to Assess the Value of New Technology for Patients. *Health Care Reform and Health Services Research Symposium, University of Utah*. Salt Lake City, UT. 2012 Apr.
21. **Brixner DI.** Pioneering Outcomes in Personalized Medicine at the University of Utah. *University of Utah, Park City Institute*. Park City, UT. 2012 Apr.

22. **Brixner DI.** Real World Data in Health Care Decision Making. *University of Utah.* Salt Lake City, UT. 2012 Mar.
23. **Biskupiak J, Gbate S, Brixner DI.** Impact of Generic Warfarin Switching on Outcomes in Afib Patients and the Cost of Bleeding, Renal Outcomes in Afib Patients, Predictors of Adherence in Afib Patients. *Afib presentation to CARMA, University of Utah School of Medicine.* Salt Lake City, UT. 2012 Jan.

2011 Presentations

24. **Gbate SR, Said Q, Brixner DI, Hashibe M, Joy E, Porucznik CA.** "Comparison of the Trend in Prevalence of Overweight Among Adolescents on Antipsychotics to Non-Users from 2000 to 2009." Presented at the *27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.* Chicago, IL. 2011 Aug.
25. **Brixner D, Biskupiak J.** Application of Real World Databases In the U.S. *AGENS meeting (Working Group on the Use of Secondary Data) University for Health Sciences, Medical Informatics and Technology.* Hall in Tirol, Austria. 2011 Jul.
26. **Biskupiak J, McAdam Marx C, Hane CA, Deniz B, McGarry L, Brixner D.** Costs Associated with HCV and Related Complications in the United States from a Managed Care Payer's Perspective. *ISPOR 16th Annual International Meeting.* Baltimore, MD. 2011 May. *Recipient of the "Best General Podium Presentations" award.
27. **Brixner D, Kwong WJ, Gbate S, Biskupiak J, Ye X.** Cost Of Warfarin-Associated Bleeding In Atrial Fibrillation. *Academy of Managed Care Pharmacy.* Minnesota, MN. 2011 Apr.
28. **LaFleur J, Nelson RE, Hayden C, Reimer L, Kone K, Nebeker J.** Fewer than a quarter of HIV-positive Veterans adhere to medications at recommended levels. *Veterans Affairs Health Services Research and Development (HSR&D) 2011 National Meeting.* Baltimore, MD. 2011 Feb.

2010 Presentations

29. **Brixner DI** Evaluation of Support Services to Colorectal Cancer Patients in Mexico. *ISPOR 13th Annual European Congress.* Prague, Czech Republic. 2010 Nov.
30. **Brixner DI** Current and Future Use of Pharmacoeconomic and Outcomes Research Data in Decision Making in the USA. *ISPOR 13th Annual European Congress.* Prague, Czech Republic. 2010 Nov.
31. **Brixner DI,** Future Trends in Using HEOR Data in Formulary Decision Making. *AMCP 2010 Educational Conference.* St. Louis, MO. 2010 Oct. [Round-Table]

32. **Brixner DI**, Major Challenges and Opportunities for Managed Care Pharmacy. *AMCP 2010 Educational Conference*. St. Louis, MO. 2010 Oct. [Symposium]
33. **Asche CV**, Kim J, Chakravarti P, Kulkarni A, Andersson K. Assessment of Increased Heart Rate to Cardiovascular (CV) Events among Healthy Subjects: An Electronic Medical Record (EMR) Data Analysis. *The 23rd Scientific Meeting of the International Society of Hypertension (ISH)*, Vancouver, Canada. 2010 Sep.
34. **Brixner DI. Oderda G**. Healthcare and Economics – Educating researchers and health-care policy makers regarding the value of providing medicines. *Asian Health Economics Training Workshop*. Jakarta, Indonesia. 2010 Sep.
35. **Brixner DI. Oderda G**. Application of Economic Evaluation Tools from the United States and Europe Toward Pricing and Reimbursement Strategies in the Asia-Pacific Region. *ISPOR 4th Asia-Pacific Conference*. Phuket, Thailand. 2010 Aug.
36. **Brixner DI, Oderda G**, Application towards Integrated Learning of the Medical Pipeline in the PharmD Curriculum. *AACP Annual Meeting: Expanding Our Horizons*. Seattle, WA. 2010 Jul.
37. **Brixner DI, Biskupiak J**, Holtorf AP. Current and future use of health economic and outcomes research data in decision making. *European Society of Medical Decision Making Workshop*. Hall In Tyrol, Austria. 2010 May.
38. **Brixner DI**. U.S. Primary Care Practice Electronic Medical Record Database: GE Centricity. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May. [Short Course]
39. **Brixner DI**, Parkinson J, Eaddy M. Applications In Using Large Databases. *ISPOR 15th Annual International Meeting*. Atlanta, GA. 2010 May.
40. **Brixner DI**. Healthcare and Economics – Educating researchers and health-care policy makers regarding the value of providing medicines. *2nd Global Health Care Summit*. Dubai, UAE. 2010 May.
41. **Brixner DI**, Comparing Adherence Measures Against One-Year Outcomes for Patients with Epilepsy. *AMCP 22nd Annual Meeting & Showcase*. San Diego, CA. 2010 Apr.
42. **Nickman NA**. Impact of new technologies on the future of pharmacy practice. *DUPHAT 2010 Dubai International Pharmaceuticals and Technologies Conference and Exhibition*. Dubai, UAE. 2010 Mar.

43. **Brixner DI, Oderda G.** Healthcare and Economics – Educating researchers and health-care policy makers regarding the value of providing medicines. *Asian Health Economics Training Workshop*. Jakarta, Indonesia. 2010 Jan.

2009 Presentations

44. **McAdam-Marx C.** Late Phase Development of an Antidiabetic Treatment: A Case Study. *Late Phase Drug Development World 2009*. London, UK. 2009 Dec.
45. **Nickman NA.** Professional skills development in future pharmacists: a world-wide issue. *DUPHAT 2009 Dubai International Pharmaceuticals and Technologies Conference and Exhibition*. Dubai, UAE. 2009 Mar.
46. **Oderda GM.** Pharmacoeconomics. *Naresuan University*. Phitsanulok, Thailand. 2009 Mar.
47. **LaFleur J.** Clinical risk factors for fracture: Applying research to knowledge-engineering for decision support. *University of Utah, Division of Geriatrics and Veterans Affairs Salt Lake City Geriatric Research, Education and Clinical Center (GRECC) Geriatric Research Conference*. Salt Lake City, UT. 2009 Feb.
48. **Brixner DI.** Guidelines for Research Using “Real World Data”. *Enhancing the Rigor and Utility of Medication Use Research A Consensus Development Conference*. Rockville, MD. 2009 Jan. Co-sponsored by AACP, PPRA, ISPOR and USP.

2008 Presentations

49. **Brixner, DI, McAdam-Marx, C, Ye, XY, Boye, K, Fabunmi, R, Schroeder, B.** Real World Six Month Outcomes of Patients Initiating Exenatide in a Primary Care Electronic Medical Record Database. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May.
50. **Asche CV, Jacobs P, Yim R.** Economic databases for pharmacoeconomic evaluations in Canada: Overview and use. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May.
51. **Ghate SR, Said Q, Rosenblatt LC, Kim E, Pikalov A, Brixner DI.** Real World Association between Antipsychotic Treatment and Weight Gain in an Adolescent Population. *ISPOR 13th Annual International Meeting*. Toronto, Canada. 2008 May.

2007 Presentations

52. **Said Q, Rosenblatt LC, Ghate SR, Whitehead R, Brixner DI.** Real World Impact of Second Generation Antipsychotics on Weight Gain in an Adolescent Population. *59th Institute on Psychiatric Services*. New Orleans, LA. 2007 Oct.
53. **Asche CV, Cummings G.** ISPOR Digest of international databases for

pharmacoeconomics and outcomes research. *ISPOR 10th Annual European Congress*. Dublin, Ireland. 2007 Oct.

54. **Oderda G**, Lieberman M, **Asche CV**, **Brixner DI**. Use of electronic medical record (EMR) data in outcomes research. *ISPOR 10th Annual European Congress*. Dublin, Ireland. 2007 Oct.
55. **Asche CV**, Seal B, **McAdam-Marx C**, Crookston B, Svejda R, Mullins CD. Treatment costs associated with community acquired pneumonia by community level of antimicrobial resistance. *ISPOR 10th Annual European Congress*. Dublin, Ireland. 2007 Oct.
56. **Brixner DI**, **Jackson K**, Sheng X, **Biskupiak J**, Keskinaslan A. Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database. *ISPOR 10th Annual European Congress*. Dublin, Ireland. 2007 Oct.
57. **Asche CV**, **Brixner DI**, L'Italien GJ. Pharmacoeconomic Research in Latin America: Gathering the Data for Dossier Requirements. *ISPOR 1st Latin America Conference*, Cartagena, Columbia. 2007 Sep.
58. **Asche CV**, Machado M, Caro J. ISPOR Digest of International Databases for Pharmacoeconomics and Outcomes Research. *ISPOR 1st Latin America Conference*, Cartagena, Columbia. 2007 Sep.
59. **Brixner DI**, **Ghate SR**, **McAdam-Marx C**, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *ISPOR 1st Latin America Conference*, Cartagena, Columbia. 2007 Sep.
60. **LaFleur J**, **McAdam-Marx C**, **Asche CV**, Alder S, Sheng X, **Brixner DI**, Silverman S. Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting. *ASBMR 29th Annual Meeting*. Honolulu, HI. 2007 Sep.
61. **Asche CV**, **McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting. *American Diabetes Association (ADA) Scientific Sessions*. Chicago, IL. 2007 Jun.
62. **Asche CV**, Mucha L, Lenhart G, Seal B. Incremental Costs Associated Antibiotics Prescribed for Community Acquired Pneumonia Episodes. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May.
63. Seal B, Mucha L, Lenhart G, **Asche CV**. Incremental Costs Associated with Antibiotics Prescribed for Acute Otitis Media. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May.

64. Mucha L, Seal B, Lenhart G, **Asche CV**. Direct and Incremental Costs of Acute Respiratory Infections. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May.
65. **Said Q, Ghate SR, McAdam-Marx C, Brixner DI**. Correlation of weight to cardiometabolic risk as identified by ICD-9 diagnosis codes and prescriptions in primary care. *ISPOR 12th Annual International Meeting*. Arlington, VA. 2007 May.
66. **Brixner DI**. The Differences Between RCTs and “Real World” Studies. *Real World Data and the Formulary Decision Process: Bridging the Gap*. San Diego, CA. 2007.
67. **Said Q**, Gutterman E, Kim M, L’Italien G, Chi-Chang C, Whitehead R, **Brixner DI**. The Association Between Antipsychotic Treatment and Unintentional Injury in Patients Diagnosed with Psychiatric Disorder. *2007 International Congress on Schizophrenia Research*, Colorado Springs, CO / *American Psychiatric Association Annual Meeting*, San Diego, CA.
68. **McAdam-Marx C, Brixner DI**, Metrau S, Chan V, Field R. Determinants of Race and Ethnicity Reporting for Youth with Health Data in an Electronic Medical Record Database. *5th Annual University of Sciences in Philadelphia Scholarly Day*. Philadelphia, PA. 2007 Apr.
69. **Brixner DI**, Magowan S, Accortt N. Evaluation of Prescription Refill Patterns Based on Daily Dosing Regimen and Pill Load for Calcium Channel Blockers. *AMCP 19th Annual Meeting and Showcase*. San Diego, CA. 2007 Apr.
70. **Brixner DI, Oderda G, Kirkness C, Said Q**. Assessment of Cardiometabolic Risk in a National Primary Care Electronic Medical Database (EMR). *AMCP 19th Annual Meeting and Showcase*, San Diego, CA. 2007 Apr.
71. **Brixner DI**. The Prevalence and Burden of Migraine and Its Impact on Managed Care. *AMCP 19th Annual Meeting and Showcase*, San Diego, CA. 2007 Apr.
72. **Asche CV**, Young D, **Brixner DI**, Phillips A. Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database. *American College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum*. Memphis, TN. 2007 Apr.
73. **Asche CV**, Oderda LH, Pepper GA. The Economic Impact of Treatment of Falls-Related Injuries from a U.S. Employers Perspective. *Center on Aging Research Retreat*. Salt Lake City, UT. 2007 Apr.
74. **LaFleur J, Asche CV, McAdam-Marx C**, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age

in a primary-care setting. *Utah Health Services Research Conference, VA Salt Lake City Health Care System*. Salt Lake City, UT. 2007 Apr.

75. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. *Utah Health Services Research Conference, VA Salt Lake City Health Care System*. Salt Lake City, UT. 2007 Apr.
76. **LaFleur J, McAdam-Marx C, Asche CV**, Alder S, Sheng X, **Brixner DI**, Silverman S. The Risk of Clinical Vertebral Fracture for Postmenopausal Patients with Specific Combinations of Fracture Risk Factors in a Primary-Care Setting. *National Osteoporosis Foundation (NOF) 7th ISO*. Washington, DC. 2007 Apr.

2006 Presentations

77. **Asche CV**. Overview of Data used in Outcomes Research. Pharmaceutical Market Research Summit. Leverage Pre and Post Launch Market Research Strategies to Improve Initial Product Positioning and Ongoing Strategic Decision Making. *King of Prussia*. PA. 2006.
78. **Brixner DI**. Pharmacoeconomics of COPD Management. *ASHP Mid-year Meeting*. Anaheim, CA. 2006 Dec.
79. **Asche CV**. Improving Outcomes in the Treatment of Lower Respiratory Tract Infections. Independence of Washington State Pharmacy Association Continuing Education Seminars. *Washington State Pharmacy Association Mid-Year Meeting*. Renton, WA. 2006 Nov.
80. **Brixner DI**. Real World Data in Healthcare Decision Making. *European Science Foundation Conference on the Global Health Economy*. Kiel, Germany. 2006 Oct.
81. **Brixner DI** (presenter), **Joish VN, McAdam-Marx C**, Arondekar B, Hoblyuk R. Evaluation of Persistency and Outcomes in Patients on SU Combination Therapy with TZD's or Metformin. *2nd Annual Health Services Research Conference*. Salt Lake City, UT. 2006 Apr.
82. **Brixner DI**. Assessment of Cardiometabolic Risk in a Primary Care Electronic Medical Database. *AMCP 18th Annual Meeting & Showcase*. Seattle, WA. 2006 Apr.
83. **Brixner DI**. Developing and Implementing Pharmacy Policy for Insomnia Therapies within Managed Care Plans. *AMCP 18th Annual Meeting & Showcase*. Seattle, WA. 2006 Apr.

2005 Presentations

84. **Asche CV.** Overview of Data used in Outcomes Research. *Strategic Research Institute Conference Patient Level Data for the Pharmaceutical Industry*. Washington, DC. 2005 Nov.
85. **Brixner DI.** Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real World Setting. *AMCP Educational Conference*. Nashville, TN. 2005 Oct.
86. **Brixner DI.** The Case Against Excessive Cost Sharing for Biologics. *AMCP Educational Conference*. Nashville, TN. 2005 Oct.
87. **Brixner DI.** Electronic Medical Records in Outcomes Research: The New Frontier. *Jefferson Medical College*. Philadelphia, PA. 2005.
88. **Brixner DI, Corey-Lisle P, Oberg B, Tuomari V, Biskupiak JE.** Complexity of Depression Treatments: Healthcare Utilization and Costs. *APA Annual Meeting*. Toronto, Canada. 2005 May.
89. **Brixner DI.** Improving Outcomes in the Treatment of Lower Respiratory Tract Infections AMCP Framework on Quality Drug Therapy. *AMCP Annual Meeting*. Denver, CO. 2005 Apr.
90. **Brixner DI.** Managing Your Osteoporosis Formulary to Maximize Bone Strength and Minimize Fracture. *AMCP Annual Meeting*. Denver, CO. 2005 Apr.
91. **Joish VN.** Risk-adjustment in Outcomes Research: The Case of Diabetes Severity Index. *Ohio State University*. Columbus, OH. 2005.
92. **Joish VN.** Application of Pharmacoeconomics in the Western World. *Guest lecture to post-graduate students at Principale K.M. Kundnani College of Pharmacy*. Mumbai, India. 2005.
93. **Joish VN.** Cost-effectiveness Analysis and Methodological Issues in Pharmacoeconomics Research. *3 day workshop at the India Gandhi Government Medical College, Indian Clinical Epidemiologists Network (INDIACLEN)*. Nagpur, India. 2005.
94. **Asche CV.** Prospective Economic Evaluations in Clinical Trials and Examples, *First Western Pharmacoeconomics Conference*. Salt Lake City, UT. 2005 Mar.

2004 Presentations

95. **Brixner DI, Jorgenson JA.** Relationship Between Health Systems and Colleges of Pharmacy. *AACP-Sponsored Program at the ASHP Midyear Clinical Meeting*. 2004 Dec.

96. **Brixner DI.** Managing the Continuum of Treatment: Modeling the Economic Impact of Treating Diabetes. *Symposium in conjunction with the Academy of Managed Care Pharmacy.* 2004 Apr.
97. **Joish VN.** Introduction to Pharmacoeconomics and Health Outcomes Research. *Seminar of pharmaceutical company sales staff at Principal K.M. Kundnani College of Pharmacy.* Mumbai, India. 2004.

2003 Presentations

98. **Brixner DI.** Patient Management in Irritable Bowel Syndrome. *ASHP Midyear Meeting.* New Orleans, LA. 2003 Dec.
99. **Brixner DI.** The Management of COPD in Managed Care Systems. *Pre-Meeting Symposium to the AMCP Annual Meeting.* Tampa, FL. 2003 Apr.
100. **Brixner DI.** The Economics of Insomnia. *Pre-Meeting Symposium to the AMCP Annual Meeting.* Tampa, FL. 2003 Apr.
101. **Brixner DI.** Evidenced Based Treatment Approaches to Irritable Bowel Syndrome. *Pre-Meeting Symposium to the AMCP Annual Meeting.* Tampa, FL. 2003 Apr.
102. **Brixner DI.** Utilization of the AMCP Format in Medicaid, Medicaid & Medicare, the Changing Landscape. 2003.

HOSTED CONFERENCES

1. First Western Pharmacoeconomics Conference, Salt Lake City, UT, 2005.
2. Second Western Pharmacoeconomics Conference, Salt Lake City, UT, 2007.

BOOKS and CHAPTERS

1. Vailancourt A, Chisholm Burns M, **Brixner DI.** Creating and Identifying Desirable Workplaces in *Pharmacy Leadership, Marketing and Finance 2nd edition.* Jones and Bartlett Learning, Marie A. Chisholm-Burns. 2012, p. 400-415.
2. Holtorf A, Rinde H, Rupprecht F, Alder H, **Brixner DI.** The Economic Impact of Bariatric Surgery in *Advanced Bariatric and Metabolic Surgery.* Croatia, Intech, Chih-Kun Huang. 2012, p. 61-86.
3. **Brixner DI,** Joish VN, **Biskupiak JE,** Shah H. Pharmacoeconomic Research in Managed Care in *Managed Care and Pharmacoeconomics 2nd edition.* New York, Jones and Bartlett Publishers, Robert Navarro. 2008.

4. **Brixner DI**, Joish VN, **Biskupiak JE**, Shah H.
Pharmacoeconomic Research in Managed Care in *Managed Care Pharmacy Practice*. New York, Aspen Publishers, Robert Navarro. 2006.
5. **Oderda GM**, Osterhaus JT. Outcomes and Economics in Pain Management in *Pain Management for Primary Care Clinicians*. American Society Health Systems Pharmacists, Arthur Lipman. 2004, p. 271-78.

AWARDS AND HONORS

2017 Awards and Fellowships

1. **Tak, C.** Pre-doctoral Fellowship in Pharmaceutical Sciences. September 2017 – August 2018. American Foundation for Pharmaceutical Education. Amount: \$10,000
2. **Tak, C.** Skaggs Graduate Research Fellowship. August 2017 – July 2018. Skaggs Institute for Research. Amount: \$30,900

2016 Awards and Fellowships

3. **Tak, C.** Skaggs Graduate Research Fellowship August 2016 – July 2017. Skaggs Institute for Research. Amount: \$30,000
4. **Schauerhamer, M.** PhRMA Foundation Fellowship June 2016 – June 2017. Pre-Doctoral Grant in Adherence Improvement. Amount \$25,000 stipend support.
5. **Jiao, T.** The highest performing peer reviewer in 2015. Journal of Managed Care and Specialty Pharmacy, 2016.
6. **Jiao, T.** Student research grant. ISPOR Real-World Evidence (RWE) Task Force, 2016.

2015 Awards and Honors


7. **Bress, A.** Winner, New Investigator Research Presentation Podium Award, 20th Annual meeting of the International Society of Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 2015
8. **Stevens, V.** New Investigator Award: International Conference on Prevention and Infection Control (ICPIC), Geneva, Switzerland, June 2015.
9. **LaFleur, J.** University of Utah College of Pharmacy Teacher of the Year, 2015.


2014 Awards and Honors

10. **McAdam-Marx, C.** Excellent Peer Review Recognition, Journal of managed Care Pharmacy, Awarded to top 8% (28 of 359) of reviews, 2014.

11. **McAdam-Marx, C.** National institute of Health, VA, and Harvard University – Training Institute for Dissemination and Impelementation in Health Research Conference Participant, July 22-25, 2014, Boston, MA (competitive process with 45 of 250 applicants selected to attend).
12. **Brixner, D.** AMCP Fellow, 2014.

Pharmacotherapy Outcomes Research Center Organizational Chart







Pharmacotherapy Outcomes Research Center

University of Utah L.S. Skaggs Pharmacy Institute

30 South 2000 East, 4th Floor

Salt Lake City, UT 84112

Phone: (801) 587-9639

Fax: (801) 587-7923

<http://pharmacy.utah.edu/porc/>

Last Update: 1/8/18